

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83729 A2

(51) International Patent Classification⁷: **C12N 15/00**

(21) International Application Number: PCT/EP01/04863

(22) International Filing Date: 30 April 2001 (30.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/562,934 1 May 2000 (01.05.2000) US

(71) Applicants: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/83729 A2

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.

VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

Work described herein was supported by NIH grants EY11431 and HL54352. The government has certain rights in such subject matter.

5 RELATED APPLICATIONS

This application claims the benefit of priority to U.S. application Serial No. 09/562,934, filed May 1, 2000, to Glen R. Nemerow, Daniel Von Seggern,; Martin Friedlander, entitled "VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY".

- 10 This application is related to copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000), to Daniel Von Seggern, Glen R. Nemerow, Paul Hallenbeck, Susan Stevenson, Yelena Skripchenko, filed January 14, 2000, entitled "Adenovirus Vectors, Packaging Cell Lines, Compositions, and
- 15 Methods for Preparation and Use," which is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S. Provisional Application 60/115,920 filed January 14, 1999. Where permitted, the contents and subject matter of each application and of the provisional application are incorporated in their entirety herein by reference.

20 FIELD OF INVENTION

The present invention relates to gene therapy, especially to adenovirus vector-based gene therapy. In particular, adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene

25 therapy are provided.

BACKGROUND OF THE INVENTION

Retinal dystrophies

- The eye is susceptible to a number of hereditary and/or age related degenerative disorders. In the United States, common causes of irreversible blindness or severe loss of vision are retinal dystrophies (see, e.g., Cotlier *et al.* (1995) *Surv. Ophthalmology* 40:51-61; Bird (1995) *Am. J. Ophthal.* 119: 543-562; and Adler (1996) *Arch Ophthal* 114:79-83). The retina is the sensory

-2-

tunic of the eye, containing light sensitive receptors, a complex of neurons, and pigmented epithelium, arranged in discrete layers. In humans, the macula is the portion of the retina that lies directly behind the lens. Cones, the photoreceptor cells responsible for central vision, are heavily concentrated in the macula.

5 Central dystrophies, which affect the macula, include Best's disease, age-related macular degeneration, and Stargardt's macular dystrophy. The peripheral retina is composed mainly of rods, which are responsible for side and night vision. Peripheral degenerative retinal diseases include retinitis pigmentosa, choroideremia and Bietti's crystalline dystrophy.

10 Macular degenerations are a heterogeneous group of diseases, characterized by progressive central vision loss and degeneration of the macula and underlying retinal pigmented epithelium. Age-related macular degeneration (ARMD) is the most common form of the disease, affecting an estimated 20% of persons over 75 years of age. ARMD is poorly understood in terms of etiology
15 and pathogenesis. The very late onset of the disease has made genetic mapping particularly difficult. Certain macular degenerative conditions with a clear genetic basis, such as Stargardt's and Best's diseases, share many features with ARMD, but have been more amenable to molecular and genetic analysis.

Hereditary peripheral retinopathies are also relatively common. Retinitis
20 pigmentosa (RP), for example, affects approximately 1.5 million people worldwide. Substantial genetic heterogeneity has been observed in this condition, with over 20 chromosomal loci identified. A predisposition to retinitis pigmentosa can be inherited by autosomal dominant, autosomal recessive, X-linked or digenic mode. Mutations have been identified in seven genes, four of
25 which encode proteins in the rod phototransduction cascade: rhodopsin, alpha and beta subunits of rod cGMP phosphodiesterase, and rod cGMP cation-gated channel protein .alpha. subunit. Mutations in the peripherin/RDS gene have been linked to retinitis pigmentosa and macular degeneration. A single peripherin/RDS mutation apparently caused retinitis pigmentosa, pattern dystrophy and fundus
30 flavimaculatus, in different family members.

-3-

- In spite of causal heterogeneity, there is significant clinical similarity among RP subtypes. Common signs and symptoms include early electroretinographic abnormalities, ophthalmoscopic findings, and protracted, contiguous expansion of the ring-like scotoma toward the macula,
- 5 leading to progressively worsening tunnel vision. A recent hypothesis is that active photoreceptor cell death, which is characteristic of these genetically distinct disorders, is mediated by a common induction of apoptosis. It may be possible to treat these conditions by the administration of agents that block induction of apoptosis in photoreceptors, such as neurotrophic factors.

10 Adenovirus delivery vectors

Adenovirus, which is a DNA virus with a 36 kilobase (kb) genome, is very well-characterized and its genetics and genetic organization are understood. The genetic organization of adenoviruses permits substitution of large fragments of viral DNA with foreign DNA. In addition, recombinant adenoviruses are

15 structurally stable and no rearranged viruses are observed after extensive amplification.

Adenoviruses have been employed as delivery vehicles for introducing desired genes into eukaryotic cells. The adenovirus delivers such genes to eukaryotic cells by binding to cellular receptors followed by internalization. The

20 adenovirus fiber protein is responsible for binding to cells. The fiber protein has two domains, a rod-like shaft portion and a globular head portion that contains the receptor binding region. The fiber spike is a homotrimer, and there are 12 spikes per virion. Human adenoviruses bind to and infect a broad range of cultured cell lines and primary tissues from different species.

25 The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described (see, e.g., Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Virol.* 161: 549-554, 1987).

-4-

The 35,935 bp sequence of Ad5 DNA is also known and portions of many other adenovirus genomes have been sequenced. The upper packaging limit for adenovirus virions is about 105% of the wild-type genome length (see, e.g., Bett, et al., *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this
5 would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats permit single strands of viral DNA to circularize by base-pairing of their terminal sequences to form base-paired "panhandle" structures that are
10 required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and
15 contiguous packaging sequence) have been constructed.

Ad vectors have several distinct advantages as gene delivery vehicles. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to
20 accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins. Adenovirus (Ad)-based gene delivery vectors efficiently infect many different cells and tissues. This broad tropism, however, means that gene delivery cannot be directed to a specific target cell. A large fraction of intravenously administered adenovirus is
25 retained by the liver, which could lead to undesirable side-effects. Adenovirus may potentiate immune responses. For example, Adenovirus type 5 (Ad5) also transduces dendritic cells, which present antigens very efficiently, thereby possibly exacerbating the immune response against the vector. It has been proposed that vectors with different targeting efficiencies might eliminate these
30 problems, permitting a lower total particle dose and more specific targeting (see, e.g., U.S. application Serial No. 09/482,682).

-5-

The wealth of information on adenovirus structure and mechanism of infection, its efficient infection of nondividing cells, and its large genetic capacity make adenovirus a popular gene therapy vector. The wide expression of receptors to which adenovirus binds makes targeting adenovirus vectors difficult.

5

Hence there is a need to improve delivery and targeting of adenoviral vectors and also to provide treatments for ocular disorders. Therefore, it is an object herein to provide adenoviral vectors that specifically or selectively target cells in the eye. It is also an object herein to provide these vectors for treatment 10 of ocular disorders.

SUMMARY OF THE INVENTION

Degenerative ocular diseases, such as, but not limited to, retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, and others (see, e.g., Table below), have a genetic basis. Genes expressed in 15 the photoreceptor cells at the back of the retina are implicated in these diseases. Provided herein are recombinant viral vectors for targeting therapeutic products to these cells.

Recombinant adenoviral vectors that include nucleic acid that permits specific binding to these photoreceptors are provided. In particular, the vector 20 particles contain a fiber protein of Ad37 or a modified form thereof. As shown herein, fiber protein from Ad37 permits efficient infection of photoreceptor cells. Fiber proteins from other adenovirus D serotypes may also be used. In addition, the portions of the fiber protein, particularly those that interact with other viral structural proteins, such as penton, may be modified to resemble the viral source 25 of the other structural proteins. As exemplified herein, the recombinant virus provided herein include Ad5 structural components. The N-terminus of the Ad37 fiber protein, which interacts with the penton protein, is modified to resemble the Ad5 fiber protein N-terminus to ensure production of viral particles.

The recombinant adenoviral vectors are intended for gene therapy of 30 diseases in which genes expressed in the photoreceptors are implicated. Such diseases include, but are not limited to, degenerative ocular diseases, such as retinitis pigmentosa and Stargardt's disease. These vectors are also useful for

-6-

targeting to other ocular cells, such as conjunctival cells, which also bear receptors to which fiber from Ad37 and related serotypes bind.

The vectors will deliver therapeutic agents to the targeted cells for treatment of a variety of disorders (see e.g., Tables 3 and 4, below)). The

- 5 therapeutic agents are intended for expression in the photoreceptors and for secretion from the photoreceptor cells, which are surrounded on one side by choroidal vasculature, and on the other side by retinal vasculature, thereby providing a means for delivery of products. In addition, expression of growth factors, such as VEGF and others, can be used to enhance blood flow to the
10 retina and prevent or slow the degeneration.

Therapeutic agents encoded by the recombinant adenoviral vectors include, but are not limited to, nucleic acid nucleic acid molecules encoding genes that are defective in certain hereditary disorders, nucleic acid molecules that encode antiangiogenics and antitumor agents for treatment of retinal

- 15 disorders, such as retinoblastomas; nucleic acid molecules encoding trophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF), growth factors and growth factor inhibitors, antiapoptotic factors, such as Bcl-2 (CNTF), antitumor agents, anti-angiogenics, and genes or portions thereof for gene replacement or repair of defective genes.
20 Hence, methods for treatment of inherited and acquired retinal diseases, including diseases involving neovascular and vascular degeneration are provided.

Methods for treating diseases involving genes expressed in photoreceptor cells are provided herein. The methods provided herein are practiced by

- 25 administration of the recombinant viral vectors by any means suitable for delivery to the photoreceptors. A preferred mode of administration is intraocular injection including intravitreal and subretinal injection. Other modes of administration include, but are not limited to, intrascleral, periorbital and intravenous administration. The vectors also can include photoreceptor-specific
30 promoters thereby providing a means, not only for specific targeting of expression in these cells, but also for photoreceptor-restricted transgene expression.

-7-

DETAILED DESCRIPTION OF THE INVENTION

A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, applications, published applications and other publications and sequences from GenBank and other data bases referred to anywhere in the disclosure herein are incorporated by reference in their entirety.

As used herein, the amino acids, which occur in the various amino acid sequences appearing herein, are identified according to their three-letter or one-letter abbreviations. The nucleotides, which occur in the various DNA fragments, are designated with the standard single-letter designations used routinely in the art (see, Table 1).

As used herein, amino acid residue refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. §§ 1.821 - 1.822, abbreviations for amino acid residues are shown in the following Table:

25

Table 1
Table of Correspondence

SYMBOL		
1-Letter	3-Letter	AMINO ACID
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine

30

-8-

SYMBOL		
A	Ala	alanine
S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
5 T	Thr	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
10 Q	Gln	glutamine
E	Glu	glutamic acid
Z	Glx	Glu and/or Gln
W	Trp	tryptophan
R	Arg	arginine
15 D	Asp	aspartic acid
N	Asn	asparagine
B	Asx	Asn and/or Asp
C	Cys	cysteine
20 X	Xaa	Unknown or other

- It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of
- 25 Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. §§ 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or

-9-

more amino acid residues or to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering

5 the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson *et al.* *Molecular Biology of the Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224).

10 Such substitutions are preferably made in accordance with those set forth in TABLE 2 as follows:

TABLE 2

	Original residue	Conservative substitution
15	Ala (A)	Gly; Ser
	Arg (R)	Lys
	Asn (N)	Gln; His
	Cys (C)	Ser
	Gln (Q)	Asn
	Glu (E)	Asp
20	Gly (G)	Ala; Pro
	His (H)	Asn; Gln
	Ile (I)	Leu; Val
	Leu (L)	Ile; Val
25	Lys (K)	Arg; Gln; Glu
	Met (M)	Leu; Tyr; Ile
	Phe (F)	Met; Leu; Tyr
	Ser (S)	Thr
30	Thr (T)	Ser
	Trp (W)	Tyr
	Tyr (Y)	Trp; Phe
	Val (V)	Ile; Leu

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

35 As used herein, a complementing plasmid describes plasmid vectors that deliver nucleic acids into a packaging cell line for stable integration into a chromosome in the cellular genome.

As used herein, a delivery plasmid is a plasmid vector that carries or delivers nucleic acids encoding a therapeutic gene or gene that encodes a

-10-

therapeutic product or a precursor thereof or a regulatory gene or other factor that results in a therapeutic effect when delivered *in vivo* in or into a cell line, such as, but not limited to a packaging cell line, to propagate therapeutic viral vectors.

- 5 As used herein, a variety of vectors with different requirements are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors are generally identified herein as complementing plasmids. A further type of vector described herein carries or delivers nucleic acid molecules in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is used to carry nucleic acid molecules encoding therapeutic proteins or polypeptides or regulatory proteins or are regulatory sequences to specific cells or cell types in a 10 subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or recombinant adenoviral vectors or viral Ad-derived . vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette for expressing the therapeutic gene.
- 15

As used herein, a DNA or nucleic acid homolog refers to a nucleic acid 20 that includes a preselected conserved nucleotide sequence, such as a sequence encoding a therapeutic polypeptide. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith or a lesser percentage of homology or identity and conserved biological activity or function.

25 The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482 30 (1981). Briefly, the GAP program defines similarity as the number of aligned symbols (*i.e.*, nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default

-11-

parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE 5 AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

Whether any two nucleic acid molecules have nucleotide sequences that 10 are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the National Center for Biotechnology Information database may be used to 15 determine identity.

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics 20 and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). 25 While there exist a number of methods to measure identity between two polynucleotides or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge 30 Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred

-12-

computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(1):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990)).

5 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the
10 reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and
15 reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or
20 deletions.

As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is
25 expressed and a therapeutic product encoded thereby is produced.

Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy may also be used to deliver nucleic
30 acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth

-13-

- factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified
- 5 prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, heterologous DNA is DNA that encodes RNA and proteins that are not normally produced *in vivo* by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous DNA by

10 affecting transcription, translation, or other regulatable biochemical processes. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which it is expressed is herein encompassed by heterologous DNA.

Examples of heterologous DNA include, but are not limited to, DNA that encodes

15 traceable marker proteins, such as a protein that confers drug resistance, DNA that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and DNA that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous DNA may be secreted or expressed on the surface of the cell in which the heterologous DNA has been

20 introduced.

Hence, herein heterologous DNA or foreign DNA, refers to a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in the corresponding wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or

25 from another Ad serotype.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.

30 Typically, DNA encoding the desired heterologous DNA is cloned into a plasmid vector and introduced by routine methods, such as calcium-phosphate mediated DNA uptake (see, (1981) Somat. Cell. Mol. Genet. 7:603-616) or

-14-

microinjection, into producer cells, such as packaging cells. After amplification in producer cells, the vectors that contain the heterologous DNA are introduced into selected target cells.

As used herein, an expression or delivery vector refers to any plasmid or 5 virus into which a foreign or heterologous DNA may be inserted for expression in a suitable host cell — *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors that allow cloning 10 of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

As used herein, a gene is a nucleic acid molecule whose nucleotide sequence encodes RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and 15 trailer) as well as intervening sequences (introns) between individual coding segments (exons).

As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by the fiber protein, such as by the C-terminus portion that comprises the knob.

20 As used herein, isolated with reference to a nucleic acid molecule or polypeptide or other biomolecule means that the nucleic acid or polypeptide has separated from the genetic environment from which the polypeptide or nucleic acid were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is 25 not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides 30 that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compound can be substantially purified by the one-step method described in

-15-

Smith and Johnson, *Gene* 67:31-40 (1988). The terms isolated and purified are sometimes used interchangeably.

Thus, by "isolated" is meant that the nucleic acid is free of the coding sequences of those genes that, in the naturally-occurring genome of the

5 organism (if any) immediately flank the gene encoding the nucleic acid of interest. Isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

10 Isolated or purified as it refers to preparations made from biological cells or hosts means any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of 15 interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

A preparation of DNA or protein that is "substantially pure" or "isolated" 20 should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

A cell extract that contains the DNA or protein of interest should be 25 understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.

As used herein, a packaging cell line is a cell line that provides a missing 30 gene product or its equivalent.

As used herein, an adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of

-16-

particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

As used herein, "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may 5 also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

As used herein, a plasmid refers to an autonomous self-replicating extrachromosomal circular nucleic acid molecule, typically DNA.

10 As used herein, a post-transcription regulatory element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA 15 sequence.

As used herein, pseudotyping describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 fiber protein. This may be 20 accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

As used herein, promoters of interest herein may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters do not require the presence of 25 any additional molecule to regulate gene expression. A regulatable or inducible promoter may also be described as a promoter where the rate or extent of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include, but are not limited to various compounds or compositions, light, heat, stress and chemical energy sources. Inducible, suppressible and repressible 30 promoters are considered regulatable promoters. Preferred promoters herein, are promoters that are selectively expressed in ocular cells, particularly photoreceptor cells.

-17-

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.

5 As used herein, recombinant refers to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

As used herein, a transgene or therapeutic nucleic acid molecule includes DNA and RNA molecules encoding an RNA or polypeptide. Such molecules may 10 be "native" or naturally-derived sequences; they may also be "non-native" or "foreign" that are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleic acid molecule," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

15 Therefore, therapeutic nucleotide nucleic acid molecules include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) all include nucleic acid molecules that function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic 20 nucleic acid molecule can include a sequence of nucleotides that encodes a functional protein intended for delivery into a cell which is unable to produce that functional protein.

As used herein, the vitreous of the eye refers to material that fills the chamber behind the lens of the eye (i.e., vitreous humor or vitreous body).

25 As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region 30 includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be *cis* acting or

-18-

may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

Thus, promoters are nucleic acid fragments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the

- 5 promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences that direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a
- 10 particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance efficiency of expression.

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (see, e.g., U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters.

- 20 Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then
- 25 it is expressed appropriately in the correct cell types (see, e.g., Palmiter et al. (1986) Ann. Rev. Genet. 20: 465-499).

As used herein, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form, whereby control sequences on one

- 30 segment control expression or replication or other such control of other segments. The two segments are not necessarily contiguous.

-19-

As used herein, exogenous encompasses any therapeutic composition that is administered by the therapeutic methods provided herein. Thus, exogenous may also be referred to herein as foreign, or non-native or other equivalent expression.

5 **B. Ad37 fiber tropism**

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol.* 70:2116-2123; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson *et al.* 10 (1968) *J. Virol.* 2:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek *et al.* (1995) *Curr.Top.Microbiol.Immunol.* 199:163-200; Riurok *et al.* (1990) *J.Mol.Biol.* 215:589-596; Stevenson *et al.* 15 (1995) *J. Virol.* 69:2850-2857). Fiber proteins of most adenovirus subgroups have been shown to bind specifically or selectively to the 46 kDa coxsackievirus-adenovirus receptor (CAR), (Bergelson *et al.* (1997) *Science* 275:1320-1323; Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). CAR appears to be expressed in a variety of human tissues, including the lung, at various levels (Bergelson *et al.* 20 (1997) *Science* 275:1320-1323), but Ad37 binds poorly to lung epithelial cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). This suggests that the tropism of this serotype may be influenced by factors independent of CAR expression.

Structural and biochemical data also suggest that distinct receptor binding sites are located on different regions of the Ad5 and Ad37 fiber knobs.

25 Adopting the nomenclature of Xia et al. (Xia *et al.* (1994) *Structure* 2:1259-1270), the receptor binding site for Ad5 is located at the AB-loop on the side of the fiber knob (Bewley *et al.* (1999) *Science* 286:1579-1583; Roelvink *et al.* (1999) *Science* 286:1568-1571). It is known that a lysine residue at position 240 of the Ad37 fiber, located in the CD-loop, is important for receptor binding 30 (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). The co-crystal structure of the Ad12 knob and the N-terminal domain of CAR (Bewley *et al.* (1999) *Science* 286:1579-1583) show that the CD-loop does not contact CAR. It thus appears

-20-

that different regions of the Ad5 and Ad37 fiber knobs recognize distinct cell receptors.

- A 46 kDa receptor for coxsackieviruses and adenoviruses (CAR) mediates attachment for many adenovirus serotypes. The wide distribution of CAR fails
- 5 to explain why certain adenovirus serotypes (i.e. Ad37) are highly associated with severe ocular infections such as epidemic keratoconjunctivitis (EKC). Ad37 does not use CAR, but instead uses a glycoprotein that contains sialic acid as its primary receptor (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48)). The modest number of Ad37 binding sites per cell (Huang *et al.* (1999) *J. Virol.* 73:2798-10 2802) also suggests that Ad37 recognizes a specific glycoprotein as its primary receptor for binding to conjunctival cells.

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract. The tropism of Ad37 derives from the binding preference of its fiber protein, which binds to a receptor located on the surface

15 of cells including Chang C, conjunctival epithelial cell line (Huang *et al.* (1999) *J. Virology* 73:2798-2802).

A protein receptor that is preferentially expressed on conjunctival cells to which Ad37 fiber binds is shown herein. The preferential expression of the Ad37 receptor protein on conjunctival cells suggests that this receptor likely

20 influences Ad37 tropism and should play a key role in ocular pathogenesis. It is shown herein that Ad37 uses a distinct protein receptor that is selectively expressed on conjunctival cells. It is shown that Ad37 binds well to conjunctival cells (Chang C), but poorly to lung carcinoma cells (A549). To determine if infection correlated with cell binding, an Ad5 vector containing the Ad37 fiber

25 protein was constructed. The 'pseudotyped' vector delivered transgenes to Chang C cells better than to A549 cells. Ad37 binding was abolished by protease treatment of Chang C cells, indicating the receptor is a membrane protein. Ad37 binding to conjunctival cells is shown herein to be calcium-dependent. It is also shown that Ad37 infection was not inhibited by a function-

30 blocking anti-CAR monoclonal antibody, which is a feature distinct from Ad5 fiber interaction with CAR. Using a virus overlay protein blot assay (VOPBA), calcium-dependent Ad37 binding to a 50 KDa membrane protein on Chang C

-21-

cells, but not A549 cells was detected. Ad19p a closely related serotype that fails to bind to conjunctival cells, does not recognize the 50 kDa protein. Together, these data indicate that the 50 kDa protein is a candidate receptor for Ad37 on conjunctival cells.

- 5 Significantly, it is also shown herein that, upon administration of the vector to the vitreous humor, the recombinant adenovirus with the Ad37 fiber preferentially and selectively binds to photoreceptor cells. Hence, a recombinant adenoviral delivery vehicle that has an Ad37 fiber protein can serve as a vector for delivery of therapeutic agents to the eye for treatment of ocular disorders,
10 including genetic and acquired disorders. The identification of the receptor for Ad37 and the resulting recognition of Ad37 tropism allows targeting of adenovirus vectors to specific human ocular cells.

- As noted, fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on a cell surface. Hexon, penton and fiber
15 capsomeres are the major components on the surface of the virion. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber includes three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that
20 forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus (see, e.g., Hong and Engler,
25 *Virology 185: 758-761, 1991*). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery.

- As shown herein, alteration of fiber in recombinant Ad vectors such that the fiber is derived from Ad37 or another adenovirus serotype D, provides a means for selective delivery of a recombinant virus to particular cells in the eye,
30 including conjunctival cells, and most significantly photoreceptors, thereby providing a means for targeted delivery to photoreceptor cells.

-22-

Photoreceptor cells are implicated in a number of hereditary and acquired retinal degenerative disorders. In addition, photoreceptor cells are located such that products produced therein can be delivered to other areas of the eye by virtue of the blood flow in the vicinity of the photoreceptor cells and also by 5 virtue of the proximity of the photoreceptors to the retinal pigmented epithelium (RPE) and other retinal cells.

Hence it is contemplated herein that the recombinant viral vector will include a packaged recombinant adenovirus genome containing at least the minimal elements for replication and packaging; heterologous DNA encoding a 10 desired gene product, typically a therapeutic product or plurality of products, such as several trophic factors, whose combined activity is effective for treating a disorder, such as a retinal degenerative disorder; and the resulting virion particles will include a fiber that has a sufficient portion to confer specific targeting to photoreceptor cells when the recombinant viral particles are 15 introduced into the aqueous humor of a mammalian, preferably a human, eye, or otherwise contacted with the photoreceptor cells. The fiber may be a chimeric protein that has been modified for effective interaction with other coat structural proteins, such as penton. In addition, the fiber may be modified to include other elements that alter its tropism to permit binding to other cells as well (see, e.g., 20 U.S. Patent Nos. 5,756,086 and 5,543,328, International PCT application No. WO 95/26412 and WO 98/44121 and Krasnykh, *et al.* (*J. Virol.* 70: 6839-46, 1996).

C. Construction of the viral particles

1. Selection of viral genome and fiber protein

25 Methods for preparing recombinant adenoviral vectors for gene product delivery are well known. Preferred among those are the methods exemplified herein (see EXAMPLES) and also described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000, which claims priority to U.S. 30 provisional application Serial No. 60/115,920, as does U.S. application Serial No. 09/482,682)).

-23-

As noted, any desired recombinant adenovirus is contemplated for use in the methods herein as long as the viral genome is packaged in a capsid that includes at least the portion of a fiber protein that provides selective binding to photoreceptor cells. This fiber protein is preferably from an adenovirus type D 5 serotype and is preferably an Ad37 fiber. The fiber protein should retain the knob region at the C-terminus ("head domain") from the Ad virus of subgroup D that contains the type-specific antigen and is responsible for binding to the cell surface receptor. Hence the fiber protein can be a chimeric fiber protein as long as it retains a sufficient portion of the type D serotype to specifically or 10 selectively bind to photoreceptor cells. Generally the portion retained will be all or a portion of the knob region. The precise amount of knob region required can be determined empirically by including portions thereof and identifying the minimum residues from an Ad type D serotype, preferably Ad37, to effect 15 selective targeting of a virion packaged with such fiber to photoreceptors in the eye upon introduction of the packaged virion into the aqueous humor.

Recombinant adenovirus containing heterologous nucleic acids that encode a desired product, such a gene to correct a genetic defect, may be made by any methods known to those of skill in the art. The viruses must be packaged in a cell line that results in expression of fiber on the particles that 20 specifically, electively or preferentially targets (binds and results in internalization) the viral particle to cells in the eye. The fiber protein from Ad37 and other Adenoviruses of serotype D that infect the eye effects such targeting. The resulting adenovirus particles that express such fiber is administered by intraocular injection, subretinal injection, particularly intravitreal injection, or any 25 means that results in preferential accumulation in photoreceptor cells.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in *Fields et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, 30 porcine, ovine, canine and opossum viruses and members of the Aviadenovirus genus, including bird viruses, such as CELO.

-24-

Thus it is contemplated that the methods herein can be applied to any recombinant viral vectors derived from any adenovirus species. One of skill in the art would have knowledge of the different adenoviruses (see, e.g., Shenk, *Virology*, Chapter 67, in *Fields et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) 5 and can construct recombinant viruses containing portions of the genome of any such virus.

In the exemplified embodiment, viral particles with Ad37 fiber were prepared. Site-directed mutations were made to the Ad37 fiber gene to make the tail sequence more closely match that of Ad5 to facilitate Ad37 fiber binding 10 to the Ad5 penton base. The plasmid for the expression of the Ad37 fiber protein, pDV80, contains the CMV promoter, the adenovirus type 5 tripartite leader (TPL), and the modified Ad37 fiber gene sequence. Genes of interest, such as nucleic acid encoding the β subunit of cGMP phosphodiesterase (β PDE), β -glucuronidase, rhodopsin, growth factors, anti-cancer agents, growth factor 15 receptors and other anti-angiogenic agents, and anti-apoptotic agents, can be incorporated into these vectors using the methods known to those of skill in the art and exemplified herein.

Known adenovirus vectors, previously constructed for intraocular therapy (see, e.g., Bennett *et al.* (1996) *Nature Medicine* 2:649-654, which provides an 20 Ad virus encoding β PDE for treatment of retinitis pigmentosa; Cayouette *et al.* (1998) *Human Gene Therapy* 8:423-430, which provides an Ad vector that expresses CNTF for treatment of retinitis pigmentosa and other retinal degenerative diseases; and Li *et al.* (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:7700-7704, which provides an Ad virus vector that encodes a human β - 25 glucuronidase for treatment of lysosomal storage disease caused by β -glucuronidase deficiency) can be modified by repackaging the recombinant genome using a packaging line that expresses an Ad37 fiber or other D serotype fiber.

For exemplification, nucleic acid encoding GFP was incorporated into 30 these vectors as a means to visualize their localization. Other genes, such as genes that encode therapeutic products, may be included in place of or in addition to GFP.

-25-

Plasmid pDV80 was electroporated into E1-2a S8 cells and stable lines were selected. The fiber-deleted vectors Ad5. β gal. Δ F and Ad5.GFP. Δ F were grown in cells in a resulting cell line, designated 705, to produce virions, which express the Ad37 fiber (Ad5. β gal. Δ F/37F and Ad5.GFP. Δ F/37F) and CsCl-purified. These virions selectively transduce photoreceptor cells when injected intraocularly into the vitreous humor.

2. Packaging

Recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b regions. Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, e.g., Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378).

Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

Copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or mutated in the adenovirus vector genome to

-26-

be replicated and packaged. The packaging cell line express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The 5 expression can be constitutive or under the control of a regulatable promoter. These cell lines are designed for expression of recombinant adenoviruses intended for delivery of therapeutic products.

Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, 10 regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be 15 introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D, such as Ad 37, polypeptide or fragment thereof.

For therapeutic applications, the delivery plasmid further includes a 20 nucleotide sequence encoding a foreign polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, pΔE1Bβ-gal and pΔE1sp1B. In a similar or analogous manner, therapeutic genes may be introduced.

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a 25 chromosome(s) of the cellular genome of the cell.

In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second 30 delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

-27-

- In a variation, the packaging cell line expresses fiber protein or chimeric variant thereof from an Ad virus of subgroup D, preferably Ad37, serotype or it can be any fiber protein but one that has been modified to include the portion of the Ad virus of subgroup D, such as Ad37, responsible for selective targeting to
- 5 photoreceptors upon introduction into the vitreous humor of the eye of a mammal, preferably a human. The fiber protein can be further modified to include a non-native amino acid residue sequence that targets additional specific receptors. In all instances, the modification should not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino
- 10 acid residue sequence alters the binding specificity of the fiber for a targeted cell type. The structural protein is fiber can include amino acid residue sequences from more than one adenovirus serotype. The nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein, may be modified "internally" as well as at the termini.
- 15 Additional nucleic acid fragments can encode polypeptides that are added to the fiber protein. In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker.
- 20 Suitable ligands include, but are not limited to, ligands that specifically or selectively bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, the packaging cell lines will contain nucleic acid encoding the fiber protein or modified protein stably integrated into a chromosome or chromosomes in the cellular genome.
- 25 The packaging cell line can be derived from a prokaryotic cell line or from a eukaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from among the 293, A549, W162, HeLa,
- 30 Vero, 211, and 211A cell lines, and any other cell lines suitable for such use are likewise contemplated herein.

3. Components of the nucleic acid molecule included in the particle

A recombinant viral vector or therapeutic viral vector for use in the methods herein, typically includes a nucleic acid fragment that encodes a protein or polypeptide molecule, or a biologically active fragment thereof, or other regulatory sequence, that is intended for use in therapeutic applications.

- 5 The nucleic acid molecule to be packaged in the viral particle also may include an enhancer element and/or a promoter located 3' or 5' to and controlling the expression of the therapeutic product-encoding nucleic acid molecule if the product is a protein. Further, for purposes herein, the promoter and/or other transcriptional and translational regulatory sequences controlling
10 expression of the product is preferably one that is expressed specifically in the targeted cells, such as the a photoreceptor-specific promoter, such as a rhodopsin gene promoter.

The nucleic acid molecule to be packaged in viral capsid includes at least 2 different operatively linked DNA segments. The DNA can be manipulated and
15 amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce such molecule, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous
20 replication in a cell either *in vivo* or *in vitro*. By operatively linking the enhancer element or promoter and nucleic acid molecule to the vector, the attached segments are replicated along with the vector sequences.

Thus, the recombinant DNA molecule (rDNA) is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in
25 nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. The nucleic acid molecule intended to be packaged is from about 20 base pairs to about 40,000 base pairs in length, preferably about 50 bp to about 38,000 bp in length. In various embodiments, the nucleic acid molecule is of sufficient length
30 to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, encoding nucleic acid molecules

-29-

from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic product-encoding nucleic acid molecules.

- Preferably the molecule includes an adenovirus tripartite leader (TPL)
- 5 nucleic acid sequence operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron. The intron includes any sequence of
- 10 nucleotides that function in the packaging cell line to provide RNA processing signals, including splicing signals. Introns have been well characterized from a large number of structural genes, and include but are not limited to a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs (see,
- 15 e.g., Petitclerc *et al.* (1995) *J. Biotechnol.*, 40:169; and Choi *et al.* (1991) *Mol. Cell. Biol.*, 11:3070).

- The nucleic acid molecule encoding the TPL includes either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from among the complete TPL exon 1, partial TPL
- 20 exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples.
- 25 The use of a TPL with a partial exon 1 has been reported (International PCT application No. WO 98/13499).

- The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence. An intron may not be a part of the construct. For example, the intron can be positioned
- 30 between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment,

-30-

complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral

5 systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2
10 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an
15 adenovirus TPL nucleotide sequence as described herein.

4. Complementing Plasmids

Also contemplated are the use of nucleic acid molecules, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are
20 used to complement the defective genes of a recombinant adenovirus vector genome, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product encoded by the nucleic acid
25 molecule. Expression cassettes typically contain a promoter and a structural gene operatively linked to the promoter. The complementing plasmid can further include a sequence of nucleotides encoding TPL nucleotide to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

30 A complementing plasmid can include a promoter operatively linked to a sequence of nucleotides encoding an adenovirus structural polypeptide, such as, but are not limited to, penton base; hexon; fiber; polypeptide IIIa; polypeptide V;

-31-

polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid may also include a sequence of nucleotides encoding a first adenovirus regulatory polypeptide, a second regulatory polypeptide, and/or a third regulatory 5 polypeptide, and any combination of the foregoing.

Plasmid pDV80 is a preferred plasmid herein. Other plasmids constructed in an analogous manner to encode modified fiber proteins and chimeric fiber proteins are also contemplated herein.

5. Nucleic Acid Molecule Synthesis

10 A nucleic acid molecule comprising synthetic oligonucleotides can be prepared using any suitable method, such as the phosphotriester or phosphodiester methods (see, e.g., Narang (1979) *et al.*, *Meth. Enzymol.*, 68:90; U.S. Patent No. 4,356,270; and Brown *et al.*, (1979) *Meth. Enzymol.*, 68:109). For oligonucleotides, the synthesis of the family members can be 15 conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected 20 nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected 25 nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants (see, e.g., Ausubel *et al.* (*Current Protocols in 30 Molecular Biology*, Suppl. 8. p.2.11.7, John Wiley & Sons, Inc., New York ,1991).

-32-

Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be
5 found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures
10 are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the
15 preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and
20 ligation, as is well known.

D. Adenovirus Expression Vector Systems

The adenovirus vector genome that is encapsulated in the virus particle and that expresses exogenous genes in a gene therapy setting is a key component of the system. Thus, the components of a recombinant adenovirus
25 vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat
30 containing an adenovirus origin of replication, as is well known and described herein.

-33-

Although adenovirus include many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector). Thus, deletion of the appropriate genes from a recombinant Ad vector permits accommodation of even larger "foreign" DNA segments.

5 A preferred recombinant adenovirus vector genome is "helper independent" so that genome can replicate and be packaged without the help of a second, complementing helper virus. Complementation is provided by a packaging cell.

In a preferred embodiment, the adenovirus vector genome does not
10 encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is
15 referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

Thus, contemplated for use are helper-independent fiberless recombinant adenovirus vector genomes that include genes that (a) express all adenovirus
20 structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contain an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

25 The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

30 A vector herein includes a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, e.g., a gene or polynucleotide, can be operatively linked to bring about replication of the

attached segment. For purposes herein, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule. As noted above, therapeutic nucleic acid molecules include those encoding proteins and also those that encode regulatory factors 5 that can lead to expression or inhibition or alteration of expression of a gene product in a targeted cell.

1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also 10 feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least a portion of a therapeutic nucleotide sequence 15 operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

The choice of viral vector into which a therapeutic nucleic acid molecule is operatively linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, vector replication and protein expression, and 20 the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the use of *any* adenovirus serotype, including hybrids and derivatives thereof are contemplated.

25 A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the 30 nucleic acid material and any polypeptides that are to be inserted into the cell.

-35-

2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector may also include a promoter, particularly a tissue or cell specific promoter, preferably one expressed in ocular cells, particularly photoreceptors.

- 5 Promoters contemplated for use herein include regulatable (inducible) as well as constitutive promoters, which may be used, either on separate vectors or on the same vector. Some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, e.g., International PCT application No. WO
10 96/14061). Preferably the promoter selected is from a photoreceptor-specific gene, such as a rhodopsin gene or gene that encodes a protein that regulates rhodopsin expression.

E. Formulation and administration

- Compositions containing therapeutically effective concentrations of
15 recombinant adenovirus delivery vectors are provided. These are for delivery of therapeutic gene products to cells, particularly cells express a particular 50 kDa receptor or other receptor with which the vectors interact. These cells include cells of the eye and genital tract. Of particular interest are photoreceptor cells of the eye. Administration is effected by any means through which contacting with
20 the photoreceptors is effected. Preferable modes of administration include, but are not limited to, subretinal injection, particularly intravitreal injection, to provide access to photoreceptor cells.

- The recombinant viral compositions may also be formulated for implantation into the anterior or posterior chamber of the eye, preferably the
25 vitreous cavity, in sustained released formulations, such as those adsorbed to biodegradable supports, including collagen sponges, or in liposomes. Sustained release formulations may be formulated for multiple dosage administration, so that during a selected period of time, such as a month or up to about a year, several dosages are administered. Thus, for example, liposomes may be
30 prepared such that a total of about two to up to about five or more times the single dosage is administered in one injection.

-36-

The vectors are formulated in an ophthalmologically acceptable carrier for intraocular, preferably intravitreal, administration in a volume of between about 0.05 ml and 0.150 ml, preferably about 0.05 and 0.100 ml.

- The composition can be provided in a sealed sterile vial containing an amount of a compound of formula I, that upon intraocular administration will deliver a sufficient amount of viral particles to the photoreceptors in a volume of about 50 to 150 μ l, containing at least about 10^7 , more preferably at least about 10^8 plaque forming units in such volume. Typically, the vials will, thus, contain about 0.150 ml of the composition.
- To prepare compositions the viral particles are dialyzed into a suitable ophthalmologically acceptable carrier or viral particles, for example, may be concentrated and/or mixed therewith. The resulting mixture may be a solution, suspension or emulsion. In addition, the viral particles may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active agents for the particular disorder treated.

For administration by intraocular injection or via eyedrops, suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline (PBS), balanced salt solution (BSS), lactate Ringers solution, and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. Suitable ophthalmologically acceptable carriers are known. Solutions or mixtures intended for ophthalmic use may be formulated as 0.01% - 10% isotonic solutions, pH about 5-7, with appropriate salts [see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of ophthalmic irrigation solutions and solutions for local application]. Such solutions, which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium acetate, 10-20 mM D.L.-sodium β -hydroxybutyrate and 5-5.5 mM glucose.

- The compositions may be prepared with carriers that protect them from rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers,
- 5 such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and other types of implants that may be placed directly into the anterior or posterior chamber or vitreous cavity of the eye. The compositions may also be administered in pellets, such as Elvax pellets (ethylene-vinyl acetate copolymer resin).
- 10 Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. For example, liposome formulations may be prepared by methods known to those of skill in the art [see, e.g., Kimm *et al.* (1983) *Bioch. Bioph. Acta* 728:339-398; Assil *et al.* (1987) *Arch Ophthalmol.* 105:400; and U.S. Patent No. 4,522,811]. The viral particles
- 15 may be encapsulated into the aqueous phase of liposome systems.
- The active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action or have other action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON, which is a solution of a high
- 20 molecular weight (MW) of about 3 millions fraction of sodium hyaluronate [manufactured by Pharmacia, Inc; see, e.g., U.S. Patent Nos. 5,292,362, 5,282,851, 5,273,056, 5,229,127, 4,517,295 and 4,328,803], VISCOAT [fluorine-containing (meth)acrylates, such as, 1H,1H,2H,2H-hepta-
- 25 decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751 and 5,214,080; commercially available from Alcon Surgical, Inc.], ORCOLON [see, e.g., U.S. Patent No. 5,273,056; commercially available from Optical Radiation Corporation], methylcellulose, methyl hyaluronate, polyacrylamide and polymethacrylamide [see, e.g., U.S. Patent No. 5,273,751]. The viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%,
- 30 preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues. The compositions may also include a dye, such as

-38-

methylene blue or other inert dye, so that the composition can be seen when injected into the eye. Additional active agents may be included.

The compositions can be enclosed in ampules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material.

- 5 Such enclosed compositions can be provided in kits. In particular, kits containing vials, ampules or other containers, preferably disposable vials with sufficient amount of the composition to deliver about 0.100 ml thereof, and disposable needles, preferably self sealing 25-30 gauge needles, are provided herein.
- 10 Finally, the compounds may be packaged as articles of manufacture containing packaging material, typically a vial, an ophthalmologically acceptable composition containing the viral particles and a label that indicates the therapeutic use of the composition.

Also provided are kits for practice of the methods herein. The kits contain one or more containers, such as sealed vials, with sufficient composition for single dosage administration, and one or more needles, such as self sealing 25-33 gauge needles, preferably 33 gauge or smaller needles, precisely calibrated syringes or other precisely calibrated delivery device, suitable for intravitreal injection.

- 20 Administration of the composition is preferably by intraocular injection, although other modes of administration may be effective, if the sufficient amount of the compound achieves contact with the vitreous cavity. Intraocular injection may be effected by intravitreal injection, aqueous humor injection or injection into the external layers of the eye, such as subconjunctival injection or
- 25 subtenon injection, or by topical application to the cornea, if a penetrating formulation is used.

Administration

- The compositions containing the compounds are administered intraocularly or by other means, such as topically in the form of penetrating eyedrops, whereby contact of the recombinant vectors with the aqueous humor is effected. Intraocular administration may be effected by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as

-39-

subconjunctival injection or subtenon injection, preferably in free form, but, alternatively, in liposomes or other sustained drug delivery device.

Administration is preferably by intravitreal injection, preferably through self sealing 25-30 gauge needles or other suitably calibrated delivery device.

- 5 Injection into the eye may be through the pars plana via the self-sealing needle.

It is further understood that, for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the recombinant viruses, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed methods

- 10 10 forth herein are exemplary only and are not intended to limit the scope or practice of the claimed methods

F. Diseases, Disorders and therapeutic products

1. Disease and disorders

Retinitis pigmentosa

- 15 Methods for specifically or selectively targeting recombinant adenovirus vectors for delivery of gene products, particularly therapeutic products are provided herein. These methods are particularly suitable for targeting cells that express receptors that are selectively recognized by Ad virus of subgroup D viruses, particularly Ad37. It is shown herein that these viruses selectively recognize receptors on cells, such as conjunctival cells and photoreceptors, that are not recognized by other adenoviruses. Hence, methods for targeting to these cell types by providing vectors that are packaged in viral particles that contain a sufficient portion of a fiber protein from one of these Ad serotypes to bind to these receptors. These methods are useful for targeting to 20 photoreceptors and for treating ocular disorders, including, but are not limited to, inherited and acquired retinal, neovascular degenerative diseases (see table 25 below).

- It is estimated that 1 in 3,500 individuals in the United States suffer from one of the pigmented retinopathies. This group of retinal diseases, commonly 30 called retinitis pigmentosa, is characterized by progressive loss of peripheral and night vision. Patients may be affected at almost any age and it is not uncommon to experience symptoms in early childhood in certain inherited forms.

-40-

- It has been shown that there are a variety of mutations in genes expressed in the photoreceptors, including genes in the rhodopsin gene and pathway that appear to be responsible for these diseases. In addition to mutations in rhodopsin, changes in the retinal pigmented epithelial (RPE) cells, also undergo
- 5 degenerative changes and can form clumps of pigment that give rise to the characteristic pigmentary changes seen in patients with RP.

Angiogenesis and ocular diseases and disorders

- The vast majority of diseases that cause catastrophic loss of vision do so as a result of ocular neovascularization; age related macular degeneration
- 10 ARMD affects 12-15 million American over the age of 65 and causes visual loss in 10-15% of them as a direct effect of choroidal (sub-retinal) neovascularization. The leading cause of visual loss for Americans under the age of 65 is diabetes; 16 million individuals in the United States are diabetic and 40,000 per year suffer from ocular complications of the disease, which often are
- 15 a result of retinal neovascularization. Laser photocoagulation has been effective in preventing severe visual loss in subgroups of high risk diabetic patients, but the overall 10 year incidence of retinopathy remains essentially unchanged. For patients with choroidal neovascularization due to ARMD or inflammatory eye disease, such as ocular histoplasmosis, photocoagulation, with few exceptions,
- 20 is ineffective in preventing visual loss. While recently developed, non-destructive photodynamic therapies hold promise for temporarily reducing individual loss in patients with previously untreatable choroidal neovascularization, only 61.4% of patients treated every 3-4 months had improved or stabilized vision compared to 45.9% of the placebo-treated group.
- 25 In the normal adult, angiogenesis is tightly regulated and limited to wound healing, pregnancy and uterine cycling. Angiogenesis is turned on by specific angiogenic molecules such as basic and acidic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiogenin, transforming growth factor (TGF), tumor necrosis factor- α (TNF- α) and platelet derived growth factor
- 30 (PDGF). Angiogenesis can be suppressed by inhibitory molecules such as interferon- α , thrombospondin-1, angiostatin and endostatin. It is the balance of these naturally occurring stimulators and inhibitors that controls the normally

-41-

quiescent capillary vasculature. When this balance is upset, as in certain disease states, capillary endothelial cells are induced to proliferate, migrate and ultimately differentiate.

Angiogenesis plays a central role in a variety of diseases, including, but 5 are not limited to, cancer and ocular neovascularization. Sustained growth and metastasis of a variety of tumors has also been shown to be dependent on the growth of new host blood vessels into the tumor in response to tumor derived angiogenic factors. Proliferation of new blood vessels in response to a variety of stimuli occurs as the dominant finding in the majority of eye diseases that blind, 10 such as, but are not limited to, proliferative diabetic retinopathy (PDR), ARMD, rubeotic glaucoma, interstitial keratitis and retinopathy of prematurity. In these diseases, tissue damage can stimulate release of angiogenic factors resulting in capillary proliferation. VEGF plays a dominant role in iris neovascularization and neovascular retinopathies. While reports clearly show a correlation between 15 intraocular VEGF levels and ischemic retinopathic ocular neovascularization, FGF likely plays a role. Basic and acidic FGF are known to be present in the normal adult retina, even though detectable levels are not consistently correlated with neovascularization. This may be largely due to the fact that FGF binds very tightly to charged components of the extracellular matrix and may not be readily 20 available in a freely diffusible form that would be detected by standard assays of intraocular fluids.

A final common pathway in the angiogenic response involves integrin-mediated information exchange between a proliferating vascular endothelial cell and the extracellular matrix. This class of adhesion receptors, called integrins, 25 are expressed as heterodimers having an α and β subunit on all cells. One such integrin, $\alpha_v\beta_3$, is the most promiscuous member of this family and allows endothelial cells to interact with a wide variety of extracellular matrix components. Peptide and antibody antagonists of this integrin inhibit angiogenesis by selectively inducing apoptosis of the proliferating vascular 30 endothelial cells. Two cytokine-dependent pathways of angiogenesis exist and may be defined by their dependency on distinct vascular cell integrins, $\alpha_v\beta_3$ and $\alpha_v\beta_5$. Specifically, basic FGF- and VEGF-induced angiogenesis depend on integrin

-42-

- $\alpha_v\beta_3$ and $\alpha_v\beta_5$, respectively, since antibody antagonists of each integrin selectively block one of these angiogenic pathways in the rabbit corneal and chick chorioallantoic membrane (CAM) models. Peptide antagonists that block all α_v integrins inhibit FGF- and VEGF-stimulated angiogenesis. While normal
- 5 human ocular blood vessels do not display either integrin, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins are selectively displayed on blood vessels in tissues from patients with active neovascular eye disease. While only $\alpha_v\beta_3$ was consistently observed in tissue from patients with ARMD, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ were present in tissues from patients with PDR. Systemically administered peptide antagonists of integrins blocked
- 10 new blood vessel formation in a mouse model of retinal vasculogenesis.

In addition to adhesion events described above, cell migration through the extracellular matrix also depends on proteolysis. Matrix metalloproteinases are a family of zinc-requiring matrix-degrading enzymes that include the collagenases, gelatinases and stromelysins, all of which have been implicated in invasive cell behavior. Invasive cell processes such as tumor metastasis and angiogenesis have been found to be associated with the expression of integrins and MMP-2, MMP-2 are all found throughout the eye where they may interact to maintain a quiescent vasculature until the balance is upset, resulting in pathological angiogenesis. A non-catalytic C-terminal hemopexin-like domain of MMP-2 (PEX) can block cell surface collagenolytic activity and inhibit angiogenesis in the CAM model by preventing localization of MMP-2 to the surface of invasive cells through interaction with the integrin $\alpha_v\beta_3$.

Hence, anti-angiogenic agents have a role in treating retinal degeneration to prevent the damaging effects of these trophic and growth factors.

- 25 Angiogenic agents, also have a role in promoting desirable vascularization to retard retinal degeneration by enhancing blood flow to cells.

Members of adenovirus subgroup D, Ad8, 19A, and 37, are infectious agents that cause particularly severe cases of epidemic keratoconjunctivitis (EKC) (Arnberg *et al.* (1998) *Virology* 227:239-244; Curtis *et al.* (1998)

- 30 *J.Med.Microbiol.* 47:91-94; Ritterband *et al.* (1998) *Rev.Med.Viro.* 8:187-201; and Takeuchi *et al.* (1999) *J.Clin.Microbiol.* 37:3392-3394). There is no effective treatment for this debilitating and contagious disease and EKC

-43-

continues to be a problem in ophthalmology clinics worldwide (Curtis *et al.* (1998) *J.Med.Microbiol.* 47:91-94, Lukashok *et al.* (1998) *Curr.Clin.Top.Infec.Dis.* 18:286-304). Hence the vectors herein may be used for treating the disease.

5

Table 3
Candidate targets for ocular disease therapy

CANDIDATE TARGETS FOR OCULAR DISEASE THERAPY	
Disease	Candidate target(s)
Retinitis pigmentosa	Rhodopsin gene, and genes that regulate expression thereof <i>rds</i> /peripherin
Stargardt's disease	rim protein (ARC protein)
Choroideremia	rab geranylgeranyl transferase CHM, TCD, CHML*
Gyrate Atrophy	ornithine aminotransferase
Macular dystrophy	<i>rds</i> /peripherin

15

* see, "MSR6-yeast homologue of the choroideraemia gene," Nature Genetics 3: 193-4 (1993)

TABLE 4

Other Diseases	
Exudative Choroidal Diseases	
	ICSC, fluorescein angiogram
	ICSC with large serious detachment of RPE (retinal pigmented epithelium)
	ICSC with bullous retinal detachment
	Macular drusen, exudative, confluent
20	Drusen, sub-RPE choroidal neovascularization
25	Drusen, notched serous detachment of RPE

-44-

Other Diseases	
	Drusen, notched serous and hemorrhagic detachment of RPE
	Drusen, serous and hemorrhagic detachment of RPE and retina
	Drusen, organized RPE detachment causing bullous retinal detachment
	Drusen, geographic atrophy of RPE
5	Drusen, exudative and cuticular, vitelliform macular detachment
	Drusen, cuticular, large vitelliform macular detachment
	North Carolina dystrophy with macular staphyloma
	North Carolina dystrophy with macular staphyloma
	Angioid streaks, pseudoxanthoma elasticum (PXE), CNVM
10	Angioid streaks, PXE, large notched retinal detachment
	Myopic degeneration, Foerster-Fuchs spot
	Presumed ocular histoplasmosis syndrome (POHS)
	Submacular bacterial abscess
	<i>Toxocara canis</i> , subretinal granuloma
15	Serpiginous (geographic) choroiditis
	Posterior scleritis
	Harada's disease
	Posterior sympathetic uveitis
	Benign reactive lymphoid hyperplasia of uveal tract
20	Choroidal ruptures and CNVM
	Cavernous hemangioma of choroid
	Choroidal osteoma
	Choroidal nevus, serous macular detachment
	Choroidal nevus with CNVM
25	Diffuse sclerochoroidal melanocytic nevus
	Choroidal melanoma with serous detachment of RPE
	Metastatic lung carcinoma to choroid
	Sub-RPE reticulum cell sarcoma

-45-

Other Diseases	
RPE tear, idiopathic choroidal neovascularization	
Heredodystrophic Disorders Affecting RPE & Retina	
5	Best's vitelliform macular dystrophy
	Best's vitelliform macular dystrophy with CNVM
	Best's vitelliform macular dystrophy, multiple lesions
	Adult-onset vitelliform foveomacular dystrophy
	Pattern dystrophy simulating fundus flavimaculatus
	Stargardt's disease (fundus flavimaculatus)
	Asteroid macular dystrophy
10	Sjögren-Larsson syndrome
	Oguchi's disease, light-adapted state
	Oguchi's disease, dark-adapted state
	Fundus albipunctatus
	Retinitis pigmentosa, cystoid macular edema
15	Crystalline tapetoretinal dystrophy
	Choroideremia
	Goldmann-Favre syndrome
	Sex-linked juvenile retinoschisis
	Perivenous retinitis pigmentosa
Retinal Vascular Disorders	
20	
	Retinal arteriovenous aneurysm
	Central retinal artery occlusion
	Cilioretinal artery obstruction
	Ischemic retinopathy in systemic lupus erythematosus
25	Ischemic retinopathy in scleroderma
	Hemorrhagic detachment of internal limiting membrane, hypertensive retinopathy
	Acquired retinal arterial macroaneurysm

-46-

Other Diseases	
	Cystoid macular edema, aphakic
	Cystoid macular edema, nicotinic acid maculopathy
	Congenital retinal telangiectasis
	Acquired bilateral juxtafoveal telangiectasis
5	Acquired bilateral juxtafoveal obliterative telangiectasis
	Diabetic optic neuropathy
	X-ray radiation exudative retinopathy
	Sickle cell SC disease, macular hemorrhage
	Retinal arterial aneurysms, arteritis, neuroretinitis
10	Branch retinal vein obstruction (BRVO)
	BRVO, exudative maculopathy
	BRVO, optic disc new vessels, photocoagulation
	Waldenström's macroglobulinemia
Inflammatory Diseases of the Retina and Choroid	
15	Luetic retinal vasculitis
	Focal <i>Candida</i> retinal abscess
	Toxoplasmosis, atrophic chorioretinal scar
	Toxoplasmosis retinitis and macular detachment
	Toxoplasmosis scar, CNVM, macular detachment
20	Diffuse unilateral subacute neuroretinitis, small worm
	Diffuse unilateral subacute neuroretinitis, large worm
	Cytomegalic inclusion disease, papillitis
	Acute posterior multifocal placoid pigment epitheliopathy
	Acute macular neuroretinitis
25	Sarcoid retinitis
	Sarcoid papillitis
	Behcet's disease
	Vitiliginous (bird-shot) chorioretinitis

Other Diseases		
Multifocal choroiditis and panuveitis (pseudo-POHS)		
Retinal and Pigment Epithelial Hamartomas		
Congenital grouped albinotic RPE spots		
Congenital hyperplasia of RPE		
5	Combined RPE and retinal hamartoma, juxtapapillary	
	Combined RPE and retinal hamartoma, peripheral	
	Cystic astrocytoma, juxtapapillary	
	Astrocytoma, macula	
	Astrocytoma, juxtapapillary	
10	Cavernous hemangioma of retina	
	Juxtapapillary sessile retinal capillary hemangioma	
	Juxtapapillary endophytic retinal capillary hemangioma	
Other Tumors of the Choroid		
Choroidal metastasis		
15	Choroidal osteoma	
	Choroidal hemangioma	
	Miscellaneous uveal tumors	
Intraocular Lymphoid Tumors		
The leukemias and lymphomas		
20	Tumors of the Vitreous	
	Non-Hodgkins ("reticulum cell") lymphoma	
	Tumor involvement of the vitreous cavity	
Macular Disease		
Age-related macular degeneration -- atrophic form		
25	Exudative age-related macular degeneration	
	Choroidal neovascular membrane in degenerative myopia	
	Central serous retinopathy	
	Macular hole	

Other Diseases	
	Macular dystrophies
	Retinal Vascular Disease
	Etiologic mechanisms in diabetic retinopathy
	Background diabetic retinopathy
5	Proliferative diabetic retinopathy
	Retinal arterial obstructive disease
	Central retinal vein occlusion
	Retinal branch vein occlusion
	Pregnancy and retinal disease
10	Pregnancy-induced hypertension
	Hypertension
	The rheumatic disease
	Parafoveal telangiectasis
	Coats disease
15	Disseminated intravascular systemic coagulopathy and related vasculopathies
	Hemoglobinopathies
	Retinopathy of prematurity
	Acquired retinal macroaneurysms
	Eales disease
20	Radiation retinopathy
	The ocular ischemic syndrome
	Inflammatory Disease
	Ocular toxoplasmosis
	Ocular toxocariasis
25	Ocular cysticercosis
	Cytomegalovirus infections of the retina
	Retinal and ophthalmologic manifestations of AIDS
	Acute retinal necrosis syndrome

-49-

Other Diseases	
	Endogenous fungal infections of the retina and choroid
	Pars planitis
	Syphilis and tuberculosis
	Diffuse unilateral subacute neuroretinitis
5	Scleritis
	Birdshot retinochoroidopathy
	Punctate inner choroidopathy
	Sarcoidosis
	Acute multifocal placoid pigment epitheliopathy
10	Geographic helicoid peripapillary choroidopathy (GHPC): serpiginous choroiditis
	Sympathetic ophthalmia
	Vogt-Koyanagi-Harada syndrome (uveomeningitic syndrome)
	Ciliochoroidal (uveal) effusion
15	Reproduced from: Stereoscopic Atlas of Ocular Diseases Diagnosis and Treatment, 2nd Edition, J. Donald O. Gass, Vol. 1 & 2, C.V. Mosley Co. (1987); and Retina Vol. II, Editor, Stephen J. Ryan, Medical Retina, C.V. Mosley Co. (1989).

20 2. Therapeutic products

Therapeutic products include but are not limited to, wild-type genes that are defective in ocular disorders, such as rhodopsin, or fragments thereof sufficient to correct the genetic defect, trophic factors, including growth factors, inhibitors and agonists of trophic factors, anti-apoptosis factors and other products described herein or known to those of skill in the art to be useful for treatment of disorders of the eye or that can be treated by a product expressed by a photoreceptor.

OCULAR GENE THERAPY STRATEGIES		
GENERAL DISEASE	EXAMPLES	STRATEGY

-50-

OCULAR GENE THERAPY STRATEGIES		
Hereditary retinal and macular degeneration	<ul style="list-style-type: none"> • Retinitis pigmentosa • Stargardt's disease • Other macular dystrophies 	Growth factors (e.g., GDNF) anti-apoptotic factors (e.g., bcl2 gene) Stargardt Disease Gene (ABCR) [†]
Neovascular	<ul style="list-style-type: none"> • Diabetes • Choroidal neovascularization 	Anti-angiogenesis factors
Anti-tumor	Retinoblastoma	Antiproliferant
Glaucoma	Nerve fiber layer atrophy	Neuroprotective agent

[†] See Allikmets *et al.* (1997) *Science* 277:1805-1807.

For example, for treatment of retinitis pigmentosa the adenovirus vector can deliver a wild-type rhodopsin gene or a growth factor or trophic factor, such as ciliary neurotrophic factor CNTF; for treatment of Stargardt's disease, the vector can deliver a wild type ABCR (also called STGD1) or a growth factor or anti-angiogenic agent; for diabetic retinopathies, retinal vascularization the vector can deliver growth factors, such as a TGF (TGF β), to prevent degeneration.

15 The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Adenovirus Packaging Cell Lines

Cell lines that are commonly used for growing adenovirus are useful as host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and other epithelial-derived cell lines. As a result of the adenovirus transformation, the

-51-

293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

These cell lines allow the production and propagation of adenovirus-based gene delivery vectors that have deletions in preselected gene regions and that
5 are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a viral vector, plasmid vectors that contain preselected functional units have been designed. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such
10 complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit that is
15 alternately spliced to produce several different mRNA products. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcription unit. A DNA fragment extending from 175 nucleotides upstream of the E4 transcription start site including the natural E4 promoter to 153 nucleotides downstream of the E4
20 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Virol.*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of
25 the primers used were 5'CGGTACACAGAATTCAGGAGACACAACTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGAAAAC3' (SEQ ID NO: 2)
(backward or 3' primer referred to as E4R). To facilitate cloning of the PCR
30 fragment, these oligonucleotides were designed to create new sites for the restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute,

-52-

50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment.

The isolated BamHI-modified fragment was then cloned into the BamHI site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp. The pE4/Hygro plasmid has been deposited with the ATCC under accession number 97739. The complete nucleotide sequence of pE4/Hygro is set forth in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACCGCGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also

-53-

contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites 5 of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

10 The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter 15 provided by the pcDNA vector, a BgIII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral 20 mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-25 7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is included in SEQ ID NO: 8 bordered by BamHI/BgIII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial 30 TPL is also listed separately as SEQ ID No. 22 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt BgIII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1);

-54-

28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BgIII site.

The pCLF plasmid has been deposited with the ATCC as described in

- 5 Example 4. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA.

10 C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins

The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*, 15 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10⁶ cells were electroporated with 20 µg each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 µF. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).

Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200 µg/ml Hygromycin B (Sigma, St. Louis, MO).

From expanded colonies, genomic DNA was isolated using the 25 "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near adenovirus 5 open reading frame 6.

30 One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the product, indicating the presence of inserted DNA corresponding to most, if

-55-

not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 4. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected.

- 5 Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell
10 line, the labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event.

Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211
15 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211
20 clone was expanded by growing in RPMI medium and subjected to additional electroporation with the fiber-encoding pCLF plasmid as described above.

Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 µg/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate sublines of 211 were then screened for fiber protein expression by indirect
25 immunofluorescence as described above. The three sublines screened, 211A, 211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSV β gal (1 pfu/cell) and stained 24 hours post-infection.

Lines positive for nuclear staining in this assay were then subjected to
30 Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the predicted molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including

-56-

211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 4.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a seminative electrophoresis system demonstrated that the 5 fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein. The predicted molecular weight of a trimerized fiber is 186 kd. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in 10 complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses

In order to prepare adenoviral packaging cell lines other than those based 15 on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers 20 used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and XhoI as indicated by the underlines. The sites are used 25 to clone the amplified E1 gene fragment into the NheI/XhoI sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides 30 from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the

pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the *E. coli gpt* gene that allows stable transfecants to be isolated using hypoxanthine/amino-pterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide 5 positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C, 10 alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following 15 transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R , as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber 20 antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in 30 various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for

use in generating recombinant adenovirus viral vectors thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

5 **1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes**

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer 5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the 10 nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAACCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector 15 is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides dexamethasone-inducible E1 function as described for 20 DEX/E1 and expression of Ad5 fiber protein as described above.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998 25 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more 30 delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions preformed as

-59-

previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes

5 Plasmid pCLF prepared as described in Example 1B is partially digested with BgIII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber
10 gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4
15 gene are located at respective nucleotide positions 21 and 3149 followed by fused BgIII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BgIII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BgIII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide
20 positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

EXAMPLE 2

Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines

25 Adenoviral delivery vectors are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector is replication competent but only via a
30 non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, these adenovirus delivery vectors have a higher capacity for insertion of foreign DNA.

-60-

A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use

To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid p Δ

5 E1B β gal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli* β -galactosidase gene was isolated from pSV β gal (Promega) by digesting with Vspl, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with Bam H1. The resulting fragment was cloned into the EcoRV and BamHI

10 sites in the polylinker of p Δ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form p Δ E1B β gal that therefore contained the left end of the adenovirus genome with the Ela region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSV β gal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the

15 Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)

20 The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994) (see, also International PCT application No. WO 95/00655) using methods well known to one of skill in the art. This vector is also commercially available from Microbix and contains an Ad5 genome

25 with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme PacI. An 11.9 kb BamHI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the BamHI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. The p11.3

30 plasmid was then digested with PacI and Sall to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

-61-

This fragment was replaced with a 3,4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences:

5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17; and

5 5'CACAACGAGCTC AATTAATTGCCACATCCTC3' SEQ ID NO: 18.

These primers incorporated sites for Pael and BamHI. Cloning this fragment into the Pael and blunt ended Sall sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resulting p11.3 plasmid containing the ITR 10 and E4 regions, designated plasmid pDV43a, was then digested with BamHI. This BamHI fragment was then used to replace a BamHI fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the

15 following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb BamHI fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3.

20 The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a Sall restriction site. pDV42 was then digested with Pael,

25 which cuts at a unique site (**bold type**) in one of the PCR primers, and with Sall, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding Pael/Xhol fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique Xhol site), creating pDV43.

30 A plasmid designated pDV44 was constructed by replacing the 11.9 kb BamHI fragment of pBHG10 by the analogous BamHI fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the

-62-

deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was

- 5 constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10. pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Plasmids pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection
10 and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with pΔE1Bβgal, which contains the left end of the Ad5 genome with an SV40-driven β-galactosidase reporter gene inserted in place of the E1 region.

- 15 In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences
20 corresponding to viral gene delivery vectors.

- A selected cell line is plated in dishes and cotransfected with pDV44 and pΔE1Bβ gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a
25 full-length viral chromosome where pDV44 and pΔE1Bβ gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of
30 the recombinant virus are produced by standard methods.

Because of the fiber deletion, a pDV44-derived virus is replication-defective, cells in which it is grown must complement this defect.

-63-

The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 4) was used for rescue and propagation of the virus described here. pDV44 and pΔE1βgal were cotransfected into 211B cells, and the monolayers 5 were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

One of a total of 58 transfected dishes showed evidence of spreading cell 10 death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5.βgal.ΔF) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B cells were plated in DMEM plus 10% fetal calf serum at approximately 1×10^7 15 cells/150 cm² flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5.βgal.ΔF, at approximately 100 particles/cell. At day two, an equal volume of medium was added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis 20 via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C. Purified Ad5.βgal.ΔF virus particles containing human adenovirus Ad5.βgal.ΔF genome (described 25 further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 4.

For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at 1.5×10^6 cells/well. Duplicate dilutions of 30 virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C, virus was removed and the wells overlaid with 2

-64-

ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. β gal.wt, which is identical to Ad5. β gal. Δ F except for the fiber deletion, was constructed by cotransfection of 5 pBHG10 and p Δ E1B β gal. In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p Δ E1B β gal and pBHG10 produced virus.

In another embodiment, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector 10 having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to 15 prepare a viral vector lacking fiber. For genetic therapy, the fiber gene can be replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Methods for producing a fiberless vector with a complete TPL are described in Example 3.

Vectors for the delivery of any desired gene and preferably a therapeutic 20 gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p Δ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing pE1B β gal as described above. The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later 25 Examples.

1. Characterization of the Ad5. β gal. Δ F Genome

To confirm that the vector genomes had the proper structures and that the fiber gene was absent from the Ad5. β gal. Δ F chromosome, the DNA isolated 30 from viral particles was analyzed. Briefly, purified viral DNA was obtained by adding 10 μ l of 10 mg/ml proteinase K, 40 μ l of 0.5 M EDTA and 50 μ l of 10% SDS to 800 μ l of adenovirus-containing culture supernatant. The suspension

-65-

was then incubated at 55°C for 60 minutes. The solution was then extracted once with

400 µl of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was

- 5 washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 µl of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from Ad5.βgal.wt and Ad5.βgal.ΔF produced the expected restriction patterns following digestion with either EcoRI or with NdeI. Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the
10 presence of fiber sequence in Ad5.βgal.wt but not in Ad5.βgal.ΔF DNA. As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. E4 signal was readily detectable in both genomes at equal intensities. The complete nucleotide sequence of Ad5.βgal.ΔF is presented
15 in SEQ ID NO: 23 and is contained in the virus particle on deposit with ATCC.

2. Characterization of the Fiberless Adenovirus Ad5.βgal.ΔF

To verify that Ad5.βgal.ΔF was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5.βgal.ΔF or with Ad5.βgal.wt. Twenty-four hours post

- 20 infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5.βgal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

25 3. Growth of the Fiber-Deleted Ad5.βgal.ΔF Vector in Complementing Cells

Ad5.βgal.ΔF was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5.βgal.ΔF or Ad5.βgal.wt contained similar numbers of viral particles. The particles appeared

- 30 to band normally on CsCl gradients. Infectivity of the Ad5.βgal.ΔF particles was lower than the Ad5.βgal.wt control, as indicated by an increased particle/PFU ratio. Ad5.βgal.ΔF was also found to plaque more slowly than the control

-66-

virus. When plated on 211B cells, Ad5. β gal.wt plaques appeared within 5-7 days, while plaques of Ad5. β gal. Δ F continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5. β gal. Δ F plaques was essentially normal.

5 **4. Production of Fiberless Ad5. β gal. Δ F Particles**

As Ad5. β gal. Δ F represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the 10 determination of whether such particles would be stable and/or infectious. Either Ad5. β gal.wt or Ad5. β gal. Δ F was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5. β gal. Δ F particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating 15 that there was not a gross defect in morphogenesis of fiberless capsids.

Particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. The Ad5. β gal. Δ F particles produced in 293 cells did not contain fiber protein. 20 211B-grown Ad5. β gal. Δ F also contained less fiber than the Ad5. β gal.wt control virus. The infectivities of the different viral preparations on epithelial cells correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5. β gal. Δ F was only 25 50-100 fold less than that of Ad5. β gal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

5. **Composition and Structure of the Fiberless Ad5. β gal. Δ F Particles**

The proteins contained in particles of 293-grown Ad5. β gal. Δ F were 30 compared to those in Ad5. β gal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant. The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a

-67-

first-generation vector, with the exception of reduced intensity of the composite band resulting from proteins IIIa and IV (fiber). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the
5 low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5. β gal. Δ F and of Ad5 β gal.wt. The fiber, having an extended stalk with a knob at the end, was faintly visible in favorable
10 orientations of wild-type Ad5 particles, but not in images of the fiberless particles. Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

Three-dimensional image reconstructions of fiberless and wild-type
15 particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components
20 into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base
25 around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

6. Integrin-Dependent Infectivity of Fiberless Ad5. β gal. Δ F Particles

30 While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates

-68-

binding to the cells (via β 2 integrins) and internalization (through interaction with α v integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial

5 cells.

To investigate this, THP-1 monocytic cells were infected with Ad5. β gal.wt or with Ad5. β gal. Δ F grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2×10^5 cells at the indicated m.o.i. in 0.5 ml of complete RPMI. Forty-eight hours post-infection, the cells were fixed with 10 glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy. The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells. Large differences were seen in plaquing efficiency on epithelial (211B) cells. Infection of THP-1 cells by either Ad5. β gal. Δ F or 15 Ad5. β gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5. β gal Δ F from internalizing into the cells and delivering its genome to the 20 nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the 25 effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells 30 which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the

-69-

standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T lymphocytes directed against the vector, and the nature and magnitude of the 5 antibody response directed against viral proteins.

Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression. Following this evaluation, they are used as experimental therapeutic 10 agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins

As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber 15 proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.

Chimeric fiber proteins can be produced according to known methods 20 (see, e.g., Stevenson *et al.* (1995) *J. Virol.*, 69:2850-2857). Determinants for fiber receptor binding activity are located in the head domain of the fiber and an isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order 25 to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods herein are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in above and in U.S. application Serial No. 09/482,682) as a complementing viral vector in adenoviral packaging cells, the constructs described herein are used to transfect cells along with E4 and/or E1-encoding constructs.

30 Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotide sequences are available with the respective GenBank Accession Numbers

-70-

- M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for 5 cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

The resulting products are then used to construct chimeric fiber constructs by PCR gene overlap extension (Horton *et al.* (1990) *BioTechniques*, 8:525-535). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region 10 encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region 15 encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1. 20 The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as 25 previously described. Other fiber chimeric constructs are obtained with the various adenovirus serotypes using a similar approach.

In an alternative embodiment, the use of modified proteins including with modified epitopes (see, e.g., Michael *et al.* (1995) *Gene Therapy*, 2:660-668 and International PCT application Publication No. WO 95/26412, which describe 30 the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity). In particular, the authors described the

-71-

production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following
5 synthesis.

Similar constructs are contemplated for use in the complementing adenoviral packaging cell systems for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic.

Heterologous ligands contemplated for use herein to redirect fiber specificity
10 range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or
15 those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end using routine procedures known to those of skill in the art. The skilled artisan will be with the preparation of linkers to accomplish sufficient protein
20 presentation and to alter the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this disclosure, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

25

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example
30 1.

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20)

-72-

followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The 5 resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral 10 vector packaging systems.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously 15 described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber 20 protein relevant for the purpose at hand. As the only fiber gene present is the one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

EXAMPLE 3

25 Tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector are provided. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5 30 genomic DNA using the synthetic oligonucleotide primers
5'CTCAACAATTGTGGATCCGTACTCC3' (SEQ ID No. 24) and
5'GTGCTCAGCAGATCTTGCAGTGTG3' (SEQ ID No. 25). The resulting

-73-

- product was cloned to the BamHI and BgIII sites of pΔE1Sp1a (Microbix Biosystems) using sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then 5 amplified using primers 5'GGCGCGTTCGGATCCACTCTCTTCC3' (SEQ ID No. 26) and 5'CTACATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID No. 27), and cloned into the BamHI site of pDV52 (again using sites in the primers) to create pDV55.

This plasmid contains a 1.2 kb BamHI/BgIII fragment containing the first 10 TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID No 28 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2); 15 1141-1146 nt fused BamHI and BgIII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BgIII site.

EXAMPLE 4

Deposit of Materials

The following cell lines and plasmids were deposited on September 25, 20 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty):Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737), 25 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5.βgal.ΔF, was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were 30 deposited at the ATCC on January 5, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

-74-

EXAMPLE 5

Preparation and Use of Adenoviral Packaging Cell Lines Containing Plasmids Containing Alternative TPLs

Plasmids containing tripartite leaders (TPLs) have been constructed. The 5 resulting plasmids that contain different selectable markers, such as neomycin and zeocin, were then used to prepare fiber-complementing stable cell lines for use as for preparing adenoviral vectors.

A. pDV60

Plasmid pDV60 was constructed by inserting this TPL cassette of SEQ ID 10 No. 28 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a neomycin selectable plasmid (see, e.g., U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000); see also Von Seggern *et al.* (1998) *J. Gen Virol.*, 79: 1461-1468). The nucleotide sequence of pDV60 is 15 listed in SEQ ID NO: 29. Plasmid pDV60 has been deposited in the ATCC under accession number PTA-1144.

B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone 20 terminator was transferred from pCLF (ATCC accession number 97737; and described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000);), to a zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially available from Invitrogen and for which the sequence is known).

C. pDV67

In an analogous process, pDV67 containing complete TPL was constructed by transferring an Asp 718/XbaI fragment from pDV60 into pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is set forth in

-75-

SEQ ID No. 30. Plasmid pDV67 is available from the ATCC under accession number PTA-1145.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric

- 5 Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.* (1995) *J. Virol.*, 69: 2850-2857) using the primers 5'ATGGGAT
CAAGATGAAGCGCGCAAGACCG3' (SEQ ID No. 31) and
5'CACTATAAGCGGCCGCATTCTCAGTCATCTT3' (SEQ ID No. 32), and cloned to
the BamHI and NotI sites of pcDNA3.1/Zeo(+) via new BamHI and NotI sites
10 engineered into the primers to create pDV68. Finally, the complete TPL
fragment described above was then added to the unique BamH1 site of pDV68
to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID No. 33
and has been deposited in the ATCC under accession number PTA-1146.

E. Preparation of Stable Adenovirus Packaging Cell Lines

- 15 E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC #
CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also
referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 34) and
pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in
SEQ ID No. 35), which provide complementation of the adenoviral E1 and E2a
20 functions, respectively. This line and its derivatives were grown in Richter's
modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were
electroporated as previously described (Von Seggern *et al.* (1998) *J. Gen Virol.*,
79: 1461-1468) with pDV61, pDV67, or with pDV69, and stable lines were
selected with zeocin (600 µg/ml).

- 25 The cell line generated with pDV61 is designated 601. The cell line
generated with pDV67 is designated 633 while that generated with pDV69 is
designated 644. Candidate clones were evaluated by immunofluorescent
staining with a polyclonal antibody raised against the Ad2 fiber. Lines
expressing the highest level of fiber protein were further characterized.

- 30 For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM
of dexamethasone was added to cell cultures 16-24 hours prior to challenge
with virus for optimal growth kinetics. For preparing viral plaques, 5 X 10⁵

-76-

cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone the day prior to infection with 0.5 μ M included at a final concentration in the agar overlay after infection.

F. Development of Cell Lines for Complementation of E1⁻/E2a⁻ Vectors

5 The Adenovirus 5 genome was digested with Scal enzyme, separated on an agarose gel, and the 6,095 bp fragment containing the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A.,
10 under accession number VR-5. The Scal 6,095 bp fragment was digested further with Clal at bp 917 and BgIII at bp 3,328. The resulting 2,411 bp Clal to BgIII fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with Clal and BgIII, to form pSE280-E.

15 Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an Xhol and Sall restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:

5' end, Ad5 bp 552-585:

5'-GTCACTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATGCCACCGA

20 CC-3' (SEQ ID No 36)

3' end, Ad5 bp 922-891:

5'-CGAGATCGATCACCTCCGGTACAAGGTTGGCATAG-3' (SEQ ID No. 37)

25 This amplified DNA fragment (sometimes hereinafter referred to as Fragment A) then was digested with Xhol and Clal, which cleaves at the native Clal site (bp 917), and ligated to the Xhol and Clal sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.

30 PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an EcoRI restriction site. The primers which were employed were as follows:

5' end, Ad5 bp 3323-3360:

-77-

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID No. 38);

and

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC

5 -3' (SEQ ID No. 39).

This amplified DNA fragment (sometimes hereinafter referred to as Fragment B) was digested with BgIII, thereby cutting at the Adenovirus 5 BgIII site (bp 3,382) and EcoRI, and ligated to the BgIII and EcoRI sites of pSE280-AE to reconstruct the complete E1a and E1b region from Adenovirus 5 bp 552

10 through 4,090. The resulting plasmid is designated pSE280-E1.

A construct containing the intact E1a/b region under the control of the synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was excised from pSE280-E1, which was modified previously to contain a BamHI site 3' to the E1 gene, by digesting with Xhol and BamHI. The Xhol to BamHI

15 fragment containing the E1a/b fragment was cloned into the unique Xhol and BamHI sites of pGRE5-2/EBV (U.S. Biochemicals, Cleveland, Ohio) to form pGRE5-E1).

Bacterial transformants containing the final construct were identified.

Plasmid DNA was prepared and purified by banding in CsTFA prior to use for

20 transfection of cells.

Construction of plasmid including Adenovirus 5 E2A sequence.

The Adenovirus 5 genome was digested with BamHI and Spel, which cut at bp 21,562 and 27,080, respectively. Fragments were separated on an

agarose gel and the 5,518 bp BamHI to Spel fragment was isolated. The 5,518

25 bp BamHI to Spel fragment was digested further with SmaI, which cuts at bp 23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI.

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site

30 at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites.

The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

-78-

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID No. 40);

3' end, Ad5 bp 23,912-23,934:

5'-CACCCCCGGGGAGGC GGCG CGAC GGGG AC GGG-3' (SEQ ID No. 41)

This amplified DNA fragment was digested with SmaI and EcoRI, and
5 ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the
complete E2a region from Ad5 bp 24,730 through 21,562. The resulting
construct is pSE280-E2a.

In order to convert the BamHI site at the 3' end of E2a to a Sall site, the
E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and
10 recloned into the unique BamHI and NheI sites of pSE280. Subsequently, the
E2a region was excised from this construction with NheI and Sall in order to
clone into the NheI and Sall sites of the pMAMneo (Clonetech, Palo Alto, CA)
multiple cloning site in a 5' to 3' orientation, respectively. The resulting
construct is pMAMneo E2a.

15 Bacterial transformants containing the final pMAMneo-E2a were
identified. Plasmid DNA was prepared and purified by banding in CsTFA.
Circular plasmid DNA was linearized at the XbaI site within the ampicillin
resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform
extraction and ethanol precipitation prior to use for transfection of cells.

20 Transfection and selection of cells.

In general, this process involved the sequential introduction, by calcium
phosphate precipitation, or other means of DNA delivery, of two plasmid
constructions each with a different viral gene, into a single tissue culture cell.
The cells were transfected with a first construct and selected for expression of
25 the associated drug resistance gene to establish stable integrants. Individual cell
clones were established and assayed for function of the introduced viral gene.
Appropriate candidate clones then were transfected with a second construct
including a second viral gene and a second selectable marker. Transfected cells
then were selected to establish stable integrants of the second construct, and
30 cell clones were established. Cell clones were assayed for functional expression
of both viral genes.

-79-

A549 (ATCC Accession No. CCL-185) were used for transfection. Appropriate selection conditions were established for G418 and hygromycin B by standard kill curve determination.

Transfection of A549 cells with plasmids including E1 and E2a regions.

- 5 pMAMNeo-E2a was linearized with XmnI with the Amp^R gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, and visualizing by immunofluorescence. E2a function was
10 screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1, which contains the GRE5 promoted
15 E1a/b region plus the hygromycin^R gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus
20 establishing the expression of E1a/b and E2a in the positive cell clones.

A transfected A549 (A549 (ATCC Accession No. CCL-185);) cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

G. **Preparation of Adenoviral Vectors Containing Ad5. β gal. Δ F Genome in S8 Improved Fiber-Complementing Cell Lines**

- To prepare adenoviral vectors containing Ad5. β gal. Δ F (Ad5. β gal. Δ F has been deposited the ATCC under accession number VR2636) in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5. β gal. Δ F in
30 211B cells was followed with the exception of pretreatment with 0.3 μ M dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless

-80-

Ad5. β gal. Δ F genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5. β gal. Δ F genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

Thus, these viral preparations, prepared as described herein are useful for
5 targeting delivery of the Ad5. β gal. Δ F, Ad5.GFP. Δ F, or other similarly
constructed fiberless genome with either wild-type or modified fibers. Preferably
for purposes herein the fibers are from an Ad serotype D virus, more preferably
from Ad37.

EXAMPLE 6

10 **Pseudotyping and Infectivity of Recombinant Adenoviral Vectors
Produced with Improved Fiber-Complementing Cell Lines**

A. **Pseudotyping of Ad5. β gal. Δ F**

To verify that adenoviral vectors were produced had altered tropisms,
viral particles were purified from either 633 or 644 cells and were then Western
15 blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber
(which detects the Ad5 and chimeric 5T3H fiber proteins).

B. **Infectivity of Cells with 633 or 644 Generated Virus Particles** The
cell lines, 633 or 644, prepared as described above, were infected with the
indicated number of particles/cell of Ad5. β gal. Δ F and virus particles produced.
20 Virus was then used to infect selected cell lines, including 211B, MRC-5 human
fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells.
Unbound virus was removed by washing the cells and the cells were further
incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and
stained with X-gal. The percentage of stained cells was then determined by light
25 microscopy where all experiments were done in triplicate.

The results indicated that adenoviral vectors could be retargeted by
pseudotyping using packaging cell lines expressing different fiber proteins.
Particles containing either fiber were equally infectious on 211B cells, while
MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing
30 the chimeric fiber. The A-10 rat endothelial cells were more readily infected by
particles containing the wildtype Ad5 fiber protein.

-81-

EXAMPLE 7

Transient Transcomplementation

- The ability of adenovirus type 5 (Ad5) to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the
- 5 coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it was thought that it would be difficult to use adenoviruses to deliver genes to specific cell types. A system for testing modified fiber genes to identify tropisms of interest is described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No.
- 10 PCT/US00/00265 on January 14, 2000). An *in vitro* system has been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate modified fibers expressed on a viral particle. This system can be used to produce therapeutic quantities of
- 15 adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

Plasmids used were pDV60 and pDV55 were prepared as described herein and in U.S. application Serial No. 09/482,682 (also filed as International

20 PCT application No. PCT/US00/00265 on January 14, 2000). pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5. β gal. Δ F and 211B are described above. 293T cells are identical to 293 cells except they express an

25 integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine

30 serum.

The fiber deletion mutation of Ad5. β gal. Δ F is complemented in *trans* by passaging virions through 211B, a cell line that stably expresses functional Ad5

-82-

fiber. The present system was designed to complement Ad5. β gal. Δ F by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5. β gal. Δ F genome that does not require propagation of
5 the virus.

The feasibility of transcomplementation of Ad5. β gal. Δ F with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists
10 for at least six days. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5. β gal. Δ F passaged through 211B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber
15 expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility
20 for quickly evaluating a bank of modified fibers for other binding properties, including new tropisms and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. β gal. Δ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent
25 advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber for complementation with Ad5. β gal. Δ F. Because the Ad5. β gal. Δ F is deleted in E1, E3 and fiber, there is an additional gene deletion, which should render it very suitable for gene therapy. In addition,
30 the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. A single Ad vector preparation can be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

-83-

EXAMPLE 8

Preparation of Adenoviral Gene Delivery Vectors Containing the Ad37 fiber protein

This example describes construction of packaging cell lines expressing
5 the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as Ad5. β gal. Δ F) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would
10 efficiently bind the Ad5 penton base in these vectors.

A. Materials and methods

Cell lines and wild-type adenovirus. Human A549 lung carcinoma epithelial cells and human Chang C conjunctival cells (American Type Culture Collection) were maintained in complete Dulbecco's Modified Eagle Medium
15 (DMEM) with 10% fetal bovine serum. Wild-type Ad19p and Ad37 (ATCC) were propagated in A549 cells and purified by banding on CsCl₂ density gradients as previously described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Viral protein concentration was determined by the Bio-Rad Protein Assay, and was used to calculate the number of viral particles based on the known molecular weight of
20 Ad2 virions (1 μ g = 4 x 10⁹ particles).

B. Construction of the Ad37 fiber expressing cell lines and the recombinant Ad37 knob protein.

1. **Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)**
25 The plasmid designated pDV80 (see, SEQ ID No. 42) prepared for expression of the Ad37 fiber protein in mammalian cells, uses the same regulatory elements as the elements in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines. It was constructed in two steps.

First, the Ad37 fiber open reading frame was amplified from Ad37
30 genomic DNA using synthetic oligonucleotide primers, L37: 5' TGT CCT GGA TCC AAG ATG AAG CGC GCC CGC CCC AGC GAA GAT GAC TTC 3'(SEQ ID NO. 43) and 37FR: 5' AAA CAC GGC GGC CGC TCT TTC ATT CTT G 3' SEQ ID NO. 44). L37 contains nucleotides (underlined) that differ from the Ad37

-84-

genomic sequence in order to add a unique *Bam*H1 site (bold) before the start codon (italicized) and to create point mutations that make the N-terminal sequence of the fiber more closely match the N-terminal sequence of the Ad5 fiber protein as follows:

5 **Ad37** MSKRLRVEDDFNPV~~V~~PY (SEQ ID No. 45)
 ↓↓↓↓↓
 KRARPS (SEQ ID No. 46)
Ad5 **MKRARPSEDTFNPV**Y~~V~~PY (SEQ ID No. 47).

37FR also incorporates a unique *Not*1 site (bold). The PCR product was inserted
10 into the *Bam*H1 and *Not*1 sites of pCDNA3.1zeo(+) (Invitrogen) to create
pDV78. The correct sequence of the Ad37 fiber protein, including inserted
changes, was confirmed by sequencing.

Two point mutations in the fiber gene in the 705 line, S356 to P356 and
I362 to T362, were discovered by the sequencing. The mutations are not in the
15 receptor binding domain in Ad37 fiber gene in the 705 cell line. They are buried
in the knob trimer interface. To confirm that these mutations do not affect
receptor binding, the Ad37 fiber protein with the correct sequence was recloned,
and 293T cells transfected with the virus and subsequently infected with
Ad5.GFPΔF to produce Ad37 pseudotyped virus. The results were the same as
20 the results of the experiments with Ad37 pseudotyped virus produced from line
705 (see, Wu *et al.* (2001) *Virology* 279:78-89).

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5
tripartite leader was excised from pDV55 (see EXAMPLE 3) and inserted into the
Bam H1 site of pDV78 to create pDV80 (SEQ ID No 42). Plasmid pDV80 has
25 been deposited in the ATCC under accession number PTA-1147.

2. Construction of the recombinant Ad37 knob protein

Recombinant Ad37 knob protein containing an N-terminal T7•Tag was
produced in *E. coli* using the PET expression system (Novagen). Ad37 fiber DNA
(GenBank accession number U69132) was PCR amplified from wild-type Ad37
30 genomic DNA using the following primers (SEQ ID Nos. 48 and 49):
5' GGATCCATGGGATACTTGGTAGCA 3' (*Bam*HI site underlined and
5' GCAACTCGAGTCATTCTGGGCAATATAGG 3' (Xhol site underlined).

- The PCR reactions were performed at 94 °C (denaturation), 55 °C (annealing), 72 °C (extension, 30 cycles) using *Taq* DNA polymerase (Qiagen). The amplified DNA fragments, which contained residues 172 to 365 of the Ad37 fiber protein with the addition of an N-terminal start codon (italicized), were
- 5 purified and subcloned into the pCR-TOPO vector using the TA-Cloning Kit (Invitrogen). No replication errors were found by DNA sequencing. Plasmids from cultured transformed colonies were purified and digested with *Bam*HI and *Xhol*. The fragment was inserted into the *Bam*HI and *Xhol* sites of the bacterial expression vector, pET21a (Novagen), and transformed into (DE3)pLYS S
- 10 expression cells (Invitrogen). Colonies were selected for knob expression by induction with 1 mM IPTG for four hours at 37 °C and knob expression was determined by SDS-PAGE. The colony displaying highest knob expression was used for large-scale knob expression and induced with 0.5 mM IPTG at 30 °C for four hours.
- 15 The recombinant T7•Tagged Ad37 knob protein was purified from sonicated bacteria using the T7•Tag Affinity Purification Kit as recommended by the manufacturer (Novagen). Recovered protein was analyzed for purity by SDS-PAGE followed by Coomassie staining or Western blotting with an HRP-conjugated α -T7•Tag monoclonal antibody as described by the manufacturer
- 20 (Novagen) or an α -Ad37 fiber rabbit antibody.
3. Preparation of Cell Lines that Express the Ad37 fiber protein
- Plasmid pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (see Examples herein; see also, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178;
- 25 and Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468). Stable clones were selected with 600 μ g/ml zeocin (Invitrogen).
- Clones were expanded and were screened for fiber expression by indirect immunofluorescence (Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468) using a rabbit polyclonal antibody directed against the Ad37 fiber (α -Ad37 fiber
- 30 rabbit antibody) raised by immunizing rabbits with recombinant Ad37 fiber protein. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected.

EXAMPLE 9**Production of Pseudotyped Ad Vector Particles**

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately 5 1000 particles/cell) with Ad5. β gal. Δ F or with Ad5.GFP. Δ F.

Materials and methods**Ad5. β gal. Δ F**

The construction of Ad5. β gal. Δ F is described in Example 2 (it has been deposited on January 15, 1999, with the ATCC as listed above under accession 10 number VR2636; see also, Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; copending U.S. application Serial No. 09/482,682 filed January 14, 2000, and also International PCT application No. PCT/US00/00265, filed January 14, 2000).

Ad5.GFP. Δ F

15 Ad5.GFP. Δ F was constructed by recombination in bacteria using a modification of the AdEasy System (see, U.S. Patent No. 5,922,576; see, also He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the system is publicly available from the authors and other sources).

First, a fiber-deleted genomic plasmid was constructed by removing the 20 fiber gene from pAdEasy-1 (see, U.S. Patent No. 5,922,576; and He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the AdEasy system and vectors are publicly available from He *et al.* at Johns Hopkins University). Plasmid pAdEasy-1 contains the entire Ad5 genome, except for nucleotides 25 1-3,533, which encompass the E1 genes, and nucleotides 28,,130-30,820, which encompass the E3 gene.

Plasmid pDV43 (see Example 2; see, also Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608) was digested with *Pac*1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated to produce plasmid pDV76. The resulting plasmid pDV76 is identical to 30 pDV43 except for loss of the *Pac*1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.23 kb fragment from PDV76 was amplified using the oligonucleotide primers (SEQ ID Nos. 50 and 51:

- 5' CGC GCT GAC TCT TAA GGA **CTA GTT TC** 3', including the unique *Spe1* site in the Ad5 genome (bold); and 5' GCG CTT AAT TAA CAT CAT CAA TAA TAT ACC TTA TTT T 3', including a new *Pac1* site (bold) adjacent to the right Ad5 ITR. Hence the resulting PCR amplified fragment contains nucleotides
- 5 27,082 to 35,935 of the Ad5 genome with deletions of nucleotides 28,133 to 32,743 (the E3 and fiber genes), and was used to replace the corresponding *Spe1/Pac1* fragment of pAdEasy 1 (see, U.S. Patent No. 5,922,576) to create pDV77.

Second, *E. coli* strain BJ5183 was electroporated with a mixture of

10 pDV77 and *Pme1*-linearized pAdTrack as described (U.S. Patent No. 5,922,576; He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete Ad5 genome with E1-, E3-, and fiber-deletions with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full length

15 Ad chromosome was isolated by *Pac1* digestion, and transfected into the E1- and fiber-complementing 633 cells (Von Seggern *et al.* (2000) *J. Virol.* 74:354-362). The 633 cells were produced by electroporating pDV67 (SEQ ID No. 30, deposited under ATCC accession number PTA-1145) into the E1-2a S8 cells, described above. The recovered virus Ad5.GFP.ΔF was then plaque purified by

20 plating on 633 cells and virus stocks were prepared by freeze-thawing cell pellets.

Ad5-pseudotype particle production

Particles with Ad5 fiber

Ad5-pseudotyped particles were generated by virus growth in 633 cells,

25 which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients (Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C)). For analysis of viral proteins, ten µg of the purified particles were electrophoresed on 8-16% gradient gels and the protein

30 transferred to nylon membranes. The resulting blot was probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells.

Particles with Ad37 fiber

Cells from the Ad37 fiber producing cell line 705 were infected at approximately 1000 particles/cell with Ad5. β gal. Δ F or with Ad5.GFP. Δ F. Viral particles were isolated and purified over CsCl gradients. The bands were
5 harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C.

Viral protein analyses

For analysis of viral proteins, 10 μ g of purified Ad5. β gal. Δ F particles with no fiber (grown in 293 cells), the Ad5 fiber (grown in 633 cells), or the Ad37
10 fiber (grown in 705 cells) were electrophoresed by 8-16% polyacrylamide gradient SDS-PAGE and the proteins were transferred to nylon membranes. The blot was then probed with α -Ad37 fiber rabbit antibody. Ad5 fiber and penton base were detected by reprobing the blot with polyclonal antibodies raised against recombinant proteins expressed in baculovirus-infected cells (Wickman *et*
15 *al.* (1993) *Cell* 2:309-319).

Adenovirus infection and cell binding assays

Adherent Chang C and A549 cells were infected with GFP expressing Ad5 vectors containing the Ad5 fiber (Ad5.GFP. Δ F/5F) or the Ad37 fiber (Ad5.GFP. Δ F/37F) at 10,000 particles per cell for 3 hours at 37°C, 5% CO₂ in
20 DMEM, 10% FCS. Cells were washed twice with saline and then cultured overnight at 37°C, 5% CO₂. The next day, the cells were detached with buffer containing 0.05% (w/v) trypsin and 0.5 mM EDTA (Boehringer Mannheim) for 5 minutes at 37°C. Suspended cells were washed once with PBS and then resuspended in phosphate-buffered saline (PBS), pH 7.4. GFP fluorescence was
25 measured with a FACScan flow cytometer. A threshold established by the fluorescence of uninfected cells was used to distinguish cells expressing GFP. To assess the role of CAR in Ad infection, 10,000 attached cells were pre-incubated with 180 μ g/ml RmcB, a function-blocking anti-CAR monoclonal antibody (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), in complete DMEM for 1
30 hour at 4°C. A small volume containing Ad5.GFP. Δ F/5F or Ad5.GFP. Δ F/37F was then added at 10,000 particles per cell. The cells were infected for 3 hours, cultured overnight, harvested, and analyzed for GFP expression. Percent

-89-

cells expressing GFP was determined by the percent of cells detected above a threshold set by the fluorescence of uninfected Chang C cells.

To measure adenovirus binding to cells, wild type Ad37 was labeled with ¹²⁵I using Iodogen (Pierce) according to manufacturer instructions and separated 5 from free ¹²⁵I by gel filtration as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Binding of radiolabeled wild type Ad37 on Chang C cells was then quantitated as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Non-specific binding was determined by incubating cells and labeled Ad37 particles in the presence of 100-fold concentration of unlabeled Ad37. Specific 10 binding was calculated by subtracting the non-specific binding from the total cpm bound. To examine if divalent cations are required for binding, 10 mM ethylenediaminetetraacetic acid (EDTA) or various concentrations of CaCl₂, or MgCl₂ were added to cells before incubation with labeled virus. To examine if the receptor for Ad37 is a protein, cells were pretreated with 10 µg/ml trypsin 15 (GIBCO), subtilisin (Sigma), proteinase K (Boehringer-Mannheim), and bromelain (Sigman) at 37 °C for 1 hour, then washed twice with complete DMEM before adding labeled virus. Cells were >95% viable after protease treatment.

Ad37 binding to conjunctival cells is calcium-dependent. Specific ¹²⁵I-labeled Ad37 binding to Chang C cells was measured in the presence of 10 mM 20 EDTA and in the presence of varying concentrations of calcium chloride or magnesium chloride. Specific binding was determined by subtracting the nonspecific counts in the presence of 100-fold excess unlabeled virus from the total counts.

Pretreatment of conjunctival cells with proteases inhibits Ad37 binding. 25 Chang C cells were pretreated with various proteases for 1 hour before binding ¹²⁵I-labeled Ad37 to the cells. Nonspecific binding was measured by adding 100-fold unlabeled Ad37 to cells with ¹²⁵I-labeled Ad37 and subtracting from total counts for specific binding. Percent inhibition represents the difference in specific binding of untreated cells and pretreated cells as a percentage of the 30 specific binding of untreated cells.

-90-

Virus overlay protein blot assay (VOPBA)

For VOPBA of human conjunctival membrane proteins probed with Ad37 in the presence of EDTA or calcium chloride, Chang C membrane fractions were separated by 8% SDS-PAGE and transferred to a PVDF membrane. The

5 membrane was subsequently probed with or without whole Ad37 particles, a polyclonal antibody against Ad37 fiber, and finally a horseradish peroxidase conjugated anti-rabbit antibody, in the presence of EDTA or calcium chloride. Transferred Chang C membrane proteins were probed with recombinant Ad37 knob protein, instead of Ad37 knob, in the presence of calcium chloride.

10 Confluent monolayers of Chang C and A549 cells were detached by scraping, pelleted by centrifugation, and then resuspended in 250 mM sucrose, 20 mM HEPES, pH 7.0, 1 mM EDTA, and 2 µg/ml aprotinin and leupeptin. Cells were transferred into a dounce homogenizer and disrupted with 30 strokes. Organelles and nuclei were pelleted at 500g for 15 min. Plasma membrane
15 fragments were then pelleted from the supernatant of cell lysates at 200,000g for 1 hour and then resuspended in 10 mM Tris•Cl, pH 8.1, 10 µg/ml aprotinin and leupeptin.

Cell membranes of Chang C or A549 cells were incubated (1:1) with a 2% SDS, non-reducing buffer and separated on an 8% polyacrylamide gel
20 without boiling. Membrane proteins were then electroblotted onto a PVDF membrane (Immobilon-P) and blocked in 5% (w/v) milk in PBS, pH 7.4, 0.02% Tween-20 (PBS-T). After blocking, the membrane was incubated with 1 µg/ml wild-type Ad19p or Ad37 in 0.5% (w/v) milk in PBS-T, 1 mM CaCl₂, for 1 hour at room temperature. The membrane was then washed once with phosphate-buffered saline, pH 7.4 (PBS), 1 mM CaCl₂, and incubated with 1:500 dilution of α-Ad37 fiber rabbit antibody in 0.5% (w/v) milk in PBS-T, 1 mM CaCl₂, for 30 minutes at room temperature. The membrane was washed again with PBS, 1 mM CaCl₂, and incubated with 1:5000 dilution of horseradish peroxidase (HRP) conjugated α-rabbit antibody (Sigma) in 0.5% (w/v) milk in PBS-T, 1 mM CaCl₂,
25 for 30 minutes at room temperature. The membrane was washed four times in PBS, 1 mM CaCl₂, once with PBS-T, 1 mM CaCl₂, and once in 1 mM CaCl₂. The blot was developed with enhanced chemiluminescence reagents (Pierce) for 5

-91-

minutes and placed onto a piece of Biomax film (Kodak) for 5 seconds to 1 minute. For divalent metal cation experiments, membranes were incubated in the presence of 2 mM EDTA instead of 1 mM CaCl₂ in all solutions. To assay fiber knob binding to cell membrane proteins, membrane filters were incubated
5 with 1 µg/ml purified T7-tagged Ad37 knob protein in Tris-buffered saline, 0.1% Tween-20, 1 mM CaCl₂, for 1 hour at room temperature. α -Ad37 fiber rabbit antibody and HRP-conjugated anti-rabbit antibody were applied and the membrane was developed with substrate solution as described above.

10 **Results: Comparison of adenovirus infection of human conjunctival and lung epithelial cells with virus particles retargeted with Ad5 or Ad37 fiber proteins**

Packaging cell lines producing the Ad37 fiber protein were generated. Since the N-terminal amino acid sequences of the Ad5 and Ad37 fiber proteins differ significantly, and to ensure that the Ad37 fiber would be efficiently incorporated into Ad5 vector particles, several residues in the wild-type Ad37
15 fiber were mutated to more closely match the Ad5 sequence. Stable cell lines producing this fiber under control of the CMV promoter and the adenovirus type 5 tripartite leader were then generated and screened for fiber expression by indirect immunofluorescence. One clone (line 705), which expressed the Ad37 fiber at a high level, was selected for further study.

20 Cells from one cell line 633, which expresses the wild-type Ad5 fiber protein, and line 705 were infected with a fiber-deleted Ad5 vector carrying a β galactosidase reporter gene. The resulting vector particles contained the Ad5 fiber protein (Ad5. β gal. Δ F/5F) and the Ad37 fiber protein (Ad5. β gal. Δ F/37F), respectively. Incorporation of the correct fiber protein into viral particles was
25 verified by Western blotting. Adenoviral vectors containing the GFP reporter gene, Ad5.GFP. Δ F/5F and Ad5.GFP. Δ F/37F, were created in the same fashion.

Infection of a variety of cell types using the retargeted adenovirus particles was examined. As assayed by GFP fluorescence, Ad5.GFP. Δ F/5F exhibited good gene delivery to lung epithelial (A549) and conjunctival cells
30 (Chang C). In contrast, Ad5.GFP. Δ F/37F efficiently delivered GFP to Chang C cells, but exhibited very poor gene delivery to A549 cells. Although CAR is expressed on the surface of A549 cells, as indicated by AD5.GFP. Δ F/5F

-92-

infection, Ad5.GFP. Δ F/37F was unable to infect these cells efficiently. This experiment shows that the Ad37 fiber protein can confer preferential infection of human conjunctival cells, but not CAR-expressing human lung epithelial cells.

Hence CAR is not the primary receptor for Ad37. Recent studies reported
5 that expression of CAR on the surface of chinese hamster ovary (CHO) cells did not improve Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 does not use CAR as a primary receptor. In order to verify this on human conjunctival cells, A549 and Chang C cells were pretreated with RmcB (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), a function-blocking monoclonal
10 antibody against CAR. The RmcB antibody inhibited infection of A549 cells by Ad5.GFP. Δ F/5F, but it had little effect on infection of Chang C cells by Ad5.GFP. Δ F/37F. This indicates that CAR is not the primary receptor for Ad37 on Chang C conjunctival cells.

Ad37 binding to conjunctival cells requires divalent metal cations. It has
15 been proposed (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) that a combination of fiber binding to CAR and penton base binding to α_v -integrins allows some adenovirus serotypes to attach to cells. Although α_v -integrin binding to the RGD motif of the adenovirus penton base is of relatively low affinity (Wickman *et al.* (1993) *Cell* 2:309-319), it may nonetheless contribute to viral attachment to the
20 cell surface. Ad37 shows a particularly strong affinity for binding to integrin $\alpha_v\beta_5$ (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675), suggesting that integrin $\alpha_v\beta_5$ might be a primary receptor for Ad37. Binding of the RGD motif by α_v -integrins requires the presence of divalent cations, such as calcium or magnesium (Stuiver
25 *et al.* (1996) *J. Cell Physiol.* 168:521-531). In contrast, no divalent cations were required for binding in the CAR-Ad12 knob complex (Bewley *et al.* (1999) *Science* 286:1579-1583).

To investigate the potential role of α_v -integrins and divalent metal cations in Ad37 receptor binding, 125 I-labeled Ad37 binding to Chang C cells was examined in the absence or presence of EDTA. EDTA inhibited Ad37 binding to
30 conjunctival cells but did not alter Ad5 binding. These findings suggest a requirement for divalent metals for Ad37 binding.

-93-

The presence of either calcium or magnesium ions helps $\alpha_v\beta_5$ organize in focal contacts (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531), suggesting that calcium and magnesium aid in integrin $\alpha_v\beta_5$ function. To further test the potential role of integrin $\alpha_v\beta_5$ in Ad37 cell attachment, ^{125}I -labeled Ad37 binding 5 to Chang C cells was measured in the presence of varying concentrations of calcium or magnesium chloride. Magnesium ions had little effect on Ad37 binding to Chang C cells. In contrast, calcium ions dramatically enhanced Ad37 binding to Chang C cells. The optimal concentration of calcium chloride for Ad37 binding was 1 mM, while higher concentrations of calcium actually 10 decreased virus binding to cells. The fact that calcium, but not magnesium, promoted Ad37 attachment is not consistent with integrin $\alpha_v\beta_5$ as the primary receptor for viral attachment to the cells since either metal will support ligand binding to integrin $\alpha_v\beta_5$. Moreover, A549 cells express abundant α_v -integrins 15 (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675) but were unable to support efficient binding of Ad37.

Wild-type Ad37 particles bind to three conjunctival membrane proteins. Recent studies reported that protease treatment of CHO cells abolished Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 bound to a protein receptor on CHO cells. Scatchard analysis of Ad37 binding to Chang C 20 cells showed that each cell expresses approximately 24,000 fiber binding sites (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). To determine if the Ad37 binding site on human conjunctival cells is also a protein, Chang C cells were treated with different proteases prior to measuring binding of ^{125}I -labeled Ad37. Digestion of surface proteins by all four proteases inhibited Ad37 binding to 25 Chang C cells by greater than 50%. This finding showed that Ad37 also binds to a protein receptor on Chang C cells.

Virus overlay protein blot assays (VOPBAs) were used to identify candidate viral protein receptors. This Western blot technique uses intact viral particles in place of antibodies to probe viral-receptors interactions. VOPBA was 30 used herein to identify Chang C membrane proteins that bind to Ad37. In the absence of Ad37 particles, no protein bands were observed, while addition of virus in the absence of calcium revealed binding to a single 45 kDa protein. In

-94-

the presence of 1 mM calcium chloride, Ad37 reacted with three proteins with approximate molecular weights of 45, 50 and 60 kDa. The same three proteins were detected using a recombinant Ad37 fiber knob alone, indicating that Ad37-receptor interactions are fiber mediated and do not involve interactions of other
5 capsid proteins such as the penton base. The size of the calcium-independent protein (45 kDa) is very similar to the known molecular weight of CAR. A direct comparison of the Ad37 VOPBA and a CAR Western blot showed that the 45 kDa receptor co-migrates with CAR on SDS-PAGE. Moreover, two other members of subgroup D adenoviruses, Ad9 and AD15, have been shown to bind
10 to CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915).

Since CAR does not appear to mediate Ad37 binding on intact Chang C cells, the possibility that the 50 or 60 kDa protein serves this function was tested by examining an adenovirus serotype that does not bind to Chang C cells. Ad19p, a closely related subgroup D adenovirus, binds poorly to Chang C cells
15 (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) and Ad19p recognition of the Ad37 receptor is therefore unlikely. Ad19p particles bound to the 45 and 60 kDa receptors in the VOPBA, but did not bind to the 50 kDa receptor. Moreover, the 50 kDa receptor is expressed on Chang C cells, but not A549 cells, which only support low levels of Ad37 binding and infection. Taken
20 together, these data indicate that the 50 kDa protein is a primary candidate receptor for Ad37 on human conjunctival cells.

Discussion

The identification of the CAR protein as a major adenovirus receptor does not explain why certain subgroup D members, such as Ad37, preferentially
25 infect ocular cells. A 50 kDa human conjunctival cell membrane protein is identified herein as a primary candidate for the receptor for Ad37. This 50 kDa protein is not present on A549 lung epithelial cells. Ad37 binding to this receptor is calcium-dependent, which is consistent with Ad37 binding and infection experiments. Ad37 also bound to a 60 kDa protein that is present on human
30 conjunctival and lung epithelial cells. It does not, however, appear to be serotype specific. The molecular weights of MHC class I heavy chain, which has been proposed as a receptor for Ad5, and $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins, receptors for

-95-

the penton base, are distinct from the 50 or to kDa receptor characterized in this study.

- The studies of Ad37-receptor interaction using VOPBAs are consistent with previous studies showing that subgroup D adenoviruses can bind to the 5 extracellular domain of CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). Biochemical and structural studies on knob-CAR interactions indicate that the CAR binding site is located on the AB-loop of the fiber knob. Alignment of the fiber sequences of Ad37 and other adenoviruses reveals that the AB-loop of Ad37 is similar to those of Ad12 and Ad5. Moreover, a phylogenetic tree of 10 adenovirus knobs (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) shows that fiber proteins of subgroup D are similar to those of subgroup C and E, which use CAR as their primary receptor. Ad37 does not, however, appear to effectively use CAR as a primary receptor, as demonstrated by virus binding and infection studies on Chang C conjunctival cells and A549 lung epithelial cells.
- 15 It has been reported that Ad37 uses sialic acid as a receptor on chinese hamster ovary (CHO) cells and human lung carcinoma (A549) cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48)). Human conjunctival cells were not studied. Human corneal epithelial (HCE) cells were the only ocular cell line studied and Ad37 binds relatively poorly to these cells, compared to binding on A549 cells 20 (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48)). In addition, $8,4 \times 10^7$ wheat germ agglutinin molecules per cell were required to significantly inhibit Ad37 binding to sialic acid on sialic acid positive CHO cells (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), three orders of magnitude higher than the number of Ad37 receptors on Chang C conjunctival cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802).
- 25 Clearly, sialic acid is not the only factor responsible for Ad37 binding to the cell surface and its influence on Ad37 tropism is unclear.

- The results herein show that Ad37 selects a 50 kDa cellular receptor for binding to conjunctival cells, but it is possible that sialic acid also plays a role in this interaction. The characterization and identification of the Ad37 receptor 30 have therapeutic implications and also explain the different tropism of Ad37. The 50 kDA receptor for Ad37 may also be the receptor for other subgroup D adenoviruses that cause severe cases of EKC, Ad19a and Ad8. Ad19p is a

-96-

nonpathogenic variant of Ad19 (Arnberg *et al.* (1998) *Virology* 227:239-244) while Ad19A, along with Ad8 and Ad37, are major causes of EKC. Ad19a and Ad37 have identical fiber proteins (Arnberg *et al.* (1998) *Virology* 227:239-244) and have similar tropism in vivo. Ad8, Ad19a, and Ad37 agglutinate dog and
5 guinea pig erythrocytes more effectively than four other serotypes that are associated with less severe forms of conjunctivitis (Arnberg *et al.* (1998)
Virology 227:239-244), implying that the receptors of Ad18, Ad19A, and Ad37 have similar characteristics. Hence, this 50 kDa receptor is an attractive drug target against EKC caused by adenoviruses to provide therapeutic intervention of
10 ocular diseases associated with these viruses.

EXAMPLE 10

Targeting of the Ad5 vector to photoreceptor cells

The fiber-deleted adenovirus vector Ad5.GFP.ΔF was propagated in 705 cells, which express a modified Ad37 fiber protein. Viral particles
15 (Ad5.GFP.Δf/37F) were harvested, CsCl-purified and dialized into 0.9% NaCl, 10 mM Tris, pH 8.1, and 10% glycerol. Two to three μ l of the resulting solution, containing approximately 1×10^9 particles/ μ l was injected into the vitreous chamber of a mouse eye. Seven days post-injection, eyes were harvested, fixed with paraformaldehyde and cryo-sectioned. Sections were stained with an anti-
20 rhodopsin antibody to identify photoreceptor cells and with DAPI to show all cell nuclei. The resulting sections showed red anti-rhodopsin staining in the photoreceptors, blue DAPI-stained nuclei, and green GFP staining in any transduced cells. The results revealed substantially exclusive transduction of photoreceptors. Co-localization of rhodopsin staining and GFP expression
25 indicated selective transduction of photoreceptor cells.

As a control, contralateral eyes were injected with a stock of the fiber-deleted vector AD5.βgal.ΔF grown in the same Ad37 fiber-expressing cells. Since this virus (Ad5.βgal.ΔF/37F) produces βgal rather than GFP, the green staining is absent from the photoreceptors.

30 Additional experiments using the AD37 fiber for targeting to the photoreceptor cells have been performed. Subretinal and intravitreal injection have been used in mouse models and the results demonstrate targeting to the

-97-

photoreceptors. As with intravitreally injected eyes, the major cell type infected via subretinal administration was the photoreceptor.

As noted, Ad5.GFP.ΔF /37F infected Chang C cells efficiently, but A549 cells poorly. Ad37 fiber protein confers preferential infection on human

- 5 conjunctival cells, but not CAR-expressing human lung epithelial cells. Binding to conjunctival cells requires divalent cations.

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule, comprising:
adenovirus inverted terminal repeat sequences; an adenovirus packaging signal operatively linked thereto; and a photoreceptor-specific promoter.
- 5 2. The isolated nucleic acid molecule of claim 1, further comprising a nucleic acid encoding a therapeutic product operatively linked to the promoter.
3. The isolated nucleic acid molecule of claim 1, wherein the promoter is a rhodopsin promoter.
4. The nucleic acid molecule of claim 1, wherein the adenovirus
10 genome does not encode a functional fiber protein such that packaging the nucleic acid requires complementation in a packaging cell.
5. A recombinant adenovirus vector, comprising the nucleic acid molecule of any of claims 1-4 packaged therein.
6. A recombinant adenovirus vector of claim 5, wherein inverted
15 terminal repeat sequences (ITR) and a packaging signal are derived from adenovirus type 2 or adenovirus type 5.
7. A recombinant adenovirus vector of claim 5, wherein the virus comprises a fiber protein.
8. A recombinant adenovirus vector of claim 7, wherein the fiber
20 protein selectively binds to photoreceptors in the eye of a mammal.
9. A recombinant adenovirus vector of claim 7, wherein the fiber is a chimera composed of N-terminal sequences from adenovirus type 2 or type 5, and a sufficient portion of an adenovirus serotype D fiber for selective binding to photoreceptors in the eye of a mammal.
- 25 10. A method for targeted delivery of a gene product to the eye of a mammal, comprising:
administering a recombinant adenovirus virus that comprises heterologous DNA encoding the gene product or resulting in expression of the gene product,
wherein the recombinant virus comprises a fiber protein that specifically or
30 selectively binds to receptors that are expressed on cells in the eye.

-99-

11. The method of claim 10, wherein the cells are photoreceptors.
12. The method of claim 10, wherein administration is effected by intraocular delivery.
13. The method of claim 10, wherein administration is effected by a
5 method selected from subretinal injection, intravenous administration, periorbital administration, and intravitreal administration.
14. The method of claim 10, wherein the recombinant virus comprises a fiber protein from an adenovirus type D serotype.
15. The method of any of claims 10-14, wherein the fiber protein is an
10 adenovirus type 37.
16. The method of any of claims 10-14, wherein the fiber is a chimeric protein containing a sufficient portion of the N-terminus of an adenovirus type 2 or type 5 fiber protein for interaction with an adenovirus type 2 or type 5 penton, and a sufficient portion of an adenovirus serotype D knob portion of the
15 fiber for selective binding to photoreceptors in the eye of a mammal.
17. The method of any of claims 10-16, wherein the recombinant virus is an adenovirus type D serotype.
18. The method of any of claims 10-17, wherein the encapsulated nucleic acid comprises a photoreceptor-specific promoter operatively linked to a
20 nucleic acid comprising the therapeutic product.
19. The method of claim 18, wherein the therapeutic product is selected from the group consisting of a trophic factor, an anti-apoptotic factor, a gene encoding a rhodopsin protein, a wild-type Stargardt disease gene (STDG1), an anti-cancer agent and a protein that regulates expression of a photoreceptor-
25 specific gene product.
20. The method of any of claims 10-19, wherein delivery is effected for treatment of an ocular disease.
21. The method of claim 20, wherein the disorder is a retinal degenerative disease.
- 30 22. The method of claim 20, wherein the disease is retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, or retinoblastoma.

-100-

23. The method of any of claims 10-22, wherein the mammal is a human.

24. The method of any of claims 10-22, wherein the viral nucleic acid comprises:

- 5 an adenovirus inverted terminal repeat (ITR) sequences; and
an adenovirus packaging signal operatively linked thereto.

25. The method of claim 24, wherein the ITRs and packaging signal are derived from an adenovirus serotype B or C.

26. The method of claim 24, wherein the ITRs and packaging signal
10 are derived from an adenovirus type 2 or 5.

27. The method of claim 24, wherein the viral nucleic acid further comprises a photoreceptor-specific promoter.

28. A method of targeted gene therapy, comprising:
administering a recombinant viral vector that comprises an adenovirus
15 type 37 fiber protein or portion thereof, whereby the vector selectively transduces photoreceptors and delivers a gene product encoded by the recombinant viral vector; wherein the portion is sufficient for selective binding to photoreceptors.

29. The method of claim 28, wherein the vector is administered into
20 the eye.

30. The method of claim 28, wherein the vector is administered to the vitreous cavity of the eye.

31. The method of claim 28, wherein administration is effected by subretinal injection, intravenous administration, periorbital administration or
25 intravitreal administration.

32. The method of any of claims 10-31, wherein at least about 10^7 plaque forming units of virus are administered.

33. The method of any of claims 10-31, wherein about 1 plaque forming unit to about 10^{14} plaque forming units of virus are administered.

SEQUENCE LISTING

<110> VON SEGGERN, DANIEL
NEMEROW, GLEN R.
FRIEDLANDER, MARTIN

<120> VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY

<130> 756.1PCT/NOV0205P

<140>

<141> 2001-05-01

<150> 09/562,934
<151> 2000-05-01

<160> 51

<170> PatentIn Ver. 2.1

<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 1
cggtacacag aattcaggag acacaactcc 30

<210> 2
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 2
gcctggatcc ggaaagttac gtaacgtggg aaaac 35

<210> 3
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: linker

<400> 3
cgcgatccg cg 12

<210> 4
<211> 8710
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 4
cacctaaatt gtaagcgtt aatattttgtt aaaattcgcg ttaaattttt gttaaatcag 60
ctcattttt aaccaatagg ccgaaatcgga caaaaatccct tataaatcaa aagaatagac 120
cgagataggg tttagtgtt ttccagtttgaacaagagt ccactattaa agaacgtgga 180
ctccaacgtc aaaggcgaa aaacacgtcta tcagggcgat ggcccactac gtgaaccatc 240
accctaatac agtttttgg ggtcgaggtg cctgtaaagca ctaaatcgga accctaaagg 300
gagccccga tttagtgcgtt gacggggaaa gcccgcgaac gtggcgagaa aggaaggaa 360
gaaagcgaaa ggacggccg cttagggcgat ggcgtacta cgggtcaccg tgcgcttaac 420
caccacaccc gccgcgtt atgcgcgcgt acaggcgcg tcccatcgccattcaggct 480
gcfgcaactgt tggttggaggc gatcggtgcg ggttaacgcca gggtttccc agtcacgacg 540
agggggatgt gctgcaaggc gattaagtttgcgacta cgtactacta tagggcgaat tgggtaccgg 600
ttgtaaaacg acggccagtg aattgtataa gcttgatatac gaattcagga gacacaactc 660
gccccccctc gaggtcgacg gtatcgataa actggcttgg ccacaactac attaatgaaa 720
caagtgcata ctctatgtca ttttcatggg acattttcatc acatttgccttccatcaggct 780
tatttgcac atcctcttac actttttcatcattttca acgtgtttat tttcaatttgcgacta 840
ttatgtttca acgtgtttat tttcaatttgcgacta cagaaaattt caagtcatgttccatcaggct 900
agtatagccc caccaccaca tagttatac agatcaccgtt accttaatca aactcacagaa 960
acccatgtat tcaacatcgcc acctccctcc acacacacag agtacacatc acctttctccc 1020
cggtgcgcct taaaaaagcat catatcatgg gtaacagaca tatttcttgcgacta 1080
cacacgttt cctgtcgagc caaacgctca tcacttaatgtcgtt gtagccacag gctgtctgtcc 1140
tcacttaatgt tcatgtcgct gtccagctgc gcctacatgg gggtagagtc ataatcgtgc 1200
tgcttaacgg gccggcgaagg agaagtccac ggcgaataaa actgctgcgcg cccggcgtcc 1260
atcaggatag ggcgggtggc ctgcagcagc tcctcagcga tgatttcgcac 1320
gtcctgcagg aataacaacat ggcagtggc tccatcaggccatcaggct 1380
ataaggcgcc ttgttctccg ggcacagcag cgcaccctga tctcaacttacatcaggct 1440
taactgcgcg acagcaccac aattttgttc aaaatccac agtgcacaggc gctgtatcca 1500
aagctcatgg cggggaccac agaaccacag tggccatcatcaccacaaggc cccggcgtcc 1560
aagtggcgc acctccataaa cacgtggac ataaacatta cctcttttgcgacta 1620
ttcaccacctt cccggtagcca tataaacctc tgattaaaca tggcccatc caccaccatc 1680
ctaaaccacgc tgccaaaacac ctgcccgcgc gctataactc gcagggaaacc gggactggaa 1740
caatgacagt ggagagccca ggactcgtaa ccatggatca tcatgtcgct 1800
atgttggcac aacacaggca cacgtgcata cacttcctca ggattacaag ctcctcccgc 1860
gttagaacca tatcccaggg aacaacccat tcctgaatca gctgtaaatcc cacactgcag 1920
ggaagacctc gcacgttaact cacgttgcg attgtcaaaag ttttgcgacta 1980
ggatgatctt ccagttatgtt agcgcgggtt tctgtcttca aaggaggtagt acgatcccta 2040
ctgtacggag tgccggagca caaccggat cgtgttgcgacta 2100
acgccggacgc tagtcatatt tcctgaagca aaacagggtg cggcgtgc acacagatct 2160
gcgtctccgg ttcgcgcgt tagatgcgtc tggtagtgcgacta 2220
caaagcatcc aggcgcggcc tggcttcggg ttctatgtaa actccttcatc 2280
cctgataaca tccaccaccc cagaataagc cacacccagc caacctacac attcgttctg 2340
cgagtcacac acgggaggag cgggaagagc tggaaagacc atgtttttt ttttattcca 2400
aaagattatc caaaacctca aatgaagat ctattaaatgt aacgcgtctcc cctccgggtgg 2460
cgtggtaaaa ctctacagcc aaagaacaga taatggcatt tgtaagatgt tgcacaatgg 2520
cttccaaaag gcaaacggcc ctcacgtcca agtggacgtt aaggctaaac ccttcagggt 2580
gaatcttcct tataaacatt ccagcacctt caaccatgcc caaataatt tcatctcgcc 2640
acccatctcaa tatatctctt agcaaatccc gaatattaaag tccggccatt gtaaaaatct 2700
gctccagggc gcccctcacc ttcgcctca agcgcgaat catgattgcgaaaattcagg 2760
ttcctcacag acctgtataa gattttaaag cggaaacatta aaaaaaataac cgcgtatccc 2820
taggtccctt cgcaaggccca gctgaacata atcgtgcagg tctgcacggc ccagcgcggc 2880
cacttccccg ccaggaaccc tgacaaaaga acccacactg attatgacac gcataactcg 2940
agctatgcta accagcgttag ccccgatgtt agcttttttgcgacta 3000
gcaagggtgtt gctaaaaaaaaa tcaggcaaaag cctcgcgcgaa aaaagaaaagc acatcgtagt 3060
catgctcatg cagataaaagg caggtaaagct cgggaaccac cacagaaaaaa gacaccattt 3120
ttctctcaa catgtctcgcc ggtttctgca taaacacaaa ataaaataac aaaaaaaacat 3180
ttaaacatca gaagcctgtc ttacaacagg aaaaacaacc ctatataagca taagacggac 3240
tacggccatg cccggcgtgac cgtaaaaaaaaa ctggcgtaccg tgattaaaaaa gcaccaccga 3300
cagtcctcg gtcatgtccg gagtataatc gtaagactcg gtaaaacacat cagggttatt 3360
catcggttag tgcataaaaaa cgaccggaaat acggccgggg aatacatacc cgcaggcgta 3420
gagacaacat tacagcccccc ataggaggta taacaaaatt aataggagag aaaaacacat 3480
aaacacactqa aaaacccctcc tgccttaqgca aaataqcaacc ctcccgctcc agaacaacat 3540

acagcgcttc	acagcggcag	cctaacagtc	agccttacca	gtaaaaaaaga	aaacctatta	3600
aaaaaacacc	actcgacacg	gcaccagctc	aatcagtcac	agtgtaaaaa	agggccaagt	3660
gcagagcgag	tatatatagg	actaaaaaat	gacgtaacgg	ttaaagtcca	caaaaaacac	3720
ccagaaaacc	gcacgcgaac	ctacgcccag	aaacgaaagc	caaaaaaccc	acaacttct	3780
caaatcgta	cttcgcgttt	cccacgttac	gtaacttccc	ggatccgccc	cattcacagt	3840
tctccgcaag	aattgattgg	ctccaattct	tggagtggtg	aatccgttag	cgaggtgcgc	3900
ccggcttcca	ttcaggtcga	ggtggcccgg	ctccatgcac	cgcgacgcaa	cgcggggagg	3960
cagacaagg	ataggcgcc	gcctacaatc	catgccaacc	cgatccatgt	gctcgccgag	4020
gcccataaa	tcgcgtgac	gatcagcggt	ccagtgatcg	aagttaggct	gtaagagcc	4080
gcgagcgatc	cttgaagctg	tccctgatgg	tcgtcatcta	cctgccttgg	cagcatggcc	4140
tgcaacgcgg	gcatcccgat	gcccgggaa	gcgagaagaa	tcataatggg	gaaggccatc	4200
cagcctcg	tcgcgaacgc	cagcaagacg	tagcccagcg	cgtcgccgc	catgccctgc	4260
ttcatcccc	tgcccggttg	ctcgcgtttg	ctggcggtgt	ccccgaaaga	aatatattt	4320
catgtctt	gttcttatgt	gacacaacc	ccgcccagcg	tcttgtcatt	gfcgaattcg	4380
aacacgcaga	tgcaagtggg	gcccgcgggt	cccaggtcca	cttcgcat	taaggtgcgc	4440
cgtgtggcct	cgaaacccga	gcgaccctgc	agcggccgc	ttaacagcgt	caacagcgt	4500
cccgagatcc	cgggcaatga	gatatggaaa	agctgaact	caccgcgacg	tctgtcgaga	4560
agtttctgt	cgaaaagg	gacacgtct	ccgacactgt	gcagctctcg	gagggcgaag	4620
aatctcg	tttcagtttc	gatgttaggag	ggcgtggata	tgtctgcgg	gtaaatagct	4680
gcccgcgtt	tttctacaaa	gatcgttatg	tttatcgca	ctttgcatcg	gccgcgcctt	4740
cgattccgg	agtgcgttgc	attgggaat	tcagcgagag	cctgacctat	tgcatctccc	4800
gccgtgcaca	gggtgtcag	ttgcaagacc	tgctgaaac	cgaactgccc	gctgttctgc	4860
agccggtegc	ggagggcatg	gatgcgtatcg	ctgcggccga	tcttagccag	acgagcgggt	4920
tcggccatt	cggaccgca	ggaatcggtc	aatacactac	atggcggtat	ttcatatgcg	4980
cgattgtga	tccccatgtg	tatcaactggc	aaactgtat	ggacgacacc	gtcagtgcgt	5040
ccgtcgcc	ggctctcgat	gagctgtatc	tttggccga	ggactgccc	gaagtccggc	5100
acetcgtga	cgcgatttc	ggcttcaaca	atgtctgc	ggacaatggc	cgcataacag	5160
cggtcattga	ctggagcgag	gcatgtttcg	gggatttccca	atacgaggtc	gccaacatct	5220
tcttctggag	gccgtgggt	gcttgtatgg	agcagcagac	gctacttc	gagcggaggc	5280
atccggagct	tgcaaggatcg	ccgcggctcc	gggcgtatat	gctccgcatt	ggtcttgacc	5340
aactctatca	gagcttggtt	gacggcaatt	tcgatgtatc	agcttggcg	cagggtcgat	5400
gcgacgcaat	cgtcgatcc	ggagccggga	ctgtcgccg	tacacaaatc	gcccgcagaa	5460
gcfgggccgt	ctggaccgat	ggctgtgtag	aagtaactcgc	cgatagtgg	aaccgacgcc	5520
ccagcactcg	tccgagggca	aaggaatagg	ggagatgggg	gaggctact	aaaacacgaa	5580
aggagacaat	accggaagg	accgcgctca	tgacggcaat	aaaaagacag	aataaaacgc	5640
acgggtgtt	ggtcgtttgt	tcataaaacgc	ggggttcgt	cccaggctg	gcactctgtc	5700
gataccac	cgagacccca	ttggggccaa	tacgcccgc	tttcttcctt	ttccccaccc	5760
cacccccc	gttcgggtga	aggcccagg	ctcgcagca	acgtcggggc	gcaaggccct	5820
gcatagcca	ctggggccgt	gggttaggg	cggggtcccc	catgggaat	gttttatgtt	5880
tcgtgggggt	tattat	ggcgttgcgt	gggggtctgt	ccacgactgg	actgagcaga	5940
cagaccatg	gttttggat	ggcctggca	tggaccgcat	gtactgggc	gacacgaaca	6000
ccgggcgtct	gtggctgca	aacaccc	accccaaaa	accacgcgc	gatattctgg	6060
cgcccagtgc	cgtcgaccgg	tcatggctgc	gccccgacac	ccgccaacac	ccgctgacgc	6120
gccctgacgg	gcttgtctgc	tcccgccatc	cgcttacaga	caagctgt	ccgtctccgg	6180
gagctgtatc	tgtcagaggt	tttcacccgtc	ataccggaaa	cgcgcgaggc	agccggatca	6240
taatcagcca	taccacatt	gtagagggtt	tacttgctt	aaaaaaacctc	cccacctccc	6300
cctgaacctg	aaacataaaa	tgaatgc	tgttgtgtt	aacttgttta	ttgcagctt	6360
taatggttac	aaataaagca	atagcatc	aaatttcaca	aataaagcat	tttttact	6420
gcattctagt	tgtgtttgt	ccaaactcat	caatgtatc	tatcatgtct	ggatccacta	6480
gttctagagc	ggccgcacc	gcggtgaggc	tccagcttt	gttcccttta	gtgagggtt	6540
atttcagat	tggcgtatc	atggtcatag	ctgtttctg	tgtgaaattt	ttatccgc	6600
acaattccac	acaacatacg	agccggaagc	ataaaagtgt	aagcctgggg	tgcctaatga	6660
gtgagctaa	tcacattaat	tgcgttgcgc	tcactgccc	ctttccagtc	gggaaaccc	6720
tcgtgc	tgcattat	aatcggccaa	cgcgcggg	gaggcggtt	gcgtatttgg	6780
cgcttccg	cttcctcgct	cactgactcg	ctgcgcgtcg	tcgttccgg	cgccgcgagcg	6840
gtatcgtctc	actcaaaggc	ggttaatacg	ttatccacag	aatcgggg	taacgcagga	6900
aagaacatgt	gagcaaaaagg	ccagcaaaag	gccaggaacc	gtaaaaaggc	cgcgttgcgt	6960
gctttttcc	ataggtccg	ccccctcgac	gagcatcaca	aaaatcgacg	ctcaagttag	7020
aggtggcgaa	acccgacagg	actataaaga	taccaggcg	ttccccctgg	aagctccctc	7080
gtgcgtctc	ctgttccgac	cctgcccgtt	acggatacc	tgtccgcctt	tctcccttc	7140
ggaagcgtgg	cgcttctca	tagctcagc	tgttaggtatc	tcagttcggt	gtaggtcgtt	7200
cgctccaagc	tgggctgtgt	gcacgaaccc	cccggttccagc	ccgaccgcgt	cgcccttatcc	7260

ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc 7320
 actggtaaca ggattagcag agcgaggat gttagcggtg ctacagagtt cttgaagtgg 7380
 tggcctaact acggctacac tagaaggaca gtatttggta tctgcgtct gctgaagcca 7440
 gttacccctcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 7500
 ggtgggtttt ttgttgc当地 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560
 cctttatct tttctacggg gtctgacgct cagtggAACG aaaactcacg ttaagggatt 7620
 ttggcatgaa gattatcaa aaggatctc acctagatcc ttttaaatta aaaaatgaagt 7680
 tttaaatcaa tctaaatgtat atatgatcaa acttggctc acagttacca atgcttaatc 7740
 agtggggcac ctatccacg gatctgtctt tttcggtcat ccatacgatc ctgactcccc 7800
 gtcgtgtaga taactacgat acggggaggc ttaccatctg gcccaggatc tgcaatgata 7860
 cccgagacc caccgtcacc ggctccagat ttatcagcaaa taaaccagcc agccggaaagg 7920
 gcccggcga gaagtggcc tgcaacttta tccgcctcca tccagtttat taattgttc 7980
 cgggaagcta gagtaagtag ttcggcaggat aatagttgc gcaacgttgt tgccattgct 8040
 acaggcatcg tgggtc当地 ctcgtcgat ggtatggctt cattcagctc cgggttcccaa 8100
 cgatcaaggc gagttacatg atccccatg ttgtcaaaa aagcggttag ctccctcggt 8160
 cctccgatcg ttgtcagaag taagttggcc gcaatgttat cactcatggt tatggcagca 8220
 ctgcataat ctctactgt catggcatcc gtaagatgtt tttctgtgac tgggtgagttac 8280
 tcaacaaatg cattctgaga atatgtatg cggcgaccga gttgtcttg cccggcgatc 8340
 atacgggata ataccgc当地 acatagcaga actttaaaag tgctcatcat tggaaaaacgt 8400
 tcttcggggc gaaaactctc aaggatctt ccgctgttga gatccaggatc gatgtaaccc 8460
 actcgtgcac ccaactgatc ttccggatct tttactttca ccagcgatcc tgggtgagca 8520
 aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata 8580
 ctcataactct tccttttca atattattga agcatttatac agggttatttgc tctcatgagc 8640
 ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgatc cacatttccc 8700
 cgaaaaatgc 8710

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 5
 atgggatcca agatgaagcg cgcaagaccg

30

<210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 6
 cataacgc当地 ccgcttcttt attcttggcc

30

<210> 7
 <211> 7148
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 7
 gagccggatccg gagatctccc gatccctat ggtcgactct cagtacaatc tgctctgatg 60
 cccgcatagtt aaggcaggat ctgctccctg cttgtgtt ggaggtcgatc gagtagtgc当地 120
 cgagcaaaat ttaagctaca acaaggcaag gcttgc当地 accatgc当地 aagaatctgc 180

ttaggttttag	gcgttttgcg	ctgcttcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggacttcc	420
attgacgtca	atgggtggac	tattiacggt	aaactgc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgc	taaatggccc	gcctggcatt	540
atgcccagt	catgacccta	tgggacttc	ctacttgc	gtacatctac	gtattagtca	600
tcgcttattac	catgttgatg	cgggtttgc	agtatcatca	tggcg	tagcg	660
actcacgggg	atttcaaga	tc	ttgacgtca	tggaggtt	tttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaattggcg	780
gtaggcgtgt	acgggtggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatacgaa	attaatacga	ctcactatag	ggagacccaa	gcttggtacc	900
gagctcgat	ccaagatgaa	g	ccgtctgaag	atacctcaa	ccccgtgtat	960
ccatatgaca	cgaaaaccgg	tc	gtgcctt	ttactc	ctttgtatcc	1020
cccaatgggt	ttaaagagag	ccccctggg	gtactctt	tg	cgaacctcta	1080
gttacccca	atggcatgt	tg	atgggcaacg	gc	ggacgaggcc	1140
ggcaaccta	c	tgtaaccact	gtgaggccac	c	aaccaagtca	1200
aacataaaacc	tggaaatate	tg	acagttac	cagaagcc	aacttgtgt	1260
gcccggcac	ctctaattgg	cg	acactc	tg	ggcccgct	1320
accgtgcacg	actccaaact	ta	accaaggac	cc	gtcagaagg	1380
aagctagccc	tgc	aggccccctc	accaccac	at	ccttactatc	1440
actgcctc	cc	actg	ggtagctt	g	gaaagagccc	1500
atttatacac	aaaatggaaa	actaggacta	a	att	tgt	1560
gacctaaca	cttgc	agcaactgg	ag	tc	ta	1620
caaactaaag	ttactggagc	cttggg	att	at	actt	1680
gcaggaggac	taaggattg	ttctcaaa	ac	gt	at	1740
tttgc	aaaaccaact	aaatctaaga	ctt	actt	ttat	1800
gcccacaact	tggatattaa	ct	agg	gtt	act	1860
tccaaa	ttgaggtaa	ct	gg	ttt	ca	1920
atagccatta	atgcaggaga	tg	cc	gg	aa	1980
cccctcaaaa	caaaaattgg	ccat	ca	at	aca	2040
aaactaggaa	ctggc	ttt	aa	at	ttt	2100
aatgataa	taactt	gac	ac	tt	ttt	2160
gagaaagat	ctaaactc	ttt	gt	tt	ttt	2220
gtttca	tgg	agg	cc	tt	ttt	2280
catcttatt	taagattg	cg	cc	tt	ttt	2340
gaatattg	actttagaa	gg	ct	tt	ttt	2400
ggatttat	ctaa	gg	ct	tt	ttt	2460
atgtc	actt	gg	at	tt	ttt	2520
ctaaac	gg	gg	aa	tt	ttt	2580
tggact	ctgg	gg	aa	tt	ttt	2640
tcatacatt	ccca	gg	aa	tt	ttt	2700
ctatag	actt	gg	aa	tt	ttt	2760
cagccatct	ttt	gg	cc	tt	ttt	2820
actgtc	ctt	ttt	tt	tt	ttt	2880
attctgg	gtt	gg	tt	tt	ttt	2940
catgttgg	at	gg	tt	tt	ttt	3000
aggggtat	cc	gg	tt	tt	ttt	3060
cgc	gg	gg	tt	tt	ttt	3120
cgact	ct	gg	tt	tt	ttt	3180
tc	tt	gg	tt	tt	ttt	3240
gggtcc	tt	gg	tt	tt	ttt	3300
tcacgt	gg	gg	tt	tt	ttt	3360
tttta	tt	gg	tt	tt	ttt	3420
tcttt	tt	gg	tt	tt	ttt	3480
taaaaaat	tta	ac	tt	tt	ttt	3540
ccccag	cc	cc	tt	tt	ttt	3600
agg	cc	cc	tt	tt	ttt	3660
tagt	cc	cc	tt	tt	ttt	3720
tagc	cc	cc	tt	tt	ttt	3780
tcggcc	cc	cc	tt	tt	ttt	3840
gcctct	cc	cc	tt	tt	ttt	3900
tgcaaa	cc	cc	tt	tt	ttt	
ggatcg	cc	cc	tt	tt	ttt	

gagaggctat tcggctatga ctgggcacaa cagacaatcg gctgctctga tgccgcccgtg 3960
 ttccggctgt cagcgcaggg ggcagcgcgg ctatcggtc agaccgaccc gtccgggtgcc 4020
 ctgaatgaac tgcaggacga tgccagctg tgctcgacgt tgcactgaa gcgggaaggg actggctgct attggggcgaa 4080
 gtgcggggcc aggatctcct gtcatctcac cttgcctctg ccgagaaagt atccatcatg 4140
 gtcgatgcaa tgcggcgct gcaacatc gcatcgagcg gatctggacg aagagcatca cgcatgcccc acggcgagga 4200
 atggtgaaaa atggccgctt gctatcagg acatagcgat gtcgaccgtc tcctcggtct tatecgcttc ttgacgagg ttcgtcgatg acccatggcg atgcctgctt gccaataatc 4260
 cgacgccccaa cctggccatca gttcggaat cgtttccgg tggagttctt cgcccaccccc atagcatcac aaatttcaaa ccaaactcat caatgtatct gtaatcgatc ttccctgtgt gaaattgtta tccgctcaca attccacaca 4320
 cgtaatcatg gtcatagctg acatacgagc cggaagcata cattaattgc gttgcgctca attaatgaat cggccaacgc cctcgctcac tgactcgctg caaaggcggt aatacggtt aaaaaggcca gcaaaaaggcc ggctccgccc ccctgacgag cgacaggact ataaaagatac ttccgaccctt gccgcttacc tttctcaatg ctcacgctgt gctgtgtgca cgaacccccc ttgagtccaa cccggtaaaga ttagcagagc gaggtatgta gtcacactag aaggacagta aaagatgg tagcttttga ttgcaagca gcagattacg ctacggggtc tgacgctc tagaaaaag gatcttacc aaagtatata ttagttaact ttcagcgat ctgtctattt ctacgatacg ggagggtta gtcacccggc tccagattta gtggctctgc aacttattcc taagtatgtt cccggttaat tgacgtctc gtcgttttgtt acgttccatc ttacatgatc ccccatgttgc tcaagaagtaa gttggccgca ttactgtcat gccatccgta tetgagaata gtgtatgcgg ccgcgccaca tagcagaact aactctcaag gatcttaccg actgatcttc agcatctttt aaaaaggcca aaaaatggcata ttatttcaata ttatttcaata aatgtatgtt gaaaaataaa ctgacgtc
 ctgggcacaa cagacaatcg gctgctctga tgccgcccgtg 3960
 ggcagcgcgg ctatcggtc agaccgaccc gtccgggtgcc 4020
 gtcactgaa gcgggaaggg actggctgct attggggcgaa 4080
 gtcatctcac cttgcctctg ccgagaaagt atccatcatg 4140
 gcaacatc gcatcgagcg gatctggcgcc ccagccgaa tgggctcgcg tgccgcccatt cgaccaccaa 4200
 agcacgtact cgatggaaag ccggcttctgt cgatcaggat 4260
 ggggctcgcg ccagccgaa tggcccgat gctcaaggcg 4320
 ttcgtcgatg acccatggcg atgcctgctt gccaataatc 4380
 ttctggattc atcgactgtg gccggctggg tggccggac 4440
 ggctaccgt gatattgtg aagagcttgg cggcgaatgg 4500
 ttacggatc gccgctcccg attcgccagcg catcgccctc 4560
 cttctgacg gactctggg gtcgaaatg accgaccaag 4620
 cgagatctcg atttccacgc cgcccttat gaaagggttg 4680
 gacgcccgtt ggtatgttcc cgacgcggg gatctcatgc 4740
 aacttggta ttgcagcttta taatggttac aaataaaagca 4800
 aataaaagcat tttttactt gcatcttagt tgggtttgt 4860
 tatcatgtct gataaccgtc gacctctagc tagagcttgg 4920
 tttccctgtgt gaaattgtta tccgctcaca attccacaca 4980
 aagtgttaaag cctgggggtgc ctaatcgatg agctaactca 5040
 ctggccgtt tccagtcggg aaacctgtcg tgccagctgc 5100
 gccggggagag ggggttgcg tattgggcgc tcttccgctt 5160
 cgctcggtcg ttccggctcg gcgagcggta tcagctcact 5220
 tccacagaaat cagggataa cgcaggaaag aacatgtgag 5280
 aggaaccgtt aaaaaggccgc gttgcggcg tttttccata 5340
 catcacaaaa atcgacgctc aagtcaaggg tggcgaaacc 5400
 caggcggttc cccctggaaag ctccctcgat cgctctccgt 5460
 ggataccgtt ccgccttcc cccctggga agcgtggcgc 5520
 aggtatotca gttcgggtta ggtcgttcgc tccaagctgg 5580
 gttcagcccg accgctgcgc cttatccgtt aactatcgatc 5640
 cacgacttat cggcaactggc agcagccact gtaacacagga 5700
 ggcgggtgtt cagagttttt gaaagggttgg ctaactactg 5760
 tttttatct ggcctctgtc gaagcagttt accttcggaa 5820
 tccgcacaaac aaaccaccgc gttgcgggtt gttttttttt 5880
 cgcagaaaaa aaggatctca agaagatctt ttgatctttt 5940
 tggAACGAAA actcacgttta agggattttt gtcatgagat 6000
 tagatccccc taaattaaaa atgaagttt aatcaatct 6060
 tggctctgaca gttaccaatg cttaatcgat gaggcaccta 6120
 cgttcatcca tagttgcctg actcccgatc gtgttagataa 6180
 ccatctggcc ccagtgcgtc aatgataccg cgagacccac 6240
 tcagcaataa accagccagc cggaaaggccc gagcgcagaa 6300
 gcctccatcc agtctttaa ttgttgcggg gaaagcttagag 6360
 agtttgcgc acgttgcgtt cattgttaca ggcatcgatgg 6420
 atggcttcatc tcagctccgg ttcccaacga tcaaggcgag 6480
 tggaaaaaa cggtagctc ttccgttccctt ccgcattcgat 6540
 tggttatcac tcattgttac ggcagactg cataatttc 6600
 agatgtttt ctgtgactgg tgatgttca accaagtcat 6660
 cgaccgagtt gctcttgcgg ggcgttcaata cgggataata 6720
 ttaaaaatgtc tcatttttttccctt ccgcattcgat 6780
 ctgtttagat ccagtgcgtt gtaacccact cgtgcacccca 6840
 actttccatc ggcgttctgg gtgagaaaa acagggaaaggc 6900
 ataaggcgat caccggaaatg ttgatgttca atactttcc 6960
 atttatttccatc gtttattgttccatc gtcgttccctt 7020
 aatgtatgtt gtttattgttccatc gtcgttccctt 7080
 caaatagggg ttccgcgcac atttcccgat aatgtgcac 7140
 ctgacgtc
 7148

<210> 8
 <211> 7469
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 8

gacggatcg ggatctcc gatccc tat ggtcgactc cagaatac tgctctgatg 60
ccgcatagtt aaggcagtat ctgctccctg cttgtgtt ggaggcgct gagtagtcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgcga caattgcatt aagaatctgc 180
ttagggttag gcgtttcgct ctgcttcgct atgtacggc cagatatacg cggtacatata 240
gattattgac tagttattaa tagtaatcaa ttacggggtt attagttcat agccccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgcatt gacgtcaata atgacgtatg cccatagt aacccaata gggactttc 420
attgacgtca atgggtggac tatttacggt aaactgccta cttggcagta catcaagtgt 480
atcatatgcc aagtacgcctc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctt tgggactttc ctacttgca gtacatctac gtattagtca 600
tcgctattac catggtgatg cgggttggc agtacatcaa tggcgttga tagcggttt 660
actcacggg atttccaagt ctccacccca ttgacgtca tggaggtttg tttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccatgtacg caaatggcg 780
gtaggcgtgt acgggtggag gtctatataa gcaagactct ctgctacta agagaaccca 840
ctgcttactg gcttacgaa attaatacgaa gggctccgat ctcaattcgta gtagacgttacc 900
gagctcgat ctgaattcgta gctcgctgtt gggctcgccg ttgaggacaa acttttcg 960
gttccatcg ttttccatcg ttttccatcg gtcggccctc gaaacgtact ccgcacccga 1020
gggaccttag cttttccatcg ttttccatcg cggaaaacct ctccgagaaag gctgtcaacc 1080
agtcacagtc gcaaggtagg ctgagcaccg tggcggccgg cttttccatcg ggtactctct 1140
tggccatcg ggaggtgctg ctgatgtatg tggcggccgg cttttccatcg aatggcaac 1200
tggtcgagg tgggtgtggc aggcttgaga acggaaaacct ctccgagaaag ggtactctct 1260
gatacctca accccgtgtt tccatatgac tttcaagaga gtcccccctgg ggtactctct 1320
cttactcctc cttttgtatc ccccaatggg aatggcattc ttgcgttcaaa aatggcaac 1380
ttgcgcctat cccgaaccttct agttacccctt acctcccaaa atgtacccac aatggcaac 1440
ggcctctctc tggacgaggc cggcaacccctt cttttccatcg ttttccatcg aatggcaac 1500
cctctcaaaa aaaccaatgtt aacacataaac ttttccatcg ttttccatcg aatggcaac 1560
tcagaagccc taactgtggc tggccggcga aatggcattc ttgcgttcaaa aatggcaac 1620
atgcaatcac agcccccgctt aaccgtgcac cttttccatcg ttttccatcg aatggcaac 1680
cccctcacag ttttccatcg aagacttagcc ttttccatcg ttttccatcg aatggcaac 1740
gatagcagta cttttccatcg cttttccatcg aactaggactt aacacataaac ttttccatcg 1800
ggcatttgcact ttttccatcg cttttccatcg aactaggactt aacacataaac ttttccatcg 1860
gtcccttgc atgtacacaga cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 1920
actattaata atacttccctt cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 1980
ggcaatatgc aacttacatgtt aacacataaac ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 2040
atacttgcat ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggacag 2100
ggccctttt ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggacag 2160
ttgtttacag cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggacag 2220
ttgatgtttt acgttacacgc cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 2280
cctaatgcac cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggacag 2340
tcaaacaagg cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggacag 2400
attacagtag gaaacaaaaaa taatgataag cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 2460
cctaactgtt gactaatgtc agagaaaagat ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 2520
ggcagtcataa taactgtctt cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg 2580
tctggaaacat ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 2640
aacaatctt ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 2700
tctggacacat ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 2760
gtaaaactg cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 2820
cctgtacacac taaccattac actaaacgggtt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 2880
gcataactcta ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 2940
gccacatctt ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3000
atgcattctt ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3060
tcgactgtgc ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3120
accctggaaat gttccacttcc cttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3180
tgtctgatg ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3240
gattggaaat gtttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3300
gaaagaacca gtttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3360
ggggcggttgc ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3420
gctccttcg ttttccatcg ttttccatcg aactaggactt aacacataaac ttttccatcg aactaggactt aacacataaac ttttccatcg 3480

ctaaatcggg gcatcccttt agggttccga tttagtgcct tacggcacct cgaccccaaa 3540
 aaacttgatt agggtgatgg ttcacgtagt gggccatcg cctgatacgac gtttttcgc 3600
 ccttgcacgt tggagtcac gttcttaat agtggactct tgttccaaac tggacaaca 3660
 ctcaacccta tctcggtcta ttctttgtat ttataaggga ttttgggat ttcggcctat 3720
 tggtaaaaaa atgagctgat ttaacaaaaa ttaacgcga attaattctg tggaatgtgt 3780
 gtcagttagg gtgtggaaag tccccaggt ccccaggcag gcagaagtat gcaaagcatg 3840
 catctcaatt agtcagcaac cagggtgtga aagtccccag gctcccacg aggcaagaat 3900
 atgcaaaaga tcgatctcaa tttagtcgca accatagtcc cggccctaaac tccgcccatt 3960
 ccccccctaa ctccggccag ttccgcctat tctccggccc atggctgact aattttttt 4020
 atttatgcag aggcggaggc ttgttggag gcctaggctt ttgcaaaaag ctcccgagg cttgtatatc cattttcgga 4140
 tctgatcaag agacaggatg aggatcgat tccatgattt aacaagatgg attgcacgca 4200
 ggttctccgg ccgcttgggt ggagaggcta ttccgctatg actggcaca acagacaatc 4260
 ggctgctctg atgcggccgt aagaccgacc tgcgcgggtgc ctggccacga cggggcgttcc gactggctgc tattggcga gggagaaatc tattccatcat acctgcctat tcgaccacca gccggcttgc tcgatcagga ctgttcgcca ggctcaaggc gatgcctgat tgccgaatat ggccggctgg gtgtggcga gaagagcttgc gcccggcaatg gattcgcagc gcatacgccctt ggttcgaaat gaccgaccaa ccgccttcata tgaagggttgc tccagcggg ggatctcatg ataattgttca caaataaagc tgcattctag ttgtggtttgc cgacctctag cttagagcttgc atccgctcac aattccacac cctaattgag tggcttgcactc gaaacctgtc gtgcagctg gtattggcgc ctcttcgct ggccggcggtt atcagctcac acgcaggaaa gaacatgtga cttgttccat caagttagag gtggcgaaac gtcctctgt ggcctctctt tccctcggtt aaggcgttgc aggtcggttgc ctttatccgg taactatcg cagcagccac tggtaacagg tgaagggttgc gcttaactac tgaaggccat tacctcggtt ctggtagcggtt aagaagatcc ttgtatctt aagggatttt ggtcatgaga aatgaagttt taaatcaatc gctaattcag tgaggcacct gactccccgt cgttagata caatgataacc gcgagaccca cgggaaggggc cgagcgcaga attgttgcgc ggaagctaga catttcgtac aggcgttgc gttcccaacg atcaaggcga cttcggttcc tccgatcgat tggcagcactc gtgagttactc aaccaagtca cggcgtcaat acggataat gaaaacgttcc ttcgggcga

tgttaaccac tcgtgcaccc aactgatctt cagcatctt tactttcacc agcgtttcg 7260
ggtagcaaa aacaggaagg caaatgccg caaaaaggg aataagggcg acacggaaat 7320
gttgaatact catactcttc cttttcaat attattgaag catttatcag gtttattgtc 7380
tcatgagcgg atacatattt gaatgtatTTT agaaaaataa acaaataggg gttccgcgc 7440
cattcccccaaaaatgtccca cctgacgtc 7469

<210> 9
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 9
tgcttaagcg gccgcgaagg agaagtcc 28

<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 10
ccgagctagc gactgaaaat gag 23

<210> 11
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 11
cctctcgaga gacagcaaga cac 23

<210> 12
<211> 11152
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 12
aagcttgggc agaaatggtt gaactccga gagtgtccta cacctagggg agaagcagcc 60
aagggttgtt ttcccaccaa ggacgaccgg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcatttctcg ctgcaaactt ggcatagctc tgctttgcct ggggctattg 180
ggggaaagttt cggttcgtgc tcgcagggtc ctacccctt actctttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttacaa gccgcacgca tttgtcctt cagaaataga aataagaatg 360
cttgcttaaaa attatatttt taccataaag accaatccaa taggttagatt attagttact 420
atgttaagaa atgaatcatt atcttttagt actatTTTta ctc当地attca gaagtttagaa 480
atggaaatag aaaatagaaaa gagacgctca acctcaattt aagaacaggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaagggg aaaaagagtg ttttgcctt aataggagac 600
agtggtggc aaccaggac ttatagggg ctttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaat tggataggtt gggatcactt caatggctat 720

aaagtgttat	atagatccct	ccctttcgt	gaaagactcg	ccagagctag	accccttgg	780
tgtatgtgt	ctcaagaaga	aaaagacac	atgaaacaac	aggtacatga	ttatatttat	840
ctaggaacag	aatgcactt	ttggggaaag	atttcata	ccaaggaggg	gacagtggct	900
ggactaatag	aacattattc	tgcaaaaact	catggcatga	gttattatga	atagcctta	960
ttggcccaac	cttgcggttc	ccagggctta	agtaagttt	tggttacaaa	ctgttcttaa	1020
aacgaggatg	tgagacaagt	ggtttcccta	cttggtttgg	tatcaaaggt	tctgatctga	1080
gtctcgatgt	ttcttatttc	ctatgttctt	ttgaaattta	tccaaatctt	atgtaaatgc	1140
ttatgtaaac	caagatataa	aagatgtctg	attttttag	taaaacttgc	acagtccctaa	1200
cattcacctc	tttgtgtttt	tggtctgttc	gccccctgt	ctccgcgt	cacttatct	1260
tcactttcca	gagggtcccc	ccgcagaccc	cgcgacccct	caggtcggcc	gactgcggca	1320
gctggcgccc	gaacaggggac	cctcgatata	gtgacccttg	tctctatttc	tactattttg	1380
tgtttgtctt	gtattgtctc	tttcttgc	ggctatcatc	acaagagcgg	aacggactca	1440
ccatagggac	caagctagcg	actgaaaatg	agacatatta	tctgccacgg	aggtgttatt	1500
accgaagaaa	tggccgcccag	tctttggac	cagctgatcg	aagaggtaact	ggctgataat	1560
cttccaccc	ctagccattt	tgaaccacct	acccttcacg	aactgtatga	tttagacgtg	1620
acggcccccg	aaagatccaa	cgaggaggcg	gttgcgaga	tttttccgaa	ctctgtatg	1680
ttggcgtgtc	aggaaggat	tgacttactc	actttccgc	cggcccccgg	ttctccggag	1740
ccgcctcacc	tttccggca	gcccggacag	ccggagcaga	gagccttggg	tccggtttct	1800
atgccaaacc	ttgtacccgga	ggtgatcgat	cttacctgcc	acgaggctgg	ctttccaccc	1860
agtgcgacg	aggatgaaga	gggtgaggag	ttttgtttag	attatgtgaa	gcaccccccgg	1920
cacggtgtca	ggtcttgc	ttatcacccg	aggaatacgg	gggaccaga	tattatgtgt	1980
tcgcttgc	atatgaggac	ctgtggcatg	tttgtctaca	gtaagtgaaa	attatggca	2040
gtgggtgata	gagtgggg	tttgggttgg	taatttttt	tttaattttt	acagttttgt	2100
ggtttaaaga	attttgtatt	gtgattttt	taaaaggtcc	tgtgtctgaa	cctgagccctg	2160
agcccgagcc	agaaccggag	cctgcaagac	ctacccgcg	tcctaaaatg	gcgcctgcta	2220
tcctgagacg	cccgacatca	cctgtgtcta	gagaatgc	tagtagtacg	gatagctgt	2280
actccgttcc	ttctaaacaca	cctcctgaga	tacaccgg	ggtcccgctg	tgcggccat	2340
aaccagtgc	cgtgagat	ggggcgtgc	gccaggctgt	ggaatgtatc	gaggacttgc	2400
ttaacgagcc	tggcaacct	tttgacttga	gctgttaacg	ccccaggcca	taaggtgtaa	2460
acctgtgatt	gcgtgtgtgg	ttaacgcctt	tggtgtctga	ataggttgc	gtaagttta	2520
taaagggtga	gataatgttt	aacttgc	ggtgtttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atcttggta	catctgac	catggaggct	tgggagtgtt	2640
tggaagattt	ttctgtgt	cgttaacttgc	tggaacagag	ctctaacagt	acctcttgc	2700
tttggaggtt	tctgtggggc	tcatccca	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atttgaagag	cttttgaat	cctgtggtga	gctgttgc	tctttgaatc	2820
tgggtcacca	ggcgcttcc	caagagaagg	tcatcaagac	tttggattt	tccacacccg	2880
ggcgcgtgc	ggctgttt	gctttttga	gttataaaa	ggataaatgg	agcgaagaaa	2940
cccatctgag	cggggggat	ctgctggatt	tttggccat	gcatctgtgg	agagcgggt	3000
tgagacaccaa	gaatcgctg	ctactgtgt	cttccgtccg	cccgccgata	ataccgacgg	3060
aggagcagca	gcagcagcag	gaggaagcca	ggcgccggcg	gcaggagcag	agcccatgga	3120
acccgagagc	cggcctggac	cctcgggaat	gaatgttgc	caggtggctg	aactgtatcc	3180
agaactgaga	cgcattttga	caattacaga	ggatggcag	ggctaaagg	gggttaaagag	3240
ggagcggggg	gtttgtgagg	ctacagagga	ggcttaggaat	ctagctttt	gcttaatgac	3300
cagacaccgt	cctgagtgt	ttactttca	acagatcaag	gataattgc	ctaatgagct	3360
tgatctgctg	gcmcagaatg	attccataga	gcagctgacc	actacttgc	tgcagccagg	3420
ggatgtttt	gaggaggct	tttaggtata	tgcaaaagg	gcacttggc	cagattgc	3480
gtacaagatc	agcaaaacttgc	taaatatcg	gaatttgc	tacatttgc	gaaacggggc	3540
cgaggtggag	atagatacgg	aggatagggt	ggcctttaga	tgtagcatga	taaatatgt	3600
gccgggggtt	cttgcacatgg	acgggggtgt	tattatgaat	gtaaggttt	ctggcccca	3660
tttagcggt	acgggtttcc	tggcaatac	caacccatc	ctacacgg	taagcttct	3720
tgggttaaac	aataacctgt	tggaaagctg	gaccgatgt	agggttgc	gtgtgcctt	3780
ttactgtgt	tggaaaggggg	tgggtgtgt	ccccaaaagc	agggttca	ttaagaaatg	3840
cctcttgc	agggttaccc	tgggtatcc	gtctgagggt	aactccagg	tgcgcccaca	3900
tgtggctcc	gactgtgg	gtttcatgt	agtaaaagc	gtggctgt	ttaagcataa	3960
catggatgt	ggcaactgc	aggacagg	ctctcagat	ctgac	cgacggccaa	4020
ctgtcaccc	ctgaagacca	ttcacgt	cagccact	cgcaagg	gcccagt	4080
tgagcataac	atactgaccc	gttgc	gcatttgg	aacaggagg	gggtgttct	4140
acccatccaa	tgcaatttga	gtcacactaa	gatattgc	gagccgaga	gcatgtccaa	4200
ggtgaacctg	aacgggggt	ttgacatgac	catgaagatc	tggaaagg	ttaggtacga	4260
tgagacccgc	accaggtgc	gaccctgc	gtgtggcg	aaacatatta	gaaaccagcc	4320
tgtgtatgt	gatgtgacc	aggagctg	gcccgtac	tttgtctgg	cctgcacccg	4380
cgctgagtt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtgggcgtt	4440

cttaagggtg	ggaaaagaata	tataaggtgg	gggtcttatg	tagtttgtt	tctgttttgc	4500
agcagccgcc	gccgccccatga	gcaccaactc	gtttagtgg	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggct	ccagcattga	4620
tgttcgcggc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggAAC	4680
gcgcgttggag	actgcagcct	ccggccgcgc	ttaagccgct	gcagccaccg	ccgcgggat	4740
tgtgactgac	tttgccttcc	tgagcccgct	tgcaggcagt	gcagctccc	tttgcattccgc	4800
ccgcgcgtgac	aagggtgacgg	ctcttttgc	acaatttggat	tctttgaccc	ggaaacttaa	4860
tgtcgtttct	cagcagctgt	tggatctgc	ccagcagggtt	tgccttgc	aggcttcctc	4920
ccttcccaat	gccccgtttaaa	acataaaataa	aaaaccagac	tctgtttgg	tttggatcaa	4980
gcaagtgtct	tgctgtctct	cgagggatct	tttgtaagga	accttacttc	tgtgggtgt	5040
cataatttgg	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgtttaaacta	ctgattctaa	tttgggtgt	attttagatt	ccaacctatg	5160
gaactgtgat	atggggagcag	tggtggaatg	ccttaatga	ggaaaacctg	ttttgtctag	5220
aagaaaatgcc	atcttagtgt	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccctc	agaatttgcta	agtttttta	5340
gtcatgctgt	gttttagtaat	agaactctt	cttgccttgc	tatttacacc	acaaggaaa	5400
aagctgcact	gtctatataaag	aaaattatgg	aaaaatattt	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatataaacc	atactgtttt	ttttacttcc	acacaggcat	agagtgtct	5520
cttattaaata	ctatgctcaa	aaattgtgt	ccttagctt	tttaattttt	aaagggttta	5580
ataaaggataa	tttgcattgtat	agtgccttgc	ctagagatca	taatcagcca	taccacattt	5640
gttagaggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaaccc	gaaacataaa	5700
atgaatgcaa	tttgttgggt	taacttgc	tttgttgc	ataatggta	caaataaagc	5760
aatagcatca	caaatttac	aaataaaagca	tttttttac	tgcattctag	tttgtgggtt	5820
tccaaactca	tcaatgttac	ttatcatgtc	ttggatccggc	tgtggatgt	gtgtcagtt	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcggaaagcat	gcattctcaat	5940
tagtcagcaa	ccaggtgtgg	aaagtccccca	gggtccccag	caggcagaag	tatgcaaaagc	6000
atgcatctca	attagtcage	aaccatagtc	ccggccctaa	cttgcggccat	ccgcggccctaa	6060
actccgcccc	gttccggcccc	tttccggccc	catggctac	taatttttt	tatttatgca	6120
gaggccgagg	ccgcctcgcc	ctctgagcta	ttccagaagat	agtgaggagg	tttttttgc	6180
ggccttaggt	tttgcaaaaaa	gtttggacac	aagacaggct	tgcggatata	ttttgagaat	6240
accactttat	cccgcgtag	ggagaggcag	tgctaaaaaa	gacgcccact	catgtgaaat	6300
actgggtttt	agtgcgcccag	atctctataa	tctcgcgca	cctattttcc	cctcgaacac	6360
tttttaagcc	gtagataaacc	aggctggac	acttcacatg	agcgaaaaat	acatcgctac	6420
ctgggacatg	ttgcagatcc	atgcacgtt	actcgcaagg	cgactgatgc	tttctgaaca	6480
atggaaaggc	attatttgc	taagccgtt	cggtctgtt	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgctatg	tcgataccgt	tttattttcc	actacatgc	acgacaacca	6600
gcccgcgtt	aaagtgtgt	aacgcgcaga	aggcgatggc	gaagggttca	tcgttatttg	6660
tgacctgggt	gataccgggt	gtactcggtt	tgccgattcg	gaaatgtatc	aaaagcgcga	6720
cttgcacc	atcttcgca	aaccggctgg	tcgtccgctg	tttgatgact	atgttgcgtt	6780
tatcccgcaa	gataaccttgg	ttgaacagcc	gtgggatatg	ggcgtcgat	tcgtccccc	6840
aatctccgg	cgctaatctt	ttcaacgcct	ggactgccc	ggcgttgc	tttttaactt	6900
caggccgggtt	acaatagttt	ccagtaagta	tttggaggc	tgcattccat	acacaggcaa	6960
acctgagcga	aaccctgttc	aaaccccgct	ttaaacatcc	tgaaacctcg	acgctagttc	7020
gcccgtttaa	tcacggcgca	caaccgcctg	tgcagtcggc	ccttgcgtt	aaaaccatcc	7080
ctcaactggta	tgcgtatgtt	aaccgtctga	tgtggatctg	gcccggccat	gaccacacgcg	7140
aaatccctcg	cgtccaggca	cgtattgtt	tgagcgatgc	cgaacatgc	gacgtatgtt	7200
tatacgatc	ggtgatggc	taccgtggcg	gcaactggat	ttatgatgtt	gccccggatc	7260
tttgtgaaagg	aaccttactt	ctgtgggtgt	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaaatat	aaaattttt	agttgtataat	gtgtttaact	actgattcta	7380
attgttgcgt	tattttagat	tccaaacccat	ggaactgatg	aatgggagca	gtgggtggat	7440
gcctttaatg	aggaaaaccc	gtttgcgtca	gaagaaaatgc	catctgtgt	tgatgaggct	7500
actgctgact	ctcaacattt	tactccctca	aaaaagaaga	gaaaggtaga	agaccccaag	7560
gactttccct	cagaattgt	aagttttt	agtcatgtc	tgttttagtaa	tagaactctt	7620
gcccgtttt	ctatttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatattt	ctgttaaccc	tataagttag	cataacagg	ataatcataa	catactgtt	7740
tttcttactt	cacacaggca	tagatgtct	gcttataata	actatgtca	aaaattgtgt	7800
acctttagct	ttttaatttg	taaagggtt	aataaggaat	atttgatgtt	tagtgccttgc	7860
actagagatc	ataatcagcc	ataccacatt	tgttagagg	ttacttgctt	taaaaaaccc	7920
cccacaccc	ccccctgaacc	tgaaacataa	aatgaatgca	attgttgcgtt	ttaacttgcgtt	7980
tattgcagct	tataatggtt	acaataaaag	caatagcatc	acaatattca	caaataaagc	8040
attttttca	ctgcattctt	gttgcgtttt	gtccaaactc	atcaatgtat	tttatcatgt	8100
ctggatcccc	aggaagctcc	tctgtgtctt	cataaaaccct	aacccctct	acttgcgagg	8160

acattccaat cataggctgc ccattccaccc tctgtgtcct cctgttaatt aggtcactta 8220
 acaaaaaagga aattgggtag gggttttca cagaccgctt tctaagggtt attttaaaat 8280
 atctggaaag tcccttccac tgctgttttc cagaagtgtt ggttaaacagc ccacaaaatgt 8340
 caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaaacaccc tgctcatcaa 8400
 gaagcactgt gggtgctgtg ttagtaatgt gcaaaacagg aggcacattt tccccaccc 8460
 ttaggttcc aaaatatcta gtgttttcat tttacttgatc cagcactca 8520
 ctggataaggc attatccctt tccaaaacag ccttgtggc agtgttcatc tgctgactgt 8580
 caactgttagc attttttggg gttacagttt gaggatata tttggcctg tagtttgcta 8640
 acacaccctg cagctccaaa ggttcccac caacagcaaa aaaatgaaaaa ttggaccott 8700
 gaatgggtt tccagcacca ttttcatgag tttttgtgt ccctgaatgc aagtttaaca 8760
 tagcagttac cccaaataacc tcagttttaa cagtaacagc ttcccacatc aaaatatttc 8820
 cacaggtaa gtcctcattt aaatttaggca aaggaattct tgaagacgaa agggcctcgt 8880
 gatacgccctt ttttatagg ttaatgtcat gataataatg gtttctttaga cgtcagggtgg 8940
 cactttcgg ggaaatgtgc gcggAACCCC tattgttta tttttctaaa tacattcaaa 9000
 tatgtatccg ctcatgagac aataaccctg ataaatgtttt caataatatt gaaaaaaggaa 9060
 gagtagatgatttcaacattt tccgtgtcg ccttattccc tttttgggg cattttgct 9120
 toctgtttt gtcaccccg aaacgctgtt gaaagttaaa gatgtgaag atcagttggg 9180
 tgcacgagtg gtttacatcg aactggatct caacagcggt aagatccctt agagtttcg 9240
 cccccgaagaa cggtttccaa ttagtggacac ttttaagtt ctgctatgtg ggcgggtatt 9300
 atcccgtgtt gacggccggc aagagcaact cggtcgccc atacactatt ctcagaatga 9360
 cttgggttag tactcaccag tcacagaaaaa gcatcttacg gatggcatga cagtaagaga 9420
 attatgcagt gctgccataa ccatgagtgta taacactgcg gccaacttac ttctgacaaac 9480
 gatcggagga ccgaaggagc taaccgcctt tttgcacaac atgggggatc atgttaactcg 9540
 cttgtatcg tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac 9600
 gatgcctgca gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660
 agcttcccg caacaattaa tagactggat ggaggcggat aaagtgtcag gaccacttct 9720
 ggcgtcgccctt cttccggctg gctgggttat tgcgtataaa tctggagccg gtgagcgtgg 9780
 gtcctcgccgt atcattgcag cactggggcc agatggtaag ccctcccgta tcgtagttat 9840
 ctacacgacg gggagtcagg caactatggta tgaacgaaat agacagatcg ctgagatagg 9900
 tgcctctactg attaaggcatt ggttaactgtc agaccaagtt tactcatata tacttttagat 9960
 tgattttaaa cttcattttt aattttaaaag gatcttaggtg aagatccctt ttgataatct 10020
 catgaccaaa atcccttaac gtgagtttc gttccactga gcgtcagacc ccgtagaaaa 10080
 gatcaaaggaa tcttcttgag atcccttttt tctgcgcgta atctgtgtc tgcaaaacaaa 10140
 aaaaccaccc ctaccagcgg tgggtttgtt gcccgttcaaa gagctaccaa ctctttttcc 10200
 gaaggtaact ggcttcagca gaggcgcagat accaaatact gtccttctag tgcagccgt 10260
 gttagggccac cacttcagaacttgcgtc actctgtacg accgcctaca tacctcgctc tgtaatct 10320
 gtaccagggt gctgtgcctt gtggcgataaa gtcgtgtctt accgggttgg actcaagacg 10380
 atagttaccg gataaggcgc ctcggagcga acgacactaca ccgaactcgatc atacctacag cgtgagctat gagaagacgc 10440
 cacgcttccc gaaggagaa aggccggacac gtagccgtt agccggcaggg tcggaaacagg 10560
 agagcgcacg agggagctt caggggaaaa cgcctggat ctttataatgc ctgtcggtt 10620
 tcggccaccc tgaatttgagc gtcgattttt gtgtatgtcg tcaggggggc ggagcctatg 10680
 gaaaaaacgcc agcaacgcgg cctttttacg gtttctggcc ttttgcgtgc cttttgctca 10740
 catgttctt cctgcgttat cccctgattt tgggatataac cgtattaccg cttttgagtg 10800
 agctgataacc gctgcggcc gccgaacac cggcgcagc gaggcgttgaa gcgaggaaac 10860
 ggaagagcgc ctgatcggtt attttcttctt taacgcattt tgcggatttt cacacccgt 10920
 atgggtgcact ctcagttacaa tctgctctga tgcgcgtat ttaagccagt atacactccg 10980
 ctatcgctac gtgactgggt catggctgcg ccccgacacc cggcaacacc cgctgacgcg 11040
 ccctgacggg cttgtctgtt cccggcatcc gtttacagac aagctgtgac cgtctccggg 11100
 agctgcgtt gtcagagggtt ttcaccgtca tcaccgaaac ggcggaggca gc 11152

<210> 13
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 13
 gacggatcg gagatctcc

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 14
ccgcctcaga agccatagag cc 22

<210> 15
<211> 14455
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 15
aagcttgggc agaaatggtt gaactccgaa gagtgcctta cacctagggg agaagcagcc 60
aagggttgtt ttcccaccaa ggacgaccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcatttcgtc ctgcacaaactt ggcatagctc tgcttgcct ggggttattt 180
ggggaaagttt cggttctgtc tcgcagggtt ctcacccttg actcttttaa tagctttct 240
gtgcaaggatt acaatctaaa caattcgag aactcgacct tcctccttag gcaaggacca 300
cagccaaactt cctcttacaa gccgcacatcga ttttgcctt cagaaataga aataagaatg 360
cttgcttaaaa atttatattt taccataaag accaatccaa taggttagatt attagttact 420
atgttaagaa atgaatcatt atcttttagt actatttta ctcaaattca gaagttagaa 480
atggaaatag aaaatagaaaa gagacgctca acctcaattt aagaacaggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaaggaa aaaaaagagt ttttgcctt aataggagac 600
agtggttggc aaccaggac ttataggga cttacatct acagaccaac agatgcccc 660
tttaccatata caggaagata tgacttaaat tggataggt gggttacagt caatggctat 720
aaagtgttat atagatccct ccctttctgt gaaagactcg ccagagctag acctcccttg 780
tgtatgttgc tctaagaaga aaaagacgac atgaaacaac aggtacatga ttatatttt 840
cttaggaacag gaatgcactt ttggggaaag attttccata ccaaggagg gacagtggct 900
ggactaataag aacattattc tgcaaaaact catggcatga gttattatga atagcctta 960
ttggcccaac cttgcgggtc ccagggctt agtaagttt tggttacaaa ctgttcttaa 1020
aacgaggatg tgagacaagt ggtttcttga ctgggtttgg tatcaaaggt tctgatctga 1080
gctctgatgt ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140
ttatgttaaac caagatataa aagagtgtcgt atttttttag taaacttgc acagtccctaa 1200
cattcacctc ttgtgtgttt gtgtctgtt gccatcccg tcccgctctg cacttatct 1260
tcactttcca gagggtcccc ccgcacggcc cggcgaccctt caggtcgcc gactgcggca 1320
gctggcgccc gaacaggac cctcggataa gtgaccctt tctctattt tactattttgg 1380
tgggtgtctt gtattgtctc ttctttgtct ggctatcata acaagagcgg aacggactca 1440
ccataggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
acccaaagaaa tggccgccc tcttttgac cagctgatcg aagaggtact ggctgataat 1560
cttccacctc ctagccattt tgaaccaccc acccttcacg aactgtatga tttagacgtg 1620
acggcccccg aagatccaa cgaggaggcg gtttgcaga tttttcccgta ctctgtatg 1680
ttggcggtgc aggaaggat tgacttactc acttttccgc cggcgccccgg ttctccggag 1740
ccgcctcacc ttcccggca gcccggacg cgggagcaga gagccttggg tccggtttct 1800
atgccaaacc ttgttaccggaa ggtgatcgat cttacacttgc acgaggctgg ctttccaccc 1860
agtgcacgacg aggatgaaga ggggtgaggag tttgtgttag attatgttgc gacaccccg 1920
caagggttgc ggtcttgc ttagtacccgg aggaatacgg gggacccaga tattatgtt 1980
tcgtttgtctt atatgaggac ctgtggcatg tttgtctaca gtaagtggaa attatggca 2040
gtgggtgata gagtggtggg tttgggtgtgg taattttttt ttaattttt acagttttgt 2100
ggtttaaaga attttgtatt gtgatttttt taaaagggtcc tggatctgaa cctgagcctg 2160
agcccgagcc agaaccggag cctgcaagac ctacccggcc tcctaaaatg ggcctgtcta 2220
tcctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgt 2280
actccggtcc ttctaacaca ctcctgttacacca tacacccggt ggtcccgctg tgccccat 2340
aaccagttgc cgtgagagtt ggtggcgctc gccaggctgt ggaatgtatc gaggacttgc 2400
ttaacgagcc tggcaaccc ttggacttgc gctgttaaacg ccccaggcca taaggtgtaa 2460

acctgtgatt gcgtgtgtgg ttaacgcctt tggggcgggg cttaaagggt 2520
 taaaagggtga gataatgttt aacttgcattt gcggttaaa tggggcgggg cttaaagggt 2580
 atataatgcg ccgtgggcta atcttggta catctgaccc catggaggct tgggagtgtt 2640
 tggaaagattt ttctgctgtg cgtaacttgc tggaacagag ctctaacagt acctcttgg 2700
 ttggaggtt tctgtggggc tcattccagg caaagttagt ctgcagaatt aaggaggatt 2760
 acaagggtggg atttgaagag cttttgaat cctgtggta gctgttgat tctttgaatc 2820
 tgggtcacca ggccgttttc caagagaagg tcatcaagac ttgggatccc tccacacccg 2880
 ggcgcgtgc ggctgtgtt gctttttaaa gtttataaa ggataaatgg agcgaagaaa 2940
 cccatcttag cggggggtag ctgctggatt ttctggccat gcatctgtgg agagcgggtg 3000
 tgagacacaa gaatgcctg aggagcagca gcagcagcag acccgagagc cggccctggac agaactgaga cgcattttga
 ggagcggggg gcttgtgagg cagacaccgt cctgagtgtt ttaggttataaa ggatggcag gggctaaagg gggtaaagag 3240
 ctagtgcgtt ctactgtgtt cttccgtccg cccggcgata ataccgacgg 3060
 gaggaagcca ggcggcgccg gcaggagcag agcccatgga 3120
 cctcgggaat gaatgttgc caggtggctg aactgtatcc 3180
 caattacaga ggatggcag gggctaaagg gggtaaagag 3240
 ctacagagga ggcttaggaat ctatgttgc tacatttgc ggaacggggc 3540
 ttactttca acagatcaag gataatttgcg ctaatgagct 3360
 attccataga gcagctgacc acttacttgc tgccagccagg 3420
 tttaggtata tgcaaaagggtt gcacttggc cagattgcaa 3480
 taaaatatcag gaatgttgc tacatttgc ggaacggggc 3540
 aggatagggt ggcctttaga ttaggttataaa ctggcccca 3660
 acgggggtgtt tattatgaat gtaagggttta ctggcccca 3660
 tggccaataac caaccttac tacacacggc taagcttcta 3720
 tggaaagcctg gaccgtgtt agggttcggg gctgtgcctt 3780
 ttactgtgc tggaaggggg cctcttggaa aggtgtaccc tgggtatccct gctgtgggt aactccagg 3900
 tggggcctcc gactgtgggt catggatgtt ggcaacttgcg ctgtcacccg ttcacgtac cagccactct
 ctgtcacccg tcaagacca tggataac atactgaccc accttacca tgcaatttga ggtgaacctg aacgggggtgt
 tgagacccgc accaggtgca tggatgtct gatgtgaccg cgtcgagttt ggctctagcg cttaaagggtg gggaaagaata
 agcagccgcc gccgcatgaa gacaacgcg atgccccat tggtcgcccc gcccctggag actgcagcct
 tggactgtac tttgtttcc cccgcgtac aagttgacgg tggatcttct cagcagctgt
 ccctcccaat gcggtttaaa gcaagtgtct tgctgtctct cataattggg caaactaccc
 gttataatggg tggtaaaacta gaactgtgta atgggagcag aagaatgcc atcttaggtat
 aaaagaagag aaaggtagaa gtcatgtgt gttagtaat aagctgcact gctataacaag
 ataacagtta taatcataac ctattaataa ctatgtcaa ataaggaaata tttgtatgtat
 gtagaggttt tacttgcattt atgaatgca ttgttgggtt aatagcatca caaatttac
 tccaaactca tcaatgtatc ggggtggaa agtccccagg tagtcagcaa ccagggtgtgg
 atgcatctca attagtcagc actccgcccc gttccgcccc gaggccgagg ccgcctcgcc
 ctctgagctt ttccagaagt agtgaggagg cttttttgtt 3840
 tgggtatccct gtcgtgggtt aactccagg 3900
 gcttcatgtt agtggaaaggc gtggctgtt gtaagcataa 3960
 aggacaggcc ctctcagatc ctgacccgtc cggacggccaa 4020
 ttcacgtac cagccactct cgcggccctt ggcgggtt 4080
 gctgttccctt gcatgggggtt aacaggagg 4140
 gtcacactaa gatatttgc ttaggttataaa tgacatgttgc
 ttgacatgac catgaagatc tggaaagggtt tgaggtacga 4260
 gaccctgcga gtgtggcggtt aaacatatta ggaaccagcc 4320
 aggagctgag gcccgttccac ttgggtctgg cctgcaccgg 4380
 atgaagatac agatttgcgtt actgaaatgtt gtgggcgtgg 4440
 tataagggtt gggctttatgt tagttttgtt tctgttttgc 4500
 gcaccaactt gttgtatggaa agcattgttgc gtcataatgg 4560
 gggccgggggtt ggcgttccat gtcgtgggtt cagcattttga 4620
 ctttttttttccaaactctac taccttgcacc tacggacccg ttttttttttgc 4680
 cccggccggcc ttccatgttgc gcaacccggc cccggggat 4740
 tgagcccgct tgcaaggatc gcaatgttcc gttcatccgc 4800
 ctcttttgc acaatttgc ttttgcacc gggacttaa 4860
 tggatctgcg ccacccgtt tctgccttgc aggcttccctc 4920
 acataaaataa aaaaccggac ttttttttttgc ttttttttttgc 4980
 cgagggttctt ttgttgcggg accttacttc ttttttttttgc 5040
 acagagatttt aaactctaa ggttttttttgc ttttttttttgc 5100
 ctgtatccat ttttttttttgc ttttttttttgc 5160
 ttttttttttgc ttttttttttgc 5220
 gatggggatctt ctgttgcggg ttttttttttgc 5280
 gaccggccggcc actttcccttca gtttttttttgc 5340
 agaacttgc ttttttttttgc 5400
 aaaattatgg aaaaatatttgc ttttttttttgc 5460
 atactgtttt ttcttactcc acacaggcat agatgtctt 5520
 aaatttgc ttttttttttgc 5580
 agtgccttgc ttttttttttgc 5640
 aaaaaaccccttccaccccttcc ttttttttttgc 5700
 taacttgc ttttttttttgc 5760
 aaataaaaggca ttttttttttgc 5820
 ttatcatgttgc ttttttttttgc 5880
 ctcccccggcc gggccggcc ttttttttttgc 5940
 aaaggccccca gggccggcc ttttttttttgc 6000
 aaccatagtc cccggcccttac ttttttttttgc 6060
 ttctccggccc catggctgac ttttttttttgc 6120
 gaggccgagg ccgcctcgcc ttttttttttgc 6180

ggcctaggct tttgcaaaaaa gcttggacac aagacaggct tgcgagatat gtttgagaat 6240
 accactttat cccgcgtcag ggagaggcag tgcgtaaaaa gacgcggact catgtgaaat 6300
 actggtttt agtgcgccag atctctataa tctcgcgcaa cctattttcc cctcgaacac 6360
 ttttaagcc gtagataaac aggctggac acttcacatg agcgaaaaat acatcgtcac 6420
 ctggacatg ttgcagatcc atgcacgtaa actcgcaaggc cgactgatgc ttctgaaaca 6480
 atggaaaaggc attattgccc taagccgtgg cggtctggta cggggtgcgt tactggcgcg 6540
 tgaactgggtt attcgcatg tcgataccgt ttgtattttcc agctacgatc acgacaacca 6600
 ggcgcagctt aaagtgcgtg aacgcgcaga aggcgatggc gaaggcttca tcgttatttg 6660
 tgacctgggt gataccgggt gtactcggtt tgcgattcgt gaaatgtatc caaaagcgcg 6720
 ctttgtcacc atcttcgaa aaccggctgg tcgtccgctg gttgatgact atgttggta 6780
 tatcccgcaa gatacctgga ttgaacagcc gtggatatg ggcgtcgtat tcgtcccgcc 6840
 aatctccgtt cgctaattttt ttcaacgcct ggcactgccc ggcgttggc ttttaactt 6900
 caggcgggtt acaatagttt ccagtaagta ttctggaggc tgcattccatg acacaggcaa 6960
 acctgagcga aacccctgttc aaaaacccgtt ttaaacatcc tgaaacctcg acgctagttc 7020
 gccgcctttaa tcacggcga caacccgcctg tgcaatcgcc ccttgcgtt aaaaaccatcc 7080
 ctcaatggta tcgcatgtt aaccgtctga tggatctg ggcgcggatt gaccacgcg 7140
 aaatcctcga cgtccaggca tatacgatc ggtgattggc cgtattgtga tgacgtatgc cgaacgtacc 7200
 taccgtggcg gcaactggat ttatgagtgg gccccggatc 7260
 tttgtgaagg aaccttactt taaaagctcta aggtaaaatatttta aacaaactacc tacagagatt 7320
 attgtttgtg tatttttagat tccaacccat ggaactgatg aatgggagca gtgggtggaaat 7440
 gcctttaatg aggaaaacctt gtttgcctca gaagaaatgc catctagtga tgatgaggct 7500
 actgctgact ctcaacatttcc tactccctca aaaaagaaga gaaaggtaga agaccccaag 7560
 gactttccctt cagaattgtc aagtttttg agtcatgtg tggatgtaa tagaactctt 7620
 gcttgctttt ctatttacac cacaaggaa aaagctgcac tgctatacaa gaaaattatgt 7680
 gaaaatatttctt ctgttaacccctt tataagttagg cataacaggat ataatcataa catactgttt 7740
 tttcttacttcc cacacaggca tagatgtct gcttattataa atactatgc taaaattgtgt 7800
 accttttagct ttttaatttg taaaagggtt aataaggaat atttgatgta tagtgcctg 7860
 actagagatc ataatcagcc ataccacatt tggatgggtt ttacttgctt taaaaaaacct 7920
 cccacacccccc cccctgaacc tggatgggtt aatgaatgca attgttggc ttaacttgg 7980
 tattgcagct tataatggtt acaaataaaag caatagcatc acaaatttca caaataaaagc 8040
 atttttttca ctgcattctt gttgtgggtt gtccaaactc atcaatgtat ttatcatgt 8100
 ctggatcccc aggaagctcc tctgtgtccct cataaaccctt aacccctctt acttgagagg 8160
 acattccaat cataggctgc ccatccaccc tctgtgtccct cctgttaattt aggtcactta 8220
 aaaaaaaaggaa aattgggttag ggggttttca cagaccgtt tctaagggtt atttttaaat 8280
 atctgggaatccccc caacaggcaga aacatacaag tctgtgttcc cagaagtgtt gttaaacagc ccacaaatgt 8340
 gtttcagctt tgccacaaggg cccaaacaccc tgctcatcaa 8400
 ttagtaatgt gcaaaacagg aggcacattt tccccacccctg 8460
 gtgtttcat ttttacttgg atcaggaacc cagcactcca 8520
 tccaaaacag ccttgcggc tggatgggtt atgttcatc tgctgactgt 8580
 gttacagttt gggcggata tttggccttg tagtttgcta 8640
 ggttcccccac caacagcaaa aaaatgaaaa ttgaccctt 8700
 gatgggttttccatcatgatg tttttgtgtt ccctgatgc agttaaca 8760
 tagtttttaa tcaatgttca cagtaacaggc tttccacatc aaaaattttc 8820
 ctggataagc attatcctt aaaaatttagca aaggaaatct tgaagacgaa agggcctgt 8880
 caactgttagc attttttggg gttttatagg ttaatgtatc gataataatg gtttcttgc gtcagggtt 8940
 acacaccctg cagctccaaa gatgggttttccatcatg gcggaacccc tatttgcgtt tttttctaaa tacattcaaa 9000
 gaatgggttttccatcatg tttttatagg tcaatgttca aataaccctt aataatgttca cttttgcgg cattttgcct 9120
 atccctgggtt gacggccggc tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9060
 cttgggttag gttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9180
 attatgcagt gttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9240
 tgcacgatgtt gttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9300
 ccccgaaaggaa cgtttccaa tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9360
 atccctgggtt gacggccggc tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9420
 cttgggttag gttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9480
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9540
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9600
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9660
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9720
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9780
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9840
 gatgggttttccatcatg tttttatagg tcaatgttca aaaaatgttca aaaaaggaa 9900

tgcctcactg	attaaggatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	9960
tgatttaaaa	cttcattttt	aatttaaaaag	gatctagggt	aagatccccc	ttgataatct	10020
catgaccaaa	atcccttaac	gtgagtttc	gttccactga	gcgtcagacc	ccgtagaaaa	10080
gatcaaaggaa	tcttcttgag	atccctttt	tctgcgcgta	atctgctgct	tgcaaacaaa	10140
aaaaccaccc	ctaccagcg	tggtttgtt	gccggatcaa	gagctaccaa	ctctttttcc	10200
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	10260
gttaggccac	cacttcaaga	actctgtatc	accgcctaca	tacctcgctc	tgctaatcct	10320
gttaccagt	gctgctgca	gtggcgataa	gtcggtgtt	accgggttg	actcaagacg	10380
atagttaccg	gataaggcgc	agcgggtcg	ctgaacgggg	ggttcgtgca	cacagccccag	10440
cttggagcga	acgacactaca	ccgaactgag	atacctacag	cgtgagctat	gagaaaagcgc	10500
cacgcttccc	gaagggagaa	aggcggacag	gtatccggta	agcggcaggg	tccgaacagg	10560
agagcgcacg	agggagctc	cagggggaaa	cgcctggtat	ctttatagtc	ctgtcggggt	10620
tcgcccaccc	tgacttgagc	gtcgatttt	gtgatgctcg	tcagggggc	ggagcctatg	10680
gaaaaacgcc	agcaacgcgg	ccttttacg	gttccctggc	ttttgtggc	cttttgccta	10740
catgttctt	cctgcgttat	ccccctgattc	tgtggataac	cgtattaccg	cctttgagtg	10800
agctgtatcc	gctgcggcga	gccaacgcac	cgagcgcage	gagtcaatgt	gcgaggaagc	10860
ggaagagcgc	ctgatgcgg	attttctctt	tacgcattctg	tgcggtattt	cacaccgcat	10920
accgcctcag	aagccataga	gccccaccga	tccccagcat	gcctgtattt	gtcttcccaa	10980
tcctccccct	tgctgtcctg	ccccacccca	ccccccagaa	tagaatgaca	cctactcaga	11040
caatgcgatg	caatttcctc	attttattag	gaaaggacag	tgggagtgcc	accttccagg	11100
gtcaaggaag	gcacggggga	ggggcaaaaca	acagatggct	ggcaactaga	aggcacagtc	11160
gaggctgatc	agcgagctct	agcatttagg	tgacactata	gaataggggc	ctctagatgc	11220
atgctcgagc	ggccgcttct	ttattcttgg	gcaatgtatg	aaaaagtgt	agaggatgt	11280
gcaaatattt	cattaatgt	gttgtggca	gaccagtccc	atgaaaatgt	catagagttat	11340
gcacttggag	ttgtgtctcc	tgtttccctgt	gtaccgttta	gtgtatgtt	tagtgttaca	11400
ggttttagtt	tgttcccg	taagtaaact	tgactgacaa	tgttactttt	ggcagttttt	11460
ccgttagatt	tttgataaagc	tgataggtt	ggcataaaatc	caacagcg	tgtataggt	11520
gtgccttcag	taagatctcc	atttctaaag	ttccaatatt	ctgggtccag	gaaggaattt	11580
tttagtagca	ctccattttc	gtcaaatctt	ataataagat	gagcactttt	aactgttcca	11640
gatattggag	ccaaactgccc	ttaaacagcc	aaaactgaaa	ctgtagcaag	tatttgactg	11700
ccacatttt	ttaagaccaa	agttagtta	gcatcttct	ctgcatttag	tctacagtta	11760
ggagatggag	ctgggtgtgt	ccacaaagtt	agcttacat	tatttttgg	tcctactgt	11820
atggcacctg	tgctgtcaaa	actaaggcc	gttccctagtt	taggaaccat	agccttgg	11880
gaatcaaaat	ctaggccatg	gccaattttt	gttttggaggg	gatttgg	tggtgcat	11940
ggtgaaccaa	attcaagcccc	atccctgtca	ttaatggct	tggctgtac	gtcaaacatc	12000
aaccccttgg	cagtgtttag	gttaacccca	agtttttgg	aatttttgg	agctgtaaac	12060
aagtaaaggc	ctttgtgt	gttaatatcc	aagttgtgg	ctgagttt	aaaaagaggg	12120
ccctgtccta	gtcttagatt	tagttggtt	tgagcatcaa	acggataact	aacatcaagt	12180
ataaggcg	tgttttgaga	atcaatcctt	agtccctctg	ctacattaag	ttgcatat	12240
ccttgtgaat	caaaaacccaa	ggctccagta	actttagttt	gcaaggaagt	attattaata	12300
gtcacacctg	gaccaggttc	tacggtcaaa	gttttaggt	cgtctgttac	atgcaaagga	12360
gccccgtact	ttagtcctag	ttttccattt	tgtgtataaa	tgggctctt	caagtcaatg	12420
cccaagctac	cagtggcagt	agtttagaggg	ggtgaggcag	tgatagtaag	gtactgtca	12480
tcgggtgtgg	tgagggggcc	tgatgttgc	aggctactgt	ttccttctg	cactgtgagg	12540
gttccttggg	tggcaatgt	aagtttggag	tcgtgcacgg	ttagggggc	ctgtgatttgc	12600
atggtgatgt	tgttcccgc	gaccattaga	ggtgcggcgg	cagccacagt	tagggcttct	12660
gaggttaact	tgaggggtgc	agatattcc	agtttatgt	ttgacttgg	ttttttgaga	12720
ggtgggctca	cagtggttac	attttggag	gtaaggttgc	cgccctcg	cagagagagg	12780
ccgttggcca	ttttgagcgc	aagcatgca	ttggaggtaa	ctagaggtt	ggataggcgc	12840
aaagagagta	ccccaggggg	actctctga	aaccattgg	gggataaaaa	gggaggagta	12900
agaaaaggca	cagttggagg	accggttcc	gtgtcatatg	gatacacgg	gttgaaggt	12960
tcttcagacg	gtcttgcgc	cttcatctt	gatctcaagc	ctgccacacc	tcacctcgac	13020
catccggcgt	ctcaagaccc	cctactttaa	ttacatcatc	agcagcacct	ccgcccagaa	13080
caacccccac	cgccacccgc	tgccgcccgc	cacgggtc	agccttaccc	gctgactgt	13140
ctggtagac	gccttctcg	agagttttc	cgatccggc	gatcggact	cgctcagg	13200
cctcggtggc	ggagtaggt	tcggaggccg	acgggttcc	gatccaagag	tactggaaag	13260
accgcgaaga	gtttgtcctc	aaccgcgagc	ccaaacagcga	gctgaattt	agatccgagc	13320
tcggtagccaa	gtttgggtct	ccctataatgt	agtctgtat	atttcgat	gccagtaagc	13380
agtgggttct	ctagtttagcc	agagagctct	gcttatata	acctcccacc	gtacacgcct	13440
accgcgcatt	tgcgtcaatg	ggcggagtt	gttacgacat	tttggaaagt	cccggttatt	13500
ttgggtccaa	aacaaactcc	cattgacgtc	aatgggttg	agacttggaa	atccccgt	13560
gtcaaacccgc	tatccacgc	cattgatgt	ctggccaaaac	cgcacatc	tggtatagc	13620

gatgactaat	acgtagatgt	actgccaagt	aggaaagtcc	cataaggtca	tgtactgggc	13680
ataatgccag	gcgggccatt	taccgtcatt	gacgtcaata	ggggcgctac	ttggcatatg	13740
atacacttga	tgtactgcca	agtggcagt	ttaccgtaaa	tagtcaccc	attgacgtca	13800
atggaaagtc	cctattggcg	ttactatggg	aacatacgtc	attattgacg	tcaatggcg	13860
ggggtcgttg	ggcggtcagc	caggcgggcc	attaccgtta	agttatgtaa	cgcggaaactc	13920
catatatggg	ctataacta	atgaccggct	aattgattac	tattaataac	tagtcaataa	13980
tcaatgtcaa	cgcgtatata	tggccgtac	atcgcgaagc	agcgaaaaac	gcctaaccct	14040
aagcagattc	tctatgtcaat	tgtcggtcaa	gccttcgtt	gtttagctt	aaattttgt	14100
cgcgcactac	tcagcgacct	ccaacacaca	agcagggagc	agataactggc	ttaactatgc	14160
ggcatcagag	cagattgtac	tgagagtcga	ccatagggga	tcgggagatc	tcccgatccg	14220
tctatgtgc	actctcagta	caatctgctc	tgtatccgca	tagttaagcc	agtatacact	14280
ccgctatcgc	tacgtgactg	ggtcatggct	gcccggcgcac	accgcacaaac	accgcgtgac	14340
gcccctgac	gggcttgcct	gctccggca	tccgcttaca	gacaagctgt	gaccgtctcc	14400
gggagctgca	tgtgtcagag	gttttacccg	tcatcaccga	aacgcgcgag	gcagc	14455

<210> 16
<211> 10610
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 16	gacggatcg	gagatccgcg	cggtacacag	aattcaggag	acacaactcc	aagtgcatac	60
	tctatgtcat	tttcatggga	ctggctcggc	cacaactaca	ttaatgaaat	atttgccaca	120
	tcctcttaca	cttttcata	cattgccccaa	gaataaaagaa	tcgtttgtgt	tatgtttcaa	180
	cgtgtttatt	tttcaattgc	agaaaatttc	aagtcatttt	tcattcagta	gtatagcccc	240
	accaccacat	agcttataca	gatcacogta	ccttaatcaa	actcacagaa	cccttagtatt	300
	caacctgcca	cctccctccc	aacacacaga	gtacacagtc	cttctcccc	ggctggccctt	360
	aaaaagcattc	atatacatggg	taacagacat	attcttaggt	gttatattcc	acacggtttc	420
	ctgtcgagcc	aaacgctcat	cagtgtat	aataaactcc	ccggcagct	cacttaagg	480
	catgtcgctg	tccagctgct	gagccacagg	ctgctgtcca	acttgcgggt	gtttaacggg	540
	cggcgaaggaa	gaagttccacg	cctacatggg	ggtagagtc	taatctgtca	tcaggatagg	600
	gggggtgtgc	tgcagcagcg	cgcgataaaa	ctgctggcgc	cgccgcctccg	ttctgcagga	660
	ataacaatcg	gcagtggct	cctcagcgt	gattcgcacc	gcccgcagca	taaggcgcct	720
	tgtcctccgg	gcacacgcgc	gcaccctgtat	ctcacttaaa	tcagcacagt	aactgcagca	780
	cagcaccaca	atattgttca	aaatcccaaca	gtgcaaggcg	ctgtatccaa	agctcatggc	840
	ggggaccaca	gaacccacgt	ggccatcata	ccacaagcgc	aggttagatta	agtggcggacc	900
	cctcataaac	acgctggaca	taaacattac	ctctttggc	atgtttaat	tcaccaccc	960
	ccggtaccat	ataaacctct	gattaaacat	ggcccatcc	accaccatcc	taaaccagct	1020
	ggccaaaacc	tgccgcgg	ctatacactg	cagggAACG	ggacttggaa	aatgacagt	1080
	gagagcccg	gactctgtac	catggatcat	catgtcgctg	atgatatcaa	tgttggcaca	1140
	acacaggcac	acgtgtcatac	acttccctcg	gattacaagc	tcctcccgcg	tttagaaccat	1200
	atcccaggga	acaacccatt	cctgaatcg	cgttaatccc	acactgcagg	gaagacctcg	1260
	cacgttaactc	acgttgtca	ttgtcaaaat	gttacattcg	ggcagcagcg	gtatgcctc	1320
	cagtatggta	gcccgggtt	ctgtctaaa	aggaggtaga	cgatccctac	tgtacggagt	1380
	gcccggagac	aacccggatc	gtgttggc	tagtgtcatg	ccaaatggaa	cgccggacgt	1440
	agtcatattt	cctgaagcaa	aaccagggtc	gggcgtgaca	aacagatctg	cgctccgg	1500
	ctcgccgctt	agatcgctc	gtgttagt	tgttagtat	ccactctctc	aaagcatcca	1560
	ggcgccccct	ggcttcgggt	tctatgtaaa	ctccctcatg	cgccgctgccc	ctgataacat	1620
	ccaccaccc	agaataagcc	acacccagcc	aacctacaca	ttcgttctgc	gagtcacaca	1680
	cgggaggagc	gggaagagct	ggaagaacca	tgtttttttt	tttattccaa	agattatcc	1740
	aaaacctcaa	aatgaagatc	tattaatgt	acgcgtccc	ctccgggtggc	gtggtcaa	1800
	tctacagcca	aagaacagat	aatggcattt	gttagatgtt	gcacaatggc	ttccaaaagg	1860
	caaacggccc	tcacgtccaa	gtggacgtaa	aggctaaacc	cttcagggtg	aatctccct	1920
	ataaacattc	cagcaccc	aaccatgccc	aaataattct	catctcgcca	cttctcaat	1980
	atatctctaa	gcaaatcccg	aatattaatgt	ccggccattt	taaaaatctg	ctccagagcg	2040
	ccctccaccc	tcagcctcaa	gcagcgaatc	atgattgca	aaattcaggt	tcctcacaga	2100
	cctgtataag	attccaaagc	ggaacattaa	caaaaatacc	gcatcccg	aggcccttc	2160
	gcagggccag	ctgaacataa	tcgtgcaggt	ctgcacggac	cagcgcggcc	acttccccc	2220

caggaacctt	gacaaaagaa	cccacactga	ttatgacacg	cataactcgga	gctatgctaa	2280
ccagcgtagc	cccgtatgtaa	gctttgttc	atgggcggcg	atataaaatg	caagggtctg	2340
ctcaaaaaat	cagggaaagc	ctcgcgaaa	aaagaaaagca	catcgtagtc	atgctcatgc	2400
agataaaaggc	aggttaagctc	cggaaccacc	acagaaaaag	acaccatttt	tctctaaac	2460
atgtctgcgg	gtttctgcat	aaacacaaaa	taaaataaca	aaaaaacatt	taaacattag	2520
aaggcgtgt	tacaacagga	aaaacaaccc	ttataagcat	aagacggact	acggccatgc	2580
cggcgtgacc	gtaaaaaaaaac	tggtcaccgt	gataaaaaaag	caccacccgac	agctcctcgg	2640
tcatgtccgg	agtcatataatg	taagactcgg	taaacacatc	aggttgattc	atcggtcagt	2700
gctaaaaagc	gaccgaaata	gccccgggga	atacataacc	gcaggcgtag	agacaacatt	2760
acagccccca	taggaggtat	aacaaaatta	ataggagaga	aaaacacata	aacacactgaa	2820
aaaccctct	gcctaggcaa	aatagcacc	tcccgctcca	gaacaacata	cagcgcttca	2880
cagcggcagc	ctaacagtca	gccttaccag	taaaaaagaa	aacctattaa	aaaaacacca	2940
ctcgacacgg	caccagctca	atcagtca	gtgtaaaaaa	gggccaagtg	cagagcgagt	3000
atatatagga	ctaaaaaatg	acgttaacgg	taaagtccac	aaaaaacacc	cagaaaacccg	3060
cacgcgaacc	tacgcccaga	aacgaaagcc	aaaaaacccca	caactcctc	aatatcgtoac	3120
ttccgttttc	ccacggttacg	taacttccg	gatcctctc	cgatcccc	ttgtcgactc	3180
tcaagtacaat	ctgctctgtat	gcccgtatgt	taagccgta	tctgctccct	gcttgtgtgt	3240
tggaggtcgc	tgagtagtgc	gcgagaaaa	tttaagctac	aacaaggcaa	ggcttgacccg	3300
acaattgcat	gaagaatctg	cttagggta	ggcggttgc	gctgcttcgc	gatgtacggg	3360
ccagatatac	gcgttgacat	tgattattga	ctagttatta	atagtaatca	attacggggt	3420
cattagttca	tagccatata	atggagttcc	gcgttacata	acttacggta	aatggcccg	3480
ctggctgacc	gcccaacgac	ccccggccat	tgacgtcaat	aatgacgtat	gttcccata	3540
taacgccaa	agggacttcc	cattgacgtc	aatgggtgga	ctattacgg	taaactgccc	3600
acttggcagt	acatcaagtgc	tatcatatgc	caagtacgccc	ccctattgc	gtcaatgacg	3660
gttaaatggcc	cgcctggcat	tatgcccagt	acatgaccc	atgggacttt	cctacttggc	3720
agtacatcta	cgtattatgc	atcgcttata	ccatgggtat	gcccgtttgg	cgtacatca	3780
atgggcgtgg	atagcggttt	gactcacggg	gatttccaag	tctccacccc	attgacgtca	3840
atgggagttt	gtttggcac	caaaatcaac	gggactttcc	aaaatgtcgt	aacaactccg	3900
ccccattgac	gcaaatgggc	ggtaggcgt	tacgggtggaa	ggtctatata	agcagagotc	3960
tctggctaac	tagagaaccc	actgcttact	ggcttatcga	aattaatacg	actcactata	4020
gggagacca	agcttggta	cgagctcgg	tctgaattcg	agtcgctgt	ttggctcgcg	4080
gtttaggaca	aactttcgc	ggtcttcca	gtactcttgg	atcgaaaacc	cgtcggcctc	4140
cgaacggta	tccggcaccg	agggacctg	gcgagtccgc	atcgaccgga	tcggaaaacc	4200
tctcgagaaa	ggcgcttaac	cagtacacgt	cgcaaggtag	gctgagcacc	gtggcggggc	4260
gcagcgggtg	gccccgggg	ttgtttctgg	cgaggtgtc	gctgtatgt	taattaaaatg	4320
aggcggctt	gagacggcgg	atggtcgagg	tgaggtgtgg	caggcttgag	atccaagatg	4380
aagcgcgcaa	gaccgtctga	agatacc	aaccccgtgt	atccatatga	cacggaaaacc	4440
ggtcctccaa	ctgtgcctt	tcttacttcc	ccctttgtat	cccccaatgg	gtttcaagag	4500
agtccccctg	gggtactctc	tttgcgccta	tccgaacctc	tagttac	caatggcatg	4560
cttgcgctca	aaatgggcaa	cggcctctc	ctggacgagg	ccggcaaccc	tacccctcaa	4620
aatgttaacca	ctgtgagccc	acctctcaa	aaaaccaagt	caaacataaa	cctggaaata	4680
tctgcacccc	tcacagtta	ctcagaagcc	ctaactgtgg	ctggccgc	acctcta	4740
gtcgccggca	acacactcac	catgcaatca	caggccccgc	taaccgtgc	cgactccaa	4800
cttagcattt	ccacccaagg	acccctcaca	gttcagaag	gaaagctgc	cctgcaaaca	4860
tcagggcccc	tcaccaccc	cgtatgcgt	acccttacta	tcactgcctc	acccctcta	4920
actactgc	ctggtagtt	gggcatttgc	ttgaaagagc	ccatttatac	aaaaatgga	4980
aaacttaggac	taaaatgcgg	ggctccttttgc	catgtacatgc	acgacccaaa	cactttgacc	5040
gtagcaactg	gtccaggtgt	gactattat	aatacttcc	tgcaactaa	agttactgga	5100
gccttgggtt	ttgattcaca	aggcaatatg	caacttaatg	tagcaggagg	actaaggatt	5160
gattctcaa	acagacgcct	tataacttgc	tttagttatc	cgtttgc	tcaaaaccaa	5220
ctaaatctaa	gacttaggaca	gggccttctt	tttataaaact	cagccacaa	tttggatatt	5280
aactacaaca	aaggccttta	cttgcattaca	gcttcaacaa	atccaaaaaa	gcttgaggtt	5340
acctaatacg	ctgccaagggg	gttgatgtt	gacgtacag	ccatagccat	taatgcagga	5400
gatgggctt	aatttggttc	acctaatacg	ccaaacacaa	atccctcaa	acaaaaaatt	5460
ggccatggcc	tagaatttga	ttcaaaacaag	gctatggtc	ctaaactagg	aactggccctt	5520
agttttgaca	gcacaggtgc	cattacagta	ggaaaacaaa	ataatgataa	gctaacttg	5580
tggaccacac	cagctccatc	tcctaactgt	agactaaatg	cagagaaaaga	tgctaaactc	5640
actttggct	taacaaaatg	tggcagtcaa	atacttgcta	cagtttcagt	tttggctgtt	5700
aaaggcagg	tggctccat	atctggaa	gttcaaagtgc	ctcatctt	tataagattt	5760
gacgaaaatg	gagtgtact	aaacaattcc	ttcctggacc	cagaatatttgc	gaactttaga	5820
aatggagatc	ttactgaagg	cacgcctat	acaaacgcgt	ttggatttat	gcctaaccta	5880
tcaagttatc	caaaatctca	cggtaaaact	gccaaggat	acattgtcag	tcaagttac	5940

ttcgttcatc catagttgcc tgactccccg tcgtgttagat aactacgata cgggagggct 9720
 taccatctgg ccccagtgc gcaatgatac cgcgagaccc acgctcaccc gctccagatt 9780
 tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggctt gcaactttat 9840
 ccgcctccat ccagctatt aattgttgc gggaaagctag agtaagttagt tcgcccagta 9900
 atagttgcg caacgttgc gccattgcta caggcatcgt ggtgtcacgc tcgtcggttg 9960
 gtatggctt attcagctcc gggtcccaac gatcaaggcg agttacatga tcccccatgt 10020
 tgtgcaaaaaa agcgggttagc tccttcggc tcctcgatcgt tgtcagaatg aagttggccg 10080
 cagtgttattc actcatggtt atggcagcac tgccataattc tcttactgtc atgcccattcg 10140
 taagatgctt ttctgtgact ggtgagtaact caaccaagtc attctgagaa tagtgtatgc 10200
 ggcgaccgag ttgctcttgc ccggcgtcaa tacggataa taccgcgcca catagcagaa 10260
 cttaaaaagt gctcatcatt ggaaaacgtt ctccggggcg aaaactctca aggatcttac 10320
 cgctgtttag atccagttcg atgtAACCCA ctcgtgcacc caactgatct tcagcatctt 10380
 ttactttcac cagcgttct gggtagccaa aaacaggaag gcaaaaatgcc gcaaaaaagg 10440
 gaataagggc gacacggaaa tggtgaatac tcatactt ccttttcaa tattattgaa 10500
 gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgttatt tagaaaaata 10560
 aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc 10610

<210> 17
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 17
 tgtacaccgg atccggcgca cacc

24

<210> 18
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 18
 cacaacgagc tcaattaatt aattgccaca tcctc

35

<210> 19
 <211> 4
 <212> PRT
 <213> adenovirus

<400> 19
 Thr Leu Trp Thr
 1

<210> 20
 <211> 12
 <212> PRT
 <213> adenovirus

<400> 20
 Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser
 1 5 10

<210> 22
 <211> 327
 <212> DNA

<213> adenovirus

<400> 22

```
agatctgaat tcgagctcg tggatggctc ggggttggagg acaaactttt cgcggcttt 60
ccagtactct tggatcgaa acccgccgc ctccgaacgg tactccgca ccgagggacc 120
tgagcgatgc cgcatcgacc ggatcgaaa acctctcgag aaaggcgctt aaccagtac 180
agtgcacagg taggtcgac accgtggcg gcggcagcgg gtggcggtcg gggttgttc 240
tggcgagggt gctgtatcg atgttaattaa agtaggcggt cttgagacgg cggatggtc 300
aggtgagggt tggcaggctt gagatct 327
```

<210> 23

<211> 32480

<212> DNA

<213> adenovirus

<400> 23

```
catcatcaat aataaacattt atttggatt gaagccaata tgataatgag ggggtggagt 60
ttgtgacgtg ggcggggcg tgggaacggg ggggtgacg tagtagtgtg gggaaagtgt 120
gatgttgcggaa gtgtggcgga acacatgtaa gcacggatg tggcaaaagt gacgttttt 180
gtgtgcgcgt gtgtacacag gaagtgacaa tttcgcgcg gttttaggcg gatgtttag 240
taaatttggg cgtaaccgag taagatttg ccatttcgcg gggaaaactg aataagagga 300
agtgaaatct gaataattttt gtgttactca tagcgcgtaa tctctagcat cgtatgtc 360
aagcttgaat tcgattaatg tgagtttagt cactcattag gcaccccagg ctttacactt 420
tatgttcccg gctcgatgt tttgtggaaat tttgagcgaa taacaatttc acacaggaaa 480
cagctatgac catgattacg aattcggcg acgaccatgg cctgaaataa cctctgaaag 540
aggaacttggg ttaggtaccc tctgaggcg aaagaaccag ctgtgaaatg tttgttc 600
agggtgtggg aagtccccag gctcccccggc aggccagaatg atgcaaaagca tgcatactcaa 660
tttgtcggca accaggtgtg gaaagtccccca aggctcccca gcaggcagaa gtatgcaaaag 720
catgcatttc aatttagtgcg caaccatagt cccgccttca actccgcctt tccgcctt 780
aactccgcctt agttccgcctt attctccgcg ccatggctga ctaatttttt ttatattatgc 840
agaggccgag gcccgcctgg cctctgagctt attccagaag tagtgaggag gcttttttgg 900
aggccttaggc ttttgcggaa agcttggat ctctataatc tcgcgcacacc tattttcccc 960
tcgaacactt tttaagccgt agataaaacag gctggacac ttcacatgag cggaaaaatac 1020
atcgatccat gggacatgtt gcaatccat gcaatggaaatc tcgcaagccg actgtatgcct 1080
totgaacaaat ggaaaggcat tattggcgta agccgtggcg gttctgtacc ggtgggtgaa 1140
gaccaggaaac agcacccgtg actgagccg gatattggcc agcgttcaat cgcgtgtat 1200
ggcgagatcg atcccgctgt tttacaacgt cgtactggg aaaaccctgg ctttacccaa 1260
cttaatcgcc ttgcagcaca tccccccttc gcaagctggc gtaatagcga agaggcccg 1320
accgatcgcc cttcccaaca gttgcgcagc ctgaatggcg aatggcgctt tgcctggtt 1380
ccggcaccag aagcggtgcc ggaaagctgg ctggagtgcg atcttctga ggccgataact 1440
gtcgtcgccc cctccaaactg gcaatgcac gtttacgatg cgcgcata caccacgt 1500
acctatccca ttacggctaa tccgcctt gttccacgg agaatccgac gggttgttac 1560
tgcgtcacat ttaatgttgcg tgaaagctgg ctacaggaag gccagacgcg aattatttt 1620
gatggcggtt actccgggtt tcatctgtg tcaacacggc gctgggtcg ttcacggccag 1680
gacagtctgtt tggcgctgcg atttgcacgg agcgttccat ttcgcgcgg agggaaaccgc 1740
ctcgccgtt tggcgctgcg ttggagtgcg ggcagttatc tggaaagatca gatgtatgtt 1800
cgatgagcg gcattttcccg tgacgtctcg ttgctgcata aaccgactac acaaattcagc 1860
gatttccatg ttgcactcg cttaatgtat gattcagcc ggcgtgtact ggaggctgaa 1920
gttcagatgt gcccggagtt ggcgtactac ctacggtaa cagtttctt atggcagggt 1980
gaaacgcagg tcgcacggg gtttatgccc atcgatgtcactt caccgcctt ttcggcggtt 2040
actacgtctg aacgtcgaaa acccgaaaact gtggagcc 2100
tgcgggtgtt gaactgcaca ccgcgcacgg cacgtgtattt 2160
cggtttcccg gaggtgcggc ttgaaaatgg tctgtgtctg 2220
gatcgaggc gtttacccgtc acgagcatca tccctctgcatt 2280
gacgtggc caggatattc tgctgtatgg gcaacaac 2340
gcattatccg aaccatccgc tggatgttacac gttgtgcgc 2400
ggatgaagcc aatattgaaa cccacggcat gttgccaatg 2460
gcccgttccgc cccgttccgc gcaacccgt aacgcgaatg 2520
cccggatgtg atcatctgtt cgttggggaa tgaatcaggc 2580
gctgtatcg tggatcaat ctgtcgatcc tcccgccccc 2640
gtgcagtcg atcgatgtcc agccgacacc acggccaccg atattatttgc cccgtatgtac 2700
gcccgttccgc gctgtgcgcg aatggtccat caaaaaaaaatgg 2760
```

ctttcgctac	ctggagagac	gcgcccgtg	atcctttgcg	aatacgcaca	cgcgatgggt	2820
aacagtcttgcg	gcgggttcgc	taaatactgg	caggcgcccc	gtcagtatcc	ccgtttacag	2880
ggccggcttcg	tctgggactg	ggtgatcg	tcgtgttata	aatatgtatga	aaacggcaac	2940
cctgtggctgg	cttacggcg	tgatgttgcg	gatacggccg	acgatcgcca	gttctgtatg	3000
aacggcttcg	tctttcccg	ccgcacggcg	cattacggcg	tgacggaaagc	aaaacaccag	3060
cagcgtttt	tccagttccg	tttacccggg	caaaccatcg	aagtgaccag	cgaatacctg	3120
ttccgtcata	gcgataaacga	gctcctgcac	tggatgggtgg	cgctggatgg	taagccgctg	3180
gcaagcggtg	aagtgcctct	ggatgtcgct	ccacaaggta	aacagttgtat	tgaactgcct	3240
gaactaccgc	agccggagag	cgccgggcaa	ctctggctca	cagtacgcgt	agtgcacaccg	3300
aacgcgaccc	catggtcaga	agccgggac	atcagcgcc	ggcagcagt	gcgtctggcg	3360
gaaaacctca	gtgtgacgct	ccccggccg	tcccacgcca	tcccgcacat	gaccaccagg	3420
gaaatggatt	tttgcacatcg	gctgggtaat	aagcggttgg	aatttaaccg	ccagtcaggc	3480
tttcttcac	agatgtggat	tggcgataaa	aaacaactgc	tgacggccgt	gchgcatcag	3540
ttcacccgtg	caccgctgg	taacgcatt	ggcgtaaatgg	aagcgacccg	cattgaccct	3600
aacgcctggg	tcgaacgcgt	gaaggcggcg	ggcattacc	aggccgaagg	agcgttgttgc	3660
cagtgcacgg	cagatacact	tgctgtatgc	gtgtgttata	cgacgcgtca	cgcgtggcag	3720
catcaggggg	aaaccttatt	tatcagccgg	aaaacctacc	ggattgtatgg	tagtggtaaa	3780
atggcgat	ccgttgcgt	tgaagtggcg	agcgatacac	cgcacccggc	gcggattggc	3840
ctgaactgccc	agctggcgca	ggtagcagag	cgggtaaact	ggctcggtt	agggccgcaa	3900
gaaaactatc	ccgaccgcct	tactggcc	tgttttgcacc	gctgggatct	gccattgtca	3960
gacatgtata	ccccgtacgt	cttcccggagc	gaaaacggtc	tgcgtgtgg	gacgcgcgaa	4020
ttgaattatg	gccccacacca	gtggcggcgc	gacttccagt	tcaacatcg	cgctacagt	4080
caacacgaa	tgatggaaac	cagccatcg	cattctgtc	acgcggaaaga	aggcacatgg	4140
ctgaatatecg	acgggttcc	tatgggatt	ggtggcgacg	actcctgg	cccgctcagta	4200
toggcgaaat	tccagctgag	cgccgggtcg	taccattacc	agttggctgc	gtgtcaaaaa	4260
taataataac	cgggcaggcc	atgtctggcc	gtatttcgc	taagggaaatc	cattatgtac	4320
tattnaaaaa	acacaaaactt	ttggatgttc	ggtttattct	ttttctttta	cttttttatac	4380
atgggagcc	acttcccgtt	tttcccgtt	tggctacatg	acatcaacca	tatcagcaa	4440
agtgatacgg	gtattat	tgccgctatt	tctctgttct	cgctattatt	ccaaaccgcgt	4500
tttggctctgc	tttctgacaa	actcggaact	tgtttattgc	agcttataat	ggttacaat	4560
aaagcaata	catcacaaat	ttcacaaata	aagcattttt	ttcactgtat	tctagttgt	4620
gtttgtccaa	actcatcaat	gtatcttata	atgtctggat	ccagatctgg	gcgtggctta	4680
aggggtggaa	agaatata	aggtgggggt	ctttagttagt	tttgcacgg	4740	
gcccggcccg	ccatgagcac	caactcg	gatggaaatc	tttgagctc	atatttgac	4800
acgcgcatgc	ccccatgggc	cggggtcggt	cagaatgtga	tgggctccag	cattgtatgt	4860
cggccccgtcc	tgccccgcaaa	ctctactacc	ttgacctacg	agaccgtgtc	tggAACGCG	4920
ttggagactg	cagccctccgc	cgccgcttca	gcccgtcag	ccaccggccg	cgggattgtg	4980
actgacttt	ctttcctgag	cccgttgc	agcagtgcag	cttcccgtt	atccggcccg	5040
gatgacaatg	tgacggctct	tttggcaca	ttggattctt	tgacccggga	acttaatgtc	5100
gtttctcagc	agctgttgg	tctgcgc	cagtttctg	ccctgaaggc	ttcctcccct	5160
cccaatgcgg	tttaaaacat	aaataaaaaa	ccagactctg	tttggatttgc	gatcaagcaa	5220
gtgtcttgc	gtcttttttgc	aggggttttgc	cgccgcgggt	aggccggga	ccagcggtct	5280
cggtcgttgc	gggtcctgtgc	tatttttcc	aggacgttgc	aaagggtact	ctggatgttc	5340
agatacatgg	gcataagccc	gtctctgggg	tggaggttgc	accactgcag	agcttcatgc	5400
tgcgggggtgg	tgtttagat	gatccagtc	tagcaggagc	gctggcggt	gtgcctaaaa	5460
atgtcttca	gtagcaagct	gattgcccagg	ggcaggccct	tgggttaat	gtttacaat	5520
cggtaagct	gggatgggtg	catacggtgg	gatatgagat	gcacatgttgc	ctgtat	5580
aggttggcta	tgttcccagc	catatccctc	cggggattca	tgttgcgt	aaccaccagg	5640
acagtgtatc	cgggtgcactt	gggaaat	tcatgtatgc	tagaaggaaa	tgcgtggaa	5700
aacttggaga	cggcccttgc	accttcaaga	tttccatgc	attcgccat	aatgtggca	5760
atgggcccac	ggggggccggc	ctgggcgaa	atatttctgg	gatcaactaa	gtcatagtt	5820
tgttccaggaa	tgagatcg	ataggccatt	tttacaaatgc	gccccgggg	gtgtccagac	5880
tgcggatataa	tggttccatc	cggcccgagg	gcgttagtac	cctcacat	ttgcattttc	5940
cacgcgttgc	gttcagatgg	ggggatcatg	tctacccgt	gggcgtatgg	aaaaacgggt	6000
tccggggtag	gggagatcg	ctgggaagaa	agcagggttcc	tgagcagct	cgacttaccg	6060
cagccgggtgg	ggccgtaaat	cacacctatt	accgggtgca	actggtagt	aagagagctg	6120
cagctgcgt	catccctgag	cagggggggcc	acttcgttac	gcacatgttgc	gactcgcat	6180
tttccctgc	ccaaatccgc	cagaaggcgc	tcggccccc	gcgtatgc	ttcttgc	6240
gaagcaaagt	ttttcaacgg	tttgagaccg	tccggccgt	gcacatgtttt	gagcgtttga	6300
ccaaagcgtt	ccaggcggtc	ccacagctcg	gtcacctgc	ctacggcatc	tgcgtccagc	6360
atatctcc	gtttcgcggg	ttggggccgc	tttcgtgttgc	cgccgtatgt	cggtgtctcg	6420
ccagacgggc	cagggtcat	tctttccac	ggccgagggt	cctcgatc	gtgtctggg	6480

tcacggtgaa	gggggtgcgt	ccgggctcg	cgctggccag	ggtgcgcctt	aggctggtcc	6540
tgctggtgc	gaagcgctgc	cggcttgc	cctgcgcgtc	ggccaggtag	catttgacca	6600
tggtgtcata	gtccagcccc	tccgcggcgt	ggcccttggc	gcmcagctt	cccttggagg	6660
aggcgcgcga	cgagggggcag	tgcagactt	tgagggcgta	gagcttggc	gcgagaaaata	6720
ccgatccgg	ggagtaggca	tccgcgcgc	aggcccccga	gacggctcg	cattccacga	6780
gccaggtgag	ctctggccgt	tcggggtaa	aaaccagggt	tcccccattgc	tttttgatgc	6840
gtttcttacc	tctgtttcc	atgagccgt	gtccacgctc	ggtgacgaaa	aggctgtccg	6900
tgtcccccgt	tacagactt	agaggctgt	cctcgagcgg	tgttccgcgg	tcctcctcgt	6960
atagaaaactc	ggaccactct	gagacaagg	ctcgcgtcca	ggccagcacg	aaggaggcta	7020
agtggggagg	gtacggctcg	ttgtccacta	gggggtccac	tcgctccagg	gtgtgaagac	7080
acatgtcgcc	ctcttcggca	tcaaggaagg	tgattggttt	gtaggtgtag	gccacgtgac	7140
ogggtgttcc	tgaagggggg	ctataaaagg	gggtggggc	gcgttcgtcc	tcactctt	7200
ccgcacatcgct	gtctgcgagg	gccagctgtt	ggggtgagta	cuccctctga	aaagcggca	7260
tgacttctgc	gctaagatt	tcagtttcca	aaacacgagga	ggatttgata	tacacctggc	7320
ccgcgggtat	gccttgggg	gtggccgc	ccatctggc	agaaaaagaca	atctttttgt	7380
tgtcaagctt	ggtgccaaac	gaccgtaga	gggcgttgg	cagcaactt	gcgatggagc	7440
gcaggggttt	gttttgcg	cgatcgccgc	gctccttgc	cgcgatgttt	agctgcacgt	7500
attcgccgc	aacgcaccgc	cattcgggaa	agacggtggt	gctgcgtcg	gcaccagggt	7560
gcacgcgc	accgcgggtt	tgcagggtga	caaggtcaac	gctgggtggc	acctctccgc	7620
gtagggcgctc	gttggtccag	cagaggccgc	cgcccttgc	cgagcagaat	ggcggtaggg	7680
ggtctagctg	cgtctcg	gggggtctg	cgtccacgg	aaagaccccg	gcagcaggc	7740
gcbcgtcgaa	gtatgtctatc	ttgcacatc	gcaagtctag	cgccctgc	catgcgcggg	7800
cgcaagcgc	gchgctcgat	gggttggat	ggggacccc	tggcatgggg	ttggtgagcg	7860
cgaggcgta	catgcgc	atgtcgtaa	cgtaggggg	ctctctgt	attccaagat	7920
atgttaggg	gcatcttcc	ccgcggatgc	tggcgcac	gtaatctgt	atttcg	7980
aggaggcgag	gaggctgg	ccgagggtgc	tacgggggg	ctgtctgt	cgaaagacta	8040
tctgcctgaa	gatggcatgt	gagttggat	atatggttt	acgcttggaa	acgttgaagc	8100
tggcgtctgt	gagacctacc	gctgcacgca	cgaaaggaggc	gtaggagtc	cgca	8160
tgaccagctc	ggcgggtgacc	tgacgtcta	gggcgcagta	gtccagggtt	tccttgc	8220
tgtcatactt	atcctgtccc	tttttttcc	acagctcg	gttggaggaca	aactcttgc	8280
ggtcttcca	gtactcttgg	atcgaaacc	cgtcggc	cgaacggtaa	gagcctagca	8340
tgtagaactg	gttgcacggcc	tggtagg	agatccctt	ttctacggg	agcgcgtatg	8400
cctgcgcggc	cttcggagc	gagggtgg	tgagcgc	ggtgcct	accatgactt	8460
tgaggactgt	gtatttgc	tcagtgctg	cgatccgc	ctgtccc	agcaaaaaagt	8520
cctgcgcgtt	tttggaaacgc	ggatttggca	gggcgaagg	gacatcg	tttgcgtat	8580
ttccgcgcg	aggcataaaag	ttgcgtgt	tgccggaaagg	tcccg	cgaccgt	8640
tgttaattac	ctggcgccg	agcacatct	cgtaaagcc	gttgatgtt	tggccacaa	8700
tgtaaagttc	caagaagcgc	gggatccct	tatggaaagg	caatttttta	atcttgc	8760
aggtgagctc	ttcagggggag	ctgagccgt	gctctgaaag	ggccca	gtcaagatgag	8820
ggtttggaaagc	gacgaatgag	ctccacaggt	cacggccat	tagcatttgc	agggtgtc	8880
gaaaggtct	aaactggcga	cctatggca	tttttctgg	ggtgatgc	tagaaggtaa	8940
gccccgtt	ttccca	tcccatccaa	ggtgcggc	tagtctc	gcggcagtc	9000
ctagaggctc	atctccgc	aactatcg	ccacgtatg	gggcac	tgcttcccaa	9060
aggccccat	ccaat	ggatctacat	cgttaggt	aaagagacgc	tcgggtcg	9120
gatgcgagcc	gatcgggaaag	aactggatct	ccgcacca	attggaggag	ttgttattga	9180
tgtggtgaaa	gtagaagtcc	ctgcgacgg	ccgaaacactc	gtgctgg	ttgtaaaaac	9240
gtgcgcgat	ctggcagcgg	tgcacgg	gtacatctg	cacgagg	acctgacgac	9300
cgcgcacaag	gaagcagagt	gggaatttga	gcccctcg	tgggggtt	ggctgggt	9360
cttctacttc	ggctgttt	ccttgaccgt	ctggctg	gagggagtt	acggtg	9420
ggaccaccac	gcccgcg	ccaaagtc	agatgtcc	gcccggcgt	cgagctt	9480
tgacaacatc	gcgcagatgg	gagctgtca	ttgtctgg	ctcccg	gtcagg	9540
gccccggatc	ctgcagg	acctcgat	gacgggt	ggcgggg	agatcc	9600
gataccta	ttccagg	tggttgg	cgcg	ggcttgc	aggccgc	9660
ccgcgcgc	gactacgg	ccgcggc	ggcggtgg	cgccgggt	tccctggat	9720
atgcata	aaagcggt	gcgggcg	cccccgg	aggggggg	ccggaccc	9780
cgggagaggg	ggcagg	cgtcggc	gcmc	aggagctt	gtcg	9840
taggttgct	gcaac	cgacgc	gttgc	tgaatct	gcctct	9900
gaagacgac	ggcccgg	gcttg	gaaagagag	tcgac	agaat	9960
gtcggtgac	gcggc	gcaaaat	ctgcacgt	cctgagtt	ttgtatagg	10020
gatctcg	atgaact	cgatctt	ctc	ttgtatagg	cggtcg	10080
cacgg	ggcgg	tggaaat	ggccat	tgcg	gagaagg	10140
tccctcg	cagac	tgttag	gac	cgccat	cgccat	10200

cacctgcgcg	agattgagct	ccacgtgccg	ggcgaagacg	gcgtagttc	gcaggcgctg	10260
aaagaggtag	ttgagggtgg	tggcggtgt	ttctgccacg	aagaagtaca	taacccagcg	10320
tcgcaacgtg	gattcggtga	tatccccaa	ggcctaagg	cgctccatgg	cctcgttagaa	10380
gtccacggcg	aagtgaaaa	actgggagtt	gcegcccac	acggtaact	cctcctccag	10440
aagacggatg	agctcgccga	cagtgtcg	caccccgcc	tcaaaggcta	cagggggccctc	10500
ttcttcttct	tcaatctct	cttcataaag	ggcctccct	tcttcttctt	ctggcgccgg	10560
tgggggaggg	gggacacggc	ggcgcacgacg	gcccaccggg	aggcggtcga	caaagcgctc	10620
gatcatctcc	ccgcggcgac	ggcgcatgtt	ctcggtacg	gcccggccgt	tctcgcgggg	10680
gcccgcgttg	aagacgcgc	ccgcgcgtt	ccggttatgg	gttggcgggg	ggctgcccatt	10740
cggcaggat	acggcgctaa	cgatgcatt	caacaattgt	tgtgttagta	ctccgcggcc	10800
gagggacctg	agcgagtcg	catcgaccgg	atcgaaaac	ctctcgagaa	aggcgctctaa	10860
ccagtcacag	tcgcaaggta	ggctgaggcac	cgtggcgggc	ggcagcgggc	gcccgtcggg	10920
gttggttctg	gcccgggtgc	tgctgtatgt	gtaattaaag	taggcggct	tgagacggcg	10980
gatggtcgac	agaagcacca	tgtctttggg	tccggcctgc	tgaatgcgc	gcccgtcggc	11040
catgccccccag	gcttcgtttt	gacatcgccg	caggttttttgc	tagtagtct	gcatgagcct	11100
ttctaccggc	actttttttt	ctccttcctc	ttgtcctgc	tcttcttgc	ctatcgctgc	11160
ggcggccggcg	gagtttggcc	gttaggtggcg	cccttttctt	ccatcgctg	tgaccccgaa	11220
gcccctcattc	ggctgaagca	gggcttaggtc	ggcgcacaacg	cgctcggtct	atatggccctg	11280
ctgcacccgtc	gtgagggttag	actggaaatc	atccatgtcc	acaaagcggt	gttatgcggcc	11340
cgtgttgcgt	gtgttaagtgc	agttggccat	aacggaccag	ttaacggct	gtgtgacccgg	11400
ctgcgagagc	tcgggttacc	tgagacgcga	gtaagccctc	gagtcaaata	cgtatgcgtt	11460
gcaagtccgc	accaggtact	ggtatccac	caaaaagtgc	ggcggcggt	gcccgttagag	11520
ggcccaagcgt	agggtggccg	gggctccggg	ggcgcagatct	tccaacataa	ggcgatgata	11580
tccgttagat	tacccgtggaca	tccagggtat	ggccgcggcg	gttgtggagg	ccgcgcggaaa	11640
gtcgccggacg	cggttccaga	tgtgtcgccag	cgccaaaaag	tgctccatgg	tcgggacgct	11700
ctggccggtc	aggcgccgc	aatctgttgc	gctctagacc	gtcggaaagg	agagcctgt	11760
agcgggact	cttcgttgtt	ctgggttgcata	aattcgcaag	gttatacatgg	ccggacgacg	11820
gggttcgagc	cccgatcccg	ggcggtccccc	gtgatccatg	cggttaccgc	ccgcgtgtcg	11880
aaccctagg	tgcgacgtca	gacaacgggg	gagtgttcc	tttggcttcc	ttccaggcgc	11940
ggcggctgt	gcccgtactt	ttttggccac	tggccgcgcg	cagcgttaagc	gtttaggctg	12000
gaaagcgaaa	gcattaagtgc	gctcgctccc	tgtagccgga	gggttatttt	ccaagggttg	12060
agtgcgggaa	ccccccgttc	gagtctcgga	ccggccggac	tgccgcgaac	gggggtttgc	12120
ctccccgtca	tgcaagaccc	cgcttgcataa	ttcttccgg	aacaggggacg	agcccccttt	12180
ttgtttttcc	cagatgcattc	cggtgtcg	gcaatgcgc	ccccctcc	agcagcggca	12240
agagcaagag	cagccggcaga	catcgaggc	accctccct	cctcttaccg	cgtcaggagg	12300
ggcgcacatcc	gggggttgcg	ccgcagcaga	ttgtgttacc	gaaccccccgc	ggcgcggggc	12360
ccggcactac	ctggacttgg	aggaggcga	gggcctggcg	cggcttaggag	cccccctctcc	12420
tgagcggtac	ccaagggtgc	agctgaagcg	tgatacgcgt	gaggcgtacg	tgccgcggca	12480
gaacctgttt	cgcgaccgcg	agggagagga	gcccggaggag	atgcgggatc	aaaagttcca	12540
cgcaggccgc	gagctgcggc	atggcctgaa	tcgcgagcgg	ttgctgcgc	aggaggactt	12600
tgagcccgac	gcccgaaccg	ggattagtc	cgccgcgc	cacgtggcg	ccgcccac	12660
ggttaaccgca	tacgagcaga	cggtgaacca	ggagattaac	tttcaaaaaaa	gtttaacaa	12720
ccacgtgcgt	acgcttgcgt	cgccgcg	gggtggctata	ggactgtatc	atctgtgg	12780
ctttgttgc	gcccgtggac	aaaacccaaa	tagcaagccg	ctcatggcgc	acgtgttct	12840
tatagtgcag	cacagcagg	acaacgggc	attcaggat	gctgtctaa	acatagtaga	12900
gcccggggc	cgctggctgc	tcgatgttgc	aaacatctcg	cagagcatag	ttgtgcagga	12960
gcccggctt	agcctggctg	acaagggtgc	cgccatcaac	tattccatgc	ttagcctgg	13020
caagttttac	gcccgcaga	tataccatac	cccttacgtt	cccatagaca	aggaggtaaa	13080
gatcgagggg	ttctacatgc	gcatggcgt	gaaggtgtt	accttgcgc	acgacactgg	13140
cgtttatcgc	aacgagcgc	tccacaaggc	cgtgagcgt	agccggccgc	gcgagctcag	13200
cgaccgcgag	ctgtatgcaca	gcctgcaaa	ggccctggct	ggcacgggc	gcccgcata	13260
agaggccgag	tcctactttg	acgcggggc	tgacactgc	tggggcccaa	gcccgcgc	13320
cctggggggc	gctggggccg	gacctgggt	ggccgtggc	cccgcgcgc	ctggcaacgt	13380
cggcggcgtg	gaggaatatg	acgaggacg	tgatgtacg	ccagaggacg	gcgagacta	13440
agcgggtatg	tttctgtatca	gatgtacaa	gacgcaacgg	acccggcggt	gccccggccgg	13500
ctgcagagcc	agccgtccgg	ccttaactcc	acgacgcact	ggcgcacgg	catggaccgc	13560
atcatgtcg	tgactgcgc	caatccgtac	gcgttccggc	agcagccgc	ggccaacccgg	13620
ctctccgc	ttcttgcgg	ggtggtcccg	gcccgcgc	acccacgc	cgagaagggt	13680
ctggcgatcg	taaacgcgc	ggccgaaaac	agggccatcc	ggcccgcacg	ggccggccctg	13740
gtctacgcac	cgctgtttca	gcccgtgt	cgttacaaca	gcccgcacgt	gcagaccaac	13800
ctggaccggc	ttgtggggga	tgtgcgcag	gcccgtggcgc	agcgtgagcg	ccgcgcagcag	13860
cagggcaacc	ttggctccat	gggtgcacta	aacgccttcc	tgagtacaca	ggccgcacca	13920

gtgccgcggg gacaggagga ctacaccaac tttgtgagcg cactgcggct aatggtgact 13980
 gagacaccgc aaagtgaggt gtaccagtct gggccagact atttttcca gaccagtaga 14040
 caaggcctgc agacccgtaaa cctgagccag gcttcaaaa acttgaggg gctgtggggg 14100
 gtgcgggctc ccacaggcga cccgcgcacc gtgtctagct tgctgacgcc caactcgcc 14160
 ctgttgcgtc tgctaatagc gcccattcacg gacagtggca gcgtgtcccg ggacacatac 14220
 ctaggtcact tgctgacact gtaccgcgag gccataggtc aggccatgt ggacgagcat 14280
 actttccagg agattacaag gtcagccgc gogctggggc aggagacac gggcagccctg 14340
 gaggcaaccc taaactacct gctgaccaac cggcggcaga agatcccctc gttgcacagt 14400
 ttaaacagcg aggaggagcg catttgcgc tacgtgcagc agagcgtgag cottaacctg 14460
 atgcgcgacg ggttaacgcc cagcgtggcg ctggacatga ccgcgcgcaa catggAACCG 14520
 ggcatgtatg cctcaaaccg gccgtttatc aaccgcctaa tggactactt gcatcgccg 14580
 gccgcccgtga accccgagta tticaccaat gccatcttga accccactg gctaccgc 14640
 cctgggttct acacccgggg attcgagggt cccgagggtt acgtggatt cctctggac 14700
 gacatagacg acagcgtgtt tttcccgcaa ccgcagacc tgctagagtt gcaacagcc 14760
 gagcaggcag aggccggct gcgaaaggaa agtccgcg gccaacgcg cttgtccgat 14820
 ctaggcgtct cggcccccg gtcagatct agtagccat ttccaagctt gatagggtct 14880
 cttaccagca ctcgcaccac cccgcgcgc ctgctggcg aggagagta ctaaaacaac 14940
 tcgctgctgc agccgcagcg cgaaaaaaac ctgcctccgg catttccaa caacgggata 15000
 gagagcctag tggacaagat ccaggcccgc gcccgcaccc gatgggggaga atgtttaaa aaaaaaaaaaag catgatgcaa 15240
 aataaaaaaaac tcaccaaggc tggacatggt ttcttgatt ccccttagta 15300
 tgcggcgcgc ggcgtatgtt gggggccctc ctacgagatgt gtggtgagcg 15360
 cggcccgagt ggcggccggc tgggttctc cttctcgatgc tcccctggac ccgcgtttt 15420
 tgcctccgcg gtacactgcgg cttacggggg ggagaaacag catccgttac tctgagttgg 15480
 cacccttatt cgacaccacc cgtgtgtacc tggtgacaa caagtcacg gatgtggcat 15540
 ccctgaacta ccagaacgcac cacagcaact ttctgaccac ggtcattcaa aacaatgact 15600
 acagcccggg ggaggcaagc acacagacca tcaatcttga cgaccgtcg cactggggcg 15660
 ggcacactgaa aaccatctg cataccaaca tgccaaatgt gaacgagttc atgtttacca 15720
 ataagttaa ggcgcgggtg atggtgcgc gcttgcctac taaggacaat caggtggagc 15780
 tgaatatacg gttgggtggag tagaccttata gaaacacgcg atcgtggagc actacttggaa atgtggcaga cagaacgggg 15900
 ttctggaaag cgacatccgg tcttgcgtcgttgggttatacaaaacgaa gccccttcat ccagacatca 16020
 ttttgctgcc aggatgcggg tccgcggcgg gggggct ttaggatcac ctacgatgat ctggagggtg 16140
 gtaacattcc cgcactgttgc aacaggccgg ggtggcgca ccttgcgttgcg ggcggcagca acagcgttgg cagcggccg 16260
 ccaacgcggc agccgcggca atgcagccgg tggaggacat gaacgatcat gccattcg 16320
 ggcacacctt tgccacacgg ctggccccc cgtgcgcgaa ccctgacaga ggacagcaag aaacgcgtt acaacctaatt aagcaatgac agcaccttca 16440
 cccagtaccc cagctggtac catggaccct gcttgcgtc tggacttca ctttgcataca actacggcga ccttcgaccc ggaatccgt 16560
 tgccagacat gatgcaagac cggtgttggg cggccggctg tctactccca actcatccgc agaaccagat tttggcgcgc cgcggccccc caccatcac caccgtcagt gaaaacgttc 16660
 ctgctctcac agatcacggg tgaccattac tgacgcccaga tccgcgcgcg cgtcttatcg ccagcaataa cacaggctgg agcgcctccga ccaacaccca acaaacgcgg cgcacttgcgaa cgcaccaccg tggacttccac gcccgttccatc ttacaaggcc tttggccatag 16740
 aggcgcgcaaa ctacacgcgc ccgtgggtggc cggagccgg gtcgcacccg caccgttgc gggggacttcccaacttgc tttggccatc gatgtttggc gggggccaaga 17100
 gtcgcacccg cggccgaccc ggcactggc cccaaacgcgc cggccggcc gggggccgc 17160
 ggcacgtcg caccggccga cggccggcc cgttatgtcta aatgaagag acggccggagg cgcgttagcac 17220
 ttgtcaactgt gccccccagg tccaggccac gagccggccgc cgcacccgaccc ggcggccattha 17280
 gtgctatgac tcagggctgcg aggggcaacg tgtattgggt ggcgcactcg gttagccccc 17340
 tgcgcgtgcc cgtgcgcacc cggccggccca tggggccgc tggggccgc tggccat 17400
 cggccacgtcg caccggccga cggccggcc tccaggccac gacggccggagg cgcgttagcac 17460
 ttgtcaactgt gccccccagg tccaggccac gagccggccgc cgcacccgaccc ggcggccattha 17520
 gtgctatgac tcagggctgcg aggggcaacg tgtattgggt ggcgcactcg gttagccccc 17580
 tgcgcgtgcc cgtgcgcacc cggccggccca tggggccgc tggggccgc tggccat 17640

actcgtactg ttgtatgtat	ccagcggcg	cggcgcgcaa	cgaagctatg	tccaagcgca	17700
aaatcaaaga agagatgctc	caggtcatcg	cgccggagat	ctatggcccc	ccgaagaagg	17760
aagagcagga ttacaagccc	cgaaagctaa	agcgggtcaa	aaagaaaaag	aaagatgatg	17820
atgatgaact tgacgacgag	gtggaaactgc	tgaacgctac	cgcgccagg	cgacgggtac	17880
agtggaaagg tcgacgcgt	aaacgtttt	tgccgaccgg	caccacgt	gtctttacgc	17940
coggtgagcg ctccacccgc	acctaaca	gcgtgtatga	tgaggttgc	ggcgacgagg	18000
acotgcttgc gcaggccaac	gagcgcctcg	gggagttgc	ctacggaaag	cggcataagg	18060
acatgctggc gttgccgtg	gacgagggca	acccaacacc	tagcctaaag	cccgtaacac	18120
tgacgcagg	cttgcacgt	ccgaagaaaa	gcgccgccta	aagcgcgagt	18180
ctggtgactt ggcacccacc	gtgcagctga	tgttacccaa	gcccgcgcga	ctggaaagatg	18240
tottggaaaa aatgaccgtg	gaacctgggc	tggagcccga	ggtcgcgt	cgcccaatca	18300
agcaggtggc gccgggactg	ggcgtgcaga	ccgtggacgt	tcagatacc	actaccaga	18360
gaaccagtat tgccaccg	acagagggca	tggagacaca	aacgtccccg	ttgcgcctcag	18420
cgtgtggcgg	tgccgcgtg	caggcggtcg	ctgcggccgc	gtccaaagacc	18480
tgcaaaacggc cccgtggat	tttcgcgtt	cagccccccg	gcccgcgcgc	gttgcgagga	18540
agtaacgcgc cccacgcgc	ctactgc	aatatgcct	acatcc	attgcgccta	18600
ccccggcta tcgtggctac	acctaccgc	ccagaagacg	agcaactacc	cgacgcccga	18660
coaccactgg aaccgcgcgc	cgccgtgc	gtgcgcagcc	cgtgctggcc	ccgatttc	18720
tgcgcagggt ggctcgaa	ggaggcagga	ccctgggtct	gccaacagcg	cgctaccacc	18780
ccagcatgt taaaagccg	gtctttgtgg	ttcttgcaga	tatggccctc	acctgcccgc	18840
tcggttccc ggtgccgg	ttccgagaa	gaatgcacc	taggagggc	atggccggc	18900
acggcctgac gggcggcat	cgtcgtgc	accaccggcg	gcccgcgcgc	tcgcaccgtc	18960
goatgcgcgg cggtatcctg	cccccttta	ttccactgtat	cgccgcggcg	attggcgccg	19020
tgcccggat tgcatccgt	gccttgcagg	cgcagagaca	ctgattaaaa	acaagttgca	19080
tgtggaaaaa tcaaaaataaa	aagtctggac	tctcacgtc	gtctggct	taaactattt	19140
ttagaattgg aagacatcaa	cttgcgtct	ctggcccccgc	gacacggctc	gcccgcgttc	19200
atgggaaact ggcaagat	cggcaccaggc	aatatgagcg	gtggccctt	cagctggggc	19260
tcgctgtgaa gcccattaa	aaatttcgtt	tccaccgtt	agaactatgg	cagcaaggcc	19320
tgaacagca gcacaggcc	gatgctgagg	gataagttg	aagagaaaa	tttccaacaa	19380
aaggtaggtg atggcttgc	ctctggcatt	agcgggggtgg	tggacctggc	caaccaggca	19440
gtcAAAata agattaacag	taagcttgc	ccccgcctc	ccgtagagga	gcctccaccc	19500
gccgtggaga cagtgtctcc	agagggcgt	ggcggaaagc	gtccgcgc	cgacaggaa	19560
gaaactctgg tgacgcaa	agacgagcc	ccctcgtacg	aggaggact	aaagcaaggc	19620
ctgcccacca cccgtccat	cgcgc	catccggag	gtctggccca	gcacacaccc	19680
gtAACGCTGG acctgcctcc	ccccgcgc	accocagcaga	aacctgtct	gcccgcgc	19740
accgcgttgc ttgtaccccg	tccatgc	gcgtccctgc	gcccgcgc	cagcggc	19800
cgtatcggtc gggccgttag	cagtggcaac	ttggcaagca	cactgaac	catcg	19860
ctgggggtgc aatccctgaa	gcccgcacca	tgottctgaa	tagtaacgt	gtcgatgt	19920
tgtcatgtat gctccatgt	cgccgc	ggagctgt	agccgcgc	cgccgc	19980
ccaaagatggc tacccttcg	atgatgcgc	agtggcttta	catgcacatc	tcggccagg	20040
acgcctcgga gtacccgt	cccggcgttgc	tgca	ccgcgc	gagacgtact	20100
tcagcctgaa taacaagttt	agaaaacccca	cggtggcgcc	tacgcac	gtgaccacag	20160
accggtccca gcggttgc	ctgcgggtca	tcctgtgg	ccgtgaggat	actgcgtact	20220
cgtacaaggc gcggttcc	ctagctgttgc	gtgataacc	tgtgtggac	atggcttca	20280
cgtacttgta catccgcggc	gtgtggaca	ggggccctac	tttaa	tactctggc	20340
ctgcctacaa cggccctgg	cccaagggt	cccaaatcc	ttgcgaatgg	gatgaagctg	20400
ctactgctct taaaataaa	ctagaagaag	aggacgat	caacgaagac	gaagtagacg	20460
agcaagctg	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	20520
ttacaaaggg gggatttca	ataggtgtcg	aaggtcaaa	acctaataat	gccgataaaa	20580
catttcaacc tgaacctaa	ataggagaat	ctca	cgaaactgaa	attaatcatg	20640
cagctggag agtcctaaa	aagactaccc	caatgaaacc	atgttacgt	tcatatgca	20700
aacccacaaa taaaatgg	gggcaaggca	ttcttgc	gcaacaaaat	gaaaagctag	20760
aaagtcaagt gggaaatgca	ttttctca	ctactgaggc	gaccgcaggc	aatggtgata	20820
attttgcactc taaaatgg	ttgtacagt	aagatgt	tatagaaacc	cacagacactc	20880
atatttcttca catgcccact	atta	gtaactc	agaacta	ggccaacaa	20940
ctatgcccac caggccta	tacattgc	ttaggacaa	tttattgt	ctaatgtatt	21000
acaacagcac gggtaatatg	ggtgttgc	cgccca	atgcgc	aatgtgtt	21060
tagatttgc	acagagctt	cata	tttgc	tccattgg	21120
atagaaccag gtactttct	atgtggatc	aggctgttgc	cagctat	ccagatgtt	21180
gaattattga aaatcatg	actgaagat	aacttccaa	ttactgc	ccactgggag	21240
gtgtgattaa tacagagact	cttaccaagg	taaaacctaa	aacagg	gaaaatggat	21300
ggaaaaaaga tgctacagaa	ttttcagata	aaaatgaaat	aagatgttgc	aataat	21360

ccatggaaat	caatctaaat	gccaacctgt	ggagaaaattt	cctgtactcc	aacatagcgc	21420		
tgtatttgcc	cgacaagcta	aagtacagtc	cttccaacgt	aaaaatttct	gataacccaa	21480		
acacctacga	ctacatgaac	aagcgagttg	tggctcccg	gttagtgac	tgctacatta	21540		
accttggagc	acgctggtcc	cttgaactata	tggacaacgt	caaccattt	aaccaccacc	21600		
gcaatgctgg	cctgcgctac	cgctcaatgt	tgctggcaa	tggtcgctat	gtgcccttcc	21660		
acatccaggta	gcctcagaag	ttctttgcca	ttaaaaacct	ccttccctg	ccgggctcat	21720		
acacctacga	gtggaaacttc	aggaaggatg	ttaacatggt	tctgcagacg	tcccttaggaa	21780		
atgacctaag	ggttgcacgga	gccagcattt	agtttgatag	catttgccct	tacgcccac	21840		
ttttcccat	ggcccaacaac	acgccttcc	cgcttgaggc	catgctttaga	aacgacacca	21900		
acgaccagtc	ctttaacgac	tatctctccg	ccgccaacat	gctctaccct	atacccgcca	21960		
acgctaccaa	cgtgcccata	tccatcccc	cccgcac	ggcggcttcc	cgccgctggg	22020		
ccttcacgcg	ccttaagact	aaggaaaccc	catcaactggg	ctcgggctac	gacccttatt	22080		
acacctactc	tggctctata	ccctacctag	atggaacctt	ttaccta	cacaccttta	22140		
agaagggtggc	cattacctt	gactcttctg	tca	gactgtggcc	tggcaatgac	22200		
cocccaacga	gtttgaaatt	aagcgctcag	ttgacggg	gggttacaac	gttggcccagt	22260		
gtaacatgac	caaagactgg	ttcctgttac	aatgctagc	taactacaac	attggctacc	22320		
agggcttctt	tatcccagag	agctacaagg	accgcatgt	ctccttctt	agaaacttcc	22380		
agcccatgag	ccgtcagggt	gtggatgata	ctaaatacaa	ggactaccaa	cagggtggca	22440		
tectacacca	acacaacaac	tctgatgtt	ttggctac	tgc	ccccaccacc	atgcgcgaag	22500	
gacaggccta	ccctgcta	ttcccctatc	cgcttatagg	caagaccgca	gttgcacagca	22560		
ttacccagaa	aaagtttctt	tgcgatcgca	cccttggcg	catcccattc	tccagtaact	22620		
ttatgtccat	gggcgcactc	acagacctgg	gcca	aaaacctt	tctctacg	actccgccc	22680	
acgcgctaga	catgactttt	gagg	tgat	ccatggacga	gcccacc	ctttatgtt	22740	
tgtttgaagt	ctttgacgtg	gtccgtgtc	accggccgca	ccgcggcgtc	atcgaaacccg	22800		
tgtacctgcg	cacgccc	tcggccg	acgcccaca	ataaagaagc	aagcaacatc	22860		
aacaacacgt	gccc	gctt	cgta	gcca	ggacttac	tc	aaagatct	22920
tgttgttggg	ccatattttt	tggg	ccat	tgaca	ggc	tttccagg	ttgtttctcc	22980
acacaagctc	gcctgcgca	tagt	caata	ggccgg	ggact	gggg	ggttacact	23040
gatggcctt	gccttgg	cgca	ctt	ctt	ggc	tttgg	ctt	23100
ttctgaccag	cgactca	agg	ttt	ttt	ttt	ttt	ttt	23160
cgccattgt	tcttcccc	acc	gtt	gtt	gtt	gtt	gtt	23220
ggggcccaac	tcggcc	gtgg	actt	ctg	ctg	ctt	ctt	23280
ctggcccaaa	actccatgg	atc	caca	ca	ccat	cc	cc	23340
ctccatgctc	aacag	agg	tac	cc	cc	cc	cc	23400
cagttcctg	gag	cc	tac	cc	cc	cc	cc	23460
cacttctt	tgtcactt	aaa	acat	ttt	ttt	ttt	ttt	23520
aggc	aaat	act	ctc	ttt	ttt	ttt	ttt	23580
cgccgtt	aaat	gg	tct	cc	cc	cc	cc	23640
gttgc	ttt	gg	tc	cc	cc	cc	cc	23700
gttga	ttt	gg	tc	cc	cc	cc	cc	23760
cgat	ttt	gg	tc	cc	cc	cc	cc	23820
gttgc	ttt	gg	tc	cc	cc	cc	cc	23880
ggagat	ttt	gg	tc	cc	cc	cc	cc	23940
tagct	ttt	gg	tc	cc	cc	cc	cc	24000
cccaaaa	agg	gg	ct	cc	cc	cc	cc	24060
cat	aaa	gg	ct	cc	cc	cc	cc	24120
gat	ttt	gg	ct	cc	cc	cc	cc	24180
gccc	aaa	gg	ct	cc	cc	cc	cc	24240
ggagat	ttt	gg	ct	cc	cc	cc	cc	24300
ctcc	ttt	gg	ct	cc	cc	cc	cc	24360
cattt	ttt	gg	ct	cc	cc	cc	cc	24420
cagcc	ttt	gg	ct	cc	cc	cc	cc	24480
cagg	ttt	gg	ct	cc	cc	cc	cc	24540
cag	ttt	gg	ct	cc	cc	cc	cc	24600
cactt	ttt	gg	ct	cc	cc	cc	cc	24660
catc	ttt	gg	ct	cc	cc	cc	cc	24720
cgg	ttt	gg	ct	cc	cc	cc	cc	24780
ccgc	ttt	gg	ct	cc	cc	cc	cc	24840
ccgc	ttt	gg	ct	cc	cc	cc	cc	24900
ccgc	ttt	gg	ct	cc	cc	cc	cc	24960
ccgc	ttt	gg	ct	cc	cc	cc	cc	25020
ctcgata	ccgc	ttt	gg	ct	cc	cc	cc	25080

cggggacgac	acgtcctcca	tggttgggg	acgtcgcc	gcaccgcgtc	cgcgctcg	25140
ggtggttcg	cgctgctct	cttcccact	ggccatttcc	ttctctata	ggcagaaaaa	25200
gatcatggag	tcagtcgaga	agaaggacag	cctaaccgcc	ccctctgagt	tcgcccacc	25260
cgcctccacc	gatgccgcca	acgcgcctac	cacctcccc	gtcgaggcac	ccccgcttga	25320
ggaggaggaa	gtgattatcg	agcaggaccc	aggtttcta	agcgaagacg	acgaggaccg	25380
ctcagtacca	acagaggata	aaaacaaga	ccaggacaac	gcagaggcaa	acgaggaaca	25440
agtcgggcgg	ggggacgaaa	ggcatggcga	ctacctatag	gtgggagacg	acgtgctgtt	25500
gaagcatctg	cagcgcaggat	gcgcattat	ctgcgacgcg	ttgcaagagc	gcagcgatgt	25560
gcccctcgcc	atagcggatg	tcagccttgc	ctacgaacgc	caccttatct	caccgcgct	25620
acccccc当地	cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	25680
cgtatttgc当地	gtgcccagagg	tgcttgc当地	ctatcacatc	tttttccaaa	actgcaagat	25740
acccctatcc	tgccgtgcca	accgcagccg	agcgacaag	cagctggct	tgcgccaggg	25800
cgctgtcata	cctgatatacg	cctcgctcaa	cgaagtgcca	aaaatctttg	agggtcttgg	25860
acgcgacgag	aagcgcgc当地	caaacgc当地	gcaacaggaa	aacagcgaaa	atgaaagtca	25920
ctctggagtg	ttggtggaaac	tcgagggtga	caacgcgc当地	ctagccgtac	taaaacgcag	25980
catcgaggtc	accacttgc当地	cctacccggc当地	acttaaccta	cccccccaagg	tcatgaggcac	26040
agtcatgagat	gagctgatcg	tgccgc当地	gcagccctg	gagagggatg	caaatttgc当地	26100
agaacaaaaca	gaggagggcc	taccgc当地	tggc当地	cagctagcgc	gtcgcttca	26160
aacgcgc当地	cctgccc当地	tggaggagcg	acgcaaacta	atgatggccg	cagtgctgt	26220
taccgtggag	cttgagtgca	tgcaaggccg	cittgctgac	ccggagatgc	agcgaagat	26280
agagggaaaca	ttgcaactaca	ccttc当地	gggctacgta	cgccaggcc	gcaagatctc	26340
caacgtggag	cctctgcaacc	tggtctccct	ccttggaaatt	ttgc当地	accgccttgg	26400
gcaaaacgtg	cttcattcca	cgctcaaggg	cgaggcgc当地	cgcgactacg	tccgc当地	26460
cgtttactta	tttctatgt	acacctggca	gacggccatg	ggcgttggc	agcagtgtt	26520
ggaggagtgc	aacctcaagg	agctgc当地	actgctaaag	caaacttga	aggacctatg	26580
gacggccttc	aacgagcgt	ccgtggccgc当地	gcaccttggc当地	gacatcattt	tccccgaacg	26640
cctgcttaaa	accctgcaac	agggtctgccc当地	agacttacc	agtcaaagca	tgttc当地	26700
ctttaggaac	tttattcttag	agcgtctcagg	aatcttgc当地	gcacactgt	gtgcaacttcc	26760
tagcgactt	gtgccc当地	agtaccgc当地	atgc当地	ccgcttggg	gccactgtca	26820
cctctgtcag	ctagccaaact	accttgc当地	ccactctgac	ataatggaaag	acgtgagccg	26880
tgacggctca	cttggagtgcc	actgtcgctg	caacctatgc	accggcacc	gtcccttgg	26940
ttgcaattcg	cagctgctta	acgaaagtca	aattatcggt	acctttgagc	tgcaagggtcc	27000
ctcgccgtac	gaaaagtccg	cggtccccc当地	gttggaaactc	actccgggg	tgtggacgtc	27060
ggcttacctt	cgcaaatttgc当地	tacctgagga	ctaccacgccc当地	cacgagatta	ggttctacga	27120
agaccaatcc	cgccc当地	atgc当地	taccgc当地	gtcatttaccc	agggccacat	27180
tcttggccaa	ttgcaaggcca	tcaacaaagc当地	ccgccaagag	tttctgctac	gaaaggggacg	27240
gggggtttac	ttggacccccc当地	agtc当地	ggagctcaac	ccaatcccc	cgccgc当地	27300
gccc当地	cagc当地	ggcccttgc当地	ttccc当地	ggcacccaaa	aagaagctgc	27360
agctgc当地	gccc当地	gacgaggagg	aatactggga	cagt当地	gaggaggttt	27420
tggacggagga	ggaggaggagg	atgttggaaag	actgggagag	cctagacgag	gaagcttccg	27480
aggtcgaaaga	ggtgtc当地	gaaacaccgt	caccctcggt	cgcatcccc	tcgc当地	27540
ccc当地	ggcaaccagg	tccagcatgg	ctacaacctc	cgtccctc当地	gccc当地	27600
caactgccc当地	tcgccc当地	aaccgtatag	gggaccaccac	tgaaccagg	gccc当地	27660
ccaagcagcc	gccc当地	gccc当地	aacaacagcg	ccaaggctac	cgctcatggc	27720
gcccccaaa	gaacgccc当地	gttgc当地	tgcaagactg	tggggcaac	atcttccctcg	27780
ccc当地	tottctctac	catcacggc当地	tggc当地	ccgtaacatc	ctgc当地	27840
accgtcatct	ctacagccca	tactgc当地	gccc当地	cagc当地	aacagcagcg	27900
gccacacaga	agcaaaggccg	accggatagc当地	aagactctga	caaagccaa	gaaatccaca	27960
gcggcggccag	cagc当地	aggagcgc当地	cgtctggc当地	ccaacgaaac	cgtatcgacc	28020
cgcgagctt	gaaacaggat	ttttccact	ctgtatgtca	tatttcaaca	gagcaggggc	28080
caagaacaag	agctgaaaat	aaaaaacagg	tctctgcat	ccctcaccc	cagctgc当地	28140
tatcacaaaa	gqaaagatca	gcttggc当地	acgttggaaag	acgc当地	tcttctcgat	28200
aaatactcg	cgtgtact	taagactg	tttc当地	tttctcaaat	ttaagcgc当地	28260
aaactacgtc	atctccaggg	ggccacacccg	ggggccaggcc	ctgtcgccg	ccccattatc当地	28320

ttcacgcctc	gtcaggcaat	cctaactctg	cagacctcg	cctctgagcc	gcgctctgga	28860
ggcattggaa	ctctgcaatt	tattgaggag	tttgcctat	cggctactt	taacccttc	28920
tcgggacctc	ccggccacta	tccggatcaa	tttattccta	actttgacgc	gttaaaggac	28980
tcggcggacg	gctacgactg	aatgttaagt	ggagaggcag	agcaactgcg	cctgaaaacac	29040
ctggtccact	gtcgccgcca	caagtgcctt	gcccgcact	ccggtaggtt	ttgtacttt	29100
gaattgccc	aggatcatat	cgagggcccc	ggcacccgc	tccggcttac	cgcccaggga	29160
gagcttgccc	gtagccctgt	tcgggagttt	accagcgcc	ccctgttagt	tgagcgggac	29220
aggggaccc	gtgttctcac	tgtgatttgc	aactgtccta	accttggatt	acatcaagat	29280
ttaattaatt	gccacatctt	cttacactt	ttcatacatt	gcccagaat	aaagaatcgt	29340
tttgttatg	tttcaacgtg	tttattttc	aattgcagaa	aatttcaagt	cattttcat	29400
tcaagtat	agccccacca	ccacatagct	tatacagatc	accgtacctt	aatcaaactc	29460
acagaacct	agtattcaac	ctgcccaccc	cctcccaaca	cacagagtac	acagtccctt	29520
ctccccggct	ggccttaaaa	agcatcatat	catgggtaac	agacatattc	ttaggtgtta	29580
tattccacac	ggtttcctgt	cgagccaaac	gctcatcagt	gatattaata	aactccccgg	29640
gcagctact	taagttcatg	tcgctgtcca	gctgctgagc	cacaggctgc	tgtccaactt	29700
gcgggtgtt	aacgggcggc	gaaggagaag	tccacgccta	catgggggt	gagtcatataat	29760
cgtgcattag	gatagggcgg	tggtgctgca	gcagcgcgc	aataaactgc	tgccgcggcc	29820
gtccgtct	gcagaaatc	aacatggcag	tggtctctc	agcgatgatt	cgcaccgccc	29880
gcagcataag	gwgcttgc	ctccggcac	agcagcgcac	cctgatctca	cttaaatctag	29940
cacagtaact	gcagcacagc	accacaat	tgttcaaaat	cccacagtgc	aaggcgctgt	30000
atccaaagct	catgggggg	accacagaac	ccacgtggcc	atcataccac	aagcgcaggt	30060
agattaagt	gwgacccctc	ataaaacacgc	tggacataaa	cattacctt	tttggcatgt	30120
tgtattcac	caccccccgg	taccatataa	accctctgatt	aaacatggcg	ccatccacca	30180
ccatcctaaa	ccagctggcc	aaaacctgcc	cgccggctat	acactgcagg	gaaccgggac	30240
tggaaacaatg	acagtggaga	gcccaggact	cgttaaccatg	gatcatcatg	ctcgctatga	30300
tatcaatgtt	ggcacaacac	aggcacacgt	gcatacactt	cctcaggatt	acaagctct	30360
cccgcgtag	aaccatatcc	caggaaacaa	cccatctctg	aatcagcgt	atccccacac	30420
tgcagggaaag	acctcgacg	taactcacgt	tgtgatttgc	caaagtgtt	cattcggcga	30480
gcagcggatg	atccctccgt	atggtagcgc	gggtttctgt	ctcaaaagga	ggttagacgat	30540
ccctactgt	cgaggtgcgc	cgagacaacc	gagatcgtgt	tggtgcttagt	gtcatgcca	30600
atggAACCC	ggacgtagtc	atatttctg	aagcaaaacc	aggtgcgggc	gtgacaaaca	30660
gatctgcgtc	tccgtctcg	ccgcttagat	cgctctgtgt	agtagttgt	gtatatccac	30720
tctctcaaag	catcaggcg	ccccctggct	tcgggttctca	tgtaaaactcc	ttcatgcgcc	30780
gtgtccctga	taacatccac	caccgcagaa	taagccacac	ccagccaacc	tacacattcg	30840
ttctgcgagt	cacacacggg	aggagcggg	agagctggaa	gaacatgtt	tttttttttta	30900
ttccaaaaaa	ttatccaaaa	cctccaaatg	aagatctatt	aagtgaacgc	gtcccccctcc	30960
ggtggcgtgg	tcaaaactcta	cagccaaaga	acagataatg	gcatttgtaa	gatgttgcac	31020
aatggcttcc	aaaaggcaaa	cgcccttcac	gttcaagtgg	acgttaaggc	taaacccttc	31080
agggtgaatc	tcctctataa	acattccagc	accttcaacc	atgcccataat	aattctcatc	31140
tcgcccaccc	ctcaatataat	ctctaagcaa	atccccgata	ttaagtccgg	ccattgtaaa	31200
aatctgtcc	agagccccct	ccaccttcag	cctcaagcag	cgaatcatga	ttgaaaaaaaaat	31260
tcaggttcc	cacagacctg	tataagattc	aaaagcgaa	cattaacaaa	aataccgcga	31320
tcccgttagt	cccttcgcag	ggccagctga	acataatcgt	gcaggtctgc	acggaccacgc	31380
ggggccactt	ccccggccagg	aaccttgaca	aaagaacccca	cactgattt	gacacgcata	31440
ctcgagact	tgcttacccag	cgtggccccc	atgttaagctt	tggtgatgg	gccccgtat	31500
aaaatgcaag	gtgctgtca	aaaaatcagg	caaaggctcg	cgcaaaaaaaaag	aaagcacatc	31560
gtagtcatgc	tcatcgat	aaaggcagg	aagctccgg	accaccacag	aaaaagacac	31620
cattttctc	tcaaaacatgt	ctgcgggttt	ctgcataaaac	acaaaataaa	ataacaaaaaa	31680
aacatttaaa	cattagaagc	ctgtcttaca	acaggaaaaaa	caacccttat	aagcataaga	31740
cggactacgg	ccatggccgc	gtgaccgtaa	aaaaactggt	caccgtgatt	aaaaagcacc	31800
accgacagct	cctcggtcat	gtccggagtc	ataatgtaa	actcgtaaaa	cacatcaggt	31860
tgattcatcg	gtcagtgtca	aaaagcgacc	gaaatagccc	ggggaaatac	ataccgcag	31920
gcgttagagac	aacattacag	cccccatagg	aggtataaca	aaattaatag	gagagaaaaaa	31980
cacataaaaca	cctggaaaaac	cctccctgcct	aggccaaaata	gcaccctccc	gtcccagaac	32040
aacatacagc	gcttcacacgc	ggcagccaa	cagtccgcct	taccagtaaa	aaagaaaaacc	32100
tataaaaaaa	acaccactcg	acacggcacc	agtcataatca	gtcacagtgt	aaaaaaaggc	32160
caagtgcaga	gctggatata	ataggactaa	aaaatgacgt	aacggttaaa	gtccacaaaa	32220
aacacccaga	aaacccgcacg	cgaacctacg	cccagaaacgc	aaagccaaaa	aacccacaac	32280
ttcctcaaat	cgtaacttcc	gtttccac	gttacgttaac	ttcccatttt	aagaaaacta	32340
caattcccaa	cacatacaag	ttactccgcc	ctaaaaccta	cgtcaccgc	cccgttccca	32400
cgcggccgc	cacgtcaca	actccacccc	ctcattatca	tattggcttc	aatccaaaat	32460
aaggtatatt	attgatgtat					32480

<210> 24
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 24
ctcaacaatt gtggatccgt actcc 25

<210> 25
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 25
gtgctcagca gatcttgcga ctgtg 25

<210> 26
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 26
ggcgcgttcg gatccactct cttcc 25

<210> 27
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 27
ctacatgcta ggcagatctc gttcggag 28

<210> 28
<211> 1240
<212> DNA
<213> adenovirus

<400> 28
ggatccactc tcttccgcat cgctgtctgc gagggccagc tgggggggtg agtactccct 60
ctgaaaagcg ggcatgactt ctgcgctaag attgtcagtt tccaaaaacg aggaggattt 120
gatattcacc tggcccgcgg tgatgcctt gaggggtggcc gcatccatct ggtcagaaaa 180
gacaatctt ttgttgtcaa gcttgggtgc aaacgaccccg tagagggcgt tggacagcaa 240
cttggcgatg gagcgcaggg tttggttttt gtccgcatecg ggcgcctt tggccgcgt 300
gtttagctgc acgtattcgc ggcgaacgca ccgcattcg gaaagacgg tggtgcgctc 360
gtcgggcacc aggtgcacgc gccaaccgcg gttgtgcagg gtgacaaggt caacgctgt 420
ggctacctct ccgcgttaggc gctcggttgt ccagcagagg cggccgcct tgcgcgagca 480
gaatggcggtt agggggctta gctgcgtctc gtcggggggg tctgcgtcca cggtaaagac 540
cccgccgcgcg caggcgcgt cgaagtagtc tatcttgcatt cttgcagaat ttagcgcctg 600

ctgccatgcg cgggcggcaa ggcgcgcgtc gtatgggtt agtggggac cccatggcat 660
 ggggtgggtg agcgcggagg cgtacatgcc gcaaattgtcg taaaacgtaga ggggctctct 720
 gagtattcca agatatgtag ggttagcatct tccaccgcgg atgctggcgc gcacgtaaatc 780
 gtatagttcg tgcgagggag cgaggaggtc gggaccgagg ttgctacggg cgggctgctc 840
 tgctcgaaag actatctgcc tgaagatgge atgtgagttt gatgatatgg ttggacgctg 900
 gaagacgttg aagctggcg tctgtgagacc taccgcgtca cgcacgaagg aggcttagga 960
 gtcgcgcagc ttgttgcacca gctcggcggt gacctgcacg tctagggcgc agtagtccag 1020
 ggtttccctt atgatgtcat acttatcctg tccctttttt ttccacagct cgcgggtttag 1080
 gacaaactct tcgcggctt tccagtaactc ttggatcgga aaccgcgtgg cctccgaacg 1140
 agatccgtac tccggccggc agggacctga gcgagtcgc atcgaccgga tcggaaaaacc 1200
 tctcgagaaa ggcgtctaact cagtcacagt cgcaagatct 1240

<210> 29
 <211> 8383
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid pDV60

<400> 29
 gacggatcg gagatctccc gatccccat ggtcgactct cagtacaatc tgctctgtat 60
 ccgcataatggtt aagccatgtt ctgtccctg ctgtgtgtt ggaggtcgct gagtagtgcg 120
 cgagcaaaat ttaagctaca acaaggcaag gctgaccga caattgcatt aagaatctgc 180
 ttagggtttag gctgtttcg tctgttcgtc atgtacgggc cagatatacg cgttgcatt 240
 gattatttgcac tagttattaa tagtaatcaa ttacgggtt attagttcat agccatata 300
 tggagttccg cgttacataa ttacggtaa atggccgcgc tggctgaccg cccaaacgacc 360
 cccgcccatt gacgtcaata atgacgtatg ttcccatatg aacgcataa gggactttcc 420
 attgacgtca atgggtggac tatttacgtt aaactgccc cttggcagta catcaagtgt 480
 atcatatgcc aagtacgccc cctattgtac tcaatgacgg taaatggccc gcctggcatt 540
 atgcccagta catgacccat tgggactttc ctacttggca gtacatctac gtattatgtca 600
 tcgcttattac catgttgc tgggtttggc agtacatcaa tgggctgttga tagcggtttg 660
 actcacgggg atttcaagt ctccacccca ttgacgtcaa tgggagttt ttttggcacc 720
 aaaatcaacg ggactttcca aatgtcgta acaactccgc cccattgtacg caaatggccg 780
 gttaggcgtgt acgggtggag gtctatataa gcaagactct ctggcttaact agagaaccga 840
 ctgcttactg gcttacatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900
 gagctcgat ccactctctt ccgcacatcgct gtgtcgagg gccagctgtt ggggtgagta 960
 ctcccctctga aaagcgggca tgacttctgc gctaagattt tcagtttcca aaaacgagga 1020
 ggattttgata ttccaccttgcg ccgcgggtat gcctttgggg gtggccgcatt ccatctggtc 1080
 agaaaagacg atctttttgt tgcataagttt ggtggcaaac gacccgttga gggcgttgg 1140
 cagcaacttgc ggcgttggagc gcagggtttt gtttttgtcg cgttgcgcgc gtccttgc 1200
 cgcgtatgtt agctgcacgt attcgcgcgc aacgcaccgc catttggaa agacgggtgt 1260
 ggcgcgtcg ggcaccaggc gcacgcgcgc accgcgggttgc tgcagggttgc caaggtcaac 1320
 gctgggtggct acctctccgc gttaggcgtc gttttgtccag cagaggcggc cgccttgc 1380
 cgagcagaat ggcgttaggg ggtctagctg cgttgcgtcc ggggggtctg cgtccacgg 1440
 aaagaccccg ggcagcaggc gcgcgtcgaa gtagtctatc ttgcatttcctt gcaagtctag 1500
 cgcctgtgc catgcgcggg cggcaagcgc gcgcgtcgat ggggttggatg gggggacccca 1560
 tggcatgggg tgggtggatcg cggaggcgta catgcgcgaa atgtcgtaaa cgtagagggg 1620
 ctctctgtat attccaaatgtt atgttagggta gcatcttcca cgcggatgc tggcgcgcac 1680
 gtaatctgtat agttcgatcg gaggagggc gaggatcgatc cggagggttgc tacggggcggg 1740
 ctgcctctgtc cgaaagacta tctgcctgaa gatggcatgt gagttggatg atatggttgg 1800
 acgctggaaag acgttgaagc tggcgtctgt gagaacctacc gcgtcacgcga cgaaggaggc 1860
 gttaggagtcg cgcagcttgc tgaccagtc ggcgggtacc tgcacgtcta gggcgcagta 1920
 gtccagggtt tccttgcataatc ttctgtccc tttttttcc acagctcg 1980
 gttgaggaca aactcttcgc ggttttcca gtactcttgg atcggaaacc cgtcggcctc 2040
 cgaacggat ccgtactccg cgcggaggc acctgagcga gtccgcacatc accggatcgg 2100
 aaaaccccttc gagaaggcgc tctaaccatgtt cacaatcgca agatccaaga tgaagcgcgc 2160
 aagaccgttgc gaaatgtatct tcaacccctgt gtatccatat gacacggaaa cccgttctcc 2220
 aactgtgcct tttcttactc tccctttgtt atcccccaat ggggttcaag agagtc 2280
 tgggttactc tctttgcgc tataccgttacc tctatgttacc tccaatggca tgcgttgc 2340
 caaaaatgggc aacggcctct ctctggacga ggcggcaac ttacccccc aaaaatgtaaac 2400
 cactgtgagc ccacccctca aaaaaaccaa gtcacaaatc aacctggaaa tatctgcacc 2460

cctcacagtt acctcagaag ccctaactgt ggctgccgcc gcacctctaa tggtcgcggg 2520
 caaacacactc accatcgaaat cacaggcccc gctaaccgtg caccgactcca aacttagcat 2580
 tgccaccccaa ggaccctca cagtgtcaga agggaaagcta gcccctgcaaa catcaggccc 2640
 cctcaccacc accgatagca gtacccttac tattactgcc tcacccctc taactactgc 2700
 cactggtagc ttggcattt acttgaaga gcccatttat acacaataatg gaaaactagg 2760
 actaaagtac ggggctcatt tgcatgtAAC agacgaccta aacacttta ccgtagcaac 2820
 tggtccagggt gtgactatta ataataactt cttgcaaaact aaagttactg gagccttggg 2880
 ttttgattca caaggcaata tgcaacttaa tgttagcagga ggactaagga ttgattctca 2940
 aaacagacgc cttatactt atgttagttt tccgtttgtat gctcaaaacc aactaaatct 3000
 aagacttagga cagggccctc tttttataaa ctcagcccad aacttggata ttaactacaa 3060
 caaaggccctt tacttgttta cagcttcaaa caattccaaa aagcttgagg ttaacctaag 3120
 cactgccaag ggggtatgt ttgacgtac aecatgcc attaatgcag gagatgggct 3180
 tgaatttgggt tcaccaatg caccaaacac aaatcccctc aaaacaaaaaa ttggccatgg 3240
 cctagaattt gattcaaaaca caggctatggt tcctaaacta ggaactggcc ttagtttga 3300
 cagcacaggt gccattacag taggaaacaa aaataatgtat aagctaactt tggaccac 3360
 accagctcca tctcttaact gtagactaaa tgcaagagaaa gatgctaaac tcactttgtt 3420
 cttAACAAAAGA tggcagtc aaataacttgc tacagttca gtttggctg ttaaaggcag 3480
 tttggctcca atatctggaa cagttcaaaag tgctcatctt attataagat ttgacgaaaa 3540
 tggagtgtcta cttaaacaatt ccttccttgc cccagaatat tggacttta gaaatggaga 3600
 tcttaactgaa ggcacagccctt atacaacgc tggggatattt atgcctaacc tatcagctta 3660
 tcccaaaatctt caccgtaaaa ctgccaaggaa taacattgtc agtcaagttt acttaaaccgg 3720
 agacaaaaactt aaacctgtaa cactaaccat tacactaaac ggtacacagg aaacaggaga 3780
 cacaactcca agtgcatact taatgaaata tttgccacat cttcttacac ttttcatac attgccccaa aataaaagaa 3900
 gcccgcgtc gagcatgtat ctcgctgatc agcctcgact cctgtgccttc ttgaccctg aaattgcattc gcattgtctg 3960
 acagcaaggg ggaggattgg tggctctgtc ggcgaaaga goggcgcatt aagcgcggcg ggcgccttagc ggcgccttc 4020
 ttccccgtca agctctaaat acctcgacc caaaaaaaaactt agacgggttt tcgcctttt aaattgcattc gcattgtctg 4080
 aacactcaac aaactggaac gggatccatc ctttagggtt ccggggcatcc ctttagggtt 4140
 gggacaataa gcaaggcatgc tggggatgcg tggggctcta 4200
 accagctggg gctctagggg ggtgtgggg ttacgcgcag cgtgaccgcg acacttgcac 4260
 ttgccttttcccttccgcacg ttcgcacg 4320
 cggggcatcc ctttagggtt ccgatttagt gctttacgac 4380
 gatttaggtt atggttcacg tagtggccca tcgcctgtat 4440
 acgttggagt ccacgttctt taatagtggaa ctcttgttcc 4500
 cctatctcgg tctattctt tgatttataa gggattttgg 4560
 aaaaatgagc tgatttaaca aaaatttaac gcaattaaat 4620
 ttgtgtgaat gtgtgtcagt gatgtccatc aattagtccatc 4680
 gtatgccaaag catgcatttc caccagggtg tggaaagtcc 4740
 cgcaggcgcg aagtgtcaa atactccgc tcaatttagtc 4800
 taactccgc catcccccc gactaatttttttccgcacg 4860
 gcaaggccctc agggccctc tcaattccgc cttatccgc 4920
 gcaaggccctc agggccctc tgcctctgag ctattccaga 4980
 ggaggccctag gctttgc当地 aaagctcccg ggagcttgc 5040
 caagagacag gatgaggato gtttcgc当地 attgaacaag 5100
 cccggccctt gggggagag gctattccgc tatgactggg 5160
 cacaacagac aatcggtgc tctgtatggcc ccgtgtccg 5220
 cggttctttt tggcaagacc gacctgtccg gtgcctgaa tgaactgc当地 5280
 cgcggctatc gtggctggcc acgacggggg ttccttgc当地 agctgtctc 5340
 ctgaagcggg aaggactgg ctgtatgg gcaagggtcc 5400
 ctcaaccttgc tccctccggc aaatgtatcc tcatggctg 5460
 cggttgcattcc ggactacgtcc ctgtgc当地 accaaggc当地 acatcgcatc 5520
 gtactcgatc ggaagccggt ctgtgc当地 aggtatctt ggacgaaagag catcaggccc 5580
 tccgc当地 cgaactgttc gccaggctca aggccgc当地 gccc当地 gagatctcg 5640
 tctgtgacccca tggcgatgcc tgcttgc当地 atatcatgg 5700
 gattcatcga ctgtggccgg ctgggtgtgg cggaccgctt 5760
 cccgtgatata tggcaagag ctggc当地 aatgggtca cccgttccctc 5820
 gtatgc当地 tcccgattcg cagcgcatc cttctatcg cttcttgc当地 gagttcttct 5880
 gagcgggact ctggggatcg aaatgaccga ccaaggc当地 cccaaacttgc 5940
 ttgc当地 accggccgct tctatgaaag gttgggttcc ggaatcg 5960
 cggctggatc atccctccaggc gccc当地 gatcttccgc当地 tccgggacgc 6000
 gtttatttgc gcttataatg gttacaataa aagcaatagc atcacaattt ccacaaaattt 6060
 agcattttttt tcactgcatt ctatgtggg tttgtccaaa 6120
 agcattttttt tcactgcatt ctatgtggg tttgtccaaa 6180

tgtctgtata	ccgtcgacct	ctagctagag	cttggcgtaa	tcatggtcat	agctgtttcc	6240
tgtgtaaaat	tgttatccgc	tcacaattcc	acacaacata	cgagccggaa	gcataaagtg	6300
taaaggctgg	ggtgccataat	gagttagacta	actcacatta	attgcgttgc	gctcaactgcc	6360
cgcttccag	tcgggaaacc	tgtcggtcc	gctgcattaa	tgaatcggcc	aacgcgcggg	6420
gagaggcggg	ttgcgttattg	ggcgcttcc	cgcgttctcg	ctcaactgact	cgctgcgcgtc	6480
ggtcgttcgg	ctgcggcgag	cggtatacgc	tcaactaaag	gcccgttatac	gttataccac	6540
agaatcaggg	gataacgcag	gaaagaacat	gtgagaaaaa	ggccagcaaa	aggccaggaa	6600
ccgtaaaaag	gccgcgttgc	tggcgtttt	ccataggctc	cgccccctg	acgagcatca	6660
caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	6720
gttccccct	ggaagctccc	tcgtgcgtc	tcctgttccg	accctgcgc	ttaccggata	6780
cctgtccgcc	tttctccctt	cgggaagcgt	ggcgcttct	caatgctcac	gctgttaggt	6840
tctcagttcg	gtgttaggtcg	ttcgctccaa	gctgggctgt	gtgcacgaac	cccccggtca	6900
gcccgaccgc	tgccgccttat	ccggtaaacta	tgcgtttag	tccaacccgg	taagacacga	6960
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcggagt	atgttaggccc	7020
tgcttacagag	ttcttgcgt	ggtggctcaa	ctacggctac	actagaagga	cagtatttgg	7080
tatctcgct	ctgcgttgc	cagttacett	cggaaaaaaa	gttggtagct	tttgatccgg	7140
caaacaacc	accgttgcgt	gcgggtgttt	ttttgttgc	aagcagcaga	ttacgcgcag	7200
aaaaaaaggaa	tctcaagaag	atcccttgc	ctttcttgc	gggtctgacg	ctcagtggaa	7260
cgaaaaactca	cgtttaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	7320
ccttttaaat	taaaaaatgaa	gttttaatc	aatctaaagt	atatatgagt	aaacttggtc	7380
tgacagttac	caatgtttaa	tcagtggggc	acctatctca	gcatctgtc	tatccgttca	7440
atccatagtt	gccttactcc	ccgtcggtgt	gataactacg	atacgggagg	gcttaccatc	7500
tggccccagt	gctgtatgt	taccgcgaga	cccacgctca	ccggcccccag	atttatcagc	7560
aataaaccag	ccagccggaa	ggggccgagcg	cagaagtgg	cctgcaactt	tatccgcctc	7620
catccagtct	attatgtt	gcccggaaagc	tagataagt	agttcgccag	ttaatagtt	7680
gcfgaacatgt	gttggcattt	ctacaggcat	cgtgggtgt	cgctcgctgt	ttggatgtgc	7740
ttcattcagc	tccgttccc	aacgatcaag	gcgagttaca	tgatccccca	ttttgtgcaa	7800
aaaagcggtt	agcttccctcg	gtcctccgat	cgttgtcaga	agtaagttgg	ccgcagtgtt	7860
atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccc	ccgtaaagatg	7920
ctttctgtg	actgtgtgat	actcaaccaa	gtcattctga	aatagtgt	tgcggcgacc	7980
gagttgtct	tgcccgccgt	caatacggga	taataccgcg	ccacatagca	gaactttaaa	8040
agtgttcatc	attggaaaac	gttcttccgg	gcaaaaactc	tcaaggatct	taccgctgtt	8100
gagatccagt	tcgtatgtac	ccactcggtc	acccaactga	tcttcagcat	cttttacttt	8160
caccaggcgtt	tctgggttag	caaaaaacagg	aaggcaaaa	gcccggaaaaaa	aggaaataag	8220
ggcgacacgg	aaatgttga	tactcatact	cttcctttt	caatattatt	gaagcattta	8280
tcagggttat	tgtctcatga	gcccatacat	atttgaatgt	atttagaaaa	ataaacaaat	8340
aggggttccg	cgcacatttc	cccggaaaat	gccacactgac	gtc		8383

<210> 30
<211> 7960
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid pDV67

<400> 30
gacggatcg ggatctccc gatccccat ggtcgactct cagtacaatc tgctctgtatg 60
ccgcataatgg aagccgtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgcggca caattgcatt aagaatctgc 180
ttagggttag gctgtttcg gctgttcccg atgtacgggc cagatatacg cggtgacatt 240
gattattgtac tagttatcaa tagtaatcaa ttacggggtc attagttcat agccccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc 360
cccgccattt gacgttacataa atgacgtatg ttcccatatg aacgcacataa gggactttcc 420
attgacgtca atgggtggac tatttacgtt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cttattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctt a tggactttc ctacttggca gtacatctac gtattatgtca 600
tcgctattac catgtgtatg cgggtttggc agtacatcaa tggcgttgg tagcggtttg 660
actcacgggg atttcaagt ctccacccca ttgacgtcaa tggagtttg tttggcacc 720
aaaatcaacg ggactttcca aaatgtgtt acaactccgc cccattgacg caaatggccg 780
gtaggcgtgt acgggtggag gtctatataa gcaagacttct ctggcttaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagacccaa gctggcttagc 900

gtttaaactt aagcttggta ccgagctcg atccactctc ttccgcacatcg ctgtctgcga 960
 gggccagctg ttgggtgag tactccctct gaaaagcggg catgacttct gcgcctaagat 1020
 tgtcagttc caaaaacgag gaggatttg tattcacctg gcccgcggtg atgccttga 1080
 gggtgtggccgc atccatctgg tcagaaaaga caatctttt gttgtcaagc ttgggtggcaa 1140
 acgaccgtgta gaggggcgtt gacagcaact tggcgatggg ggcgcagggtt tggtttttgt 1200
 cgcgcattcgcc ggcgcattcgcc gccgcgtatgt ttagctgcac gtattcgcgc gcaacgcacc 1260
 gccattcgcc aaagacgggt gtgcgcctgt cgggcacccag gtgcacgcgc caaccgcgg 1320
 tgtcagggtt gacaagggtca acgctgggtt ctacctctcc gcgtaggcgc tcgttggtcc 1380
 agcagaggcg gccgccttgc cgcgagcaga atggcggtag ggggtctagc tgcgtctcg 1440
 cgggggggtc tgcgtccacg gtaaaagaccc cgggcacccag ggcgcgcgtcg aagttagtcta 1500
 tcttcgcattcc ttgcaagtct agcgcctgtc gccatgcgc ggcggcaagc gcgcgcgtcg 1560
 atgggtttagt tgggggaccc catggcatgg ggtgggttagt cgcggaggcg tacatgcgc 1620
 aaatgtcgta aacgttagagg ggctctctga gtattccaag atatgttaggg tagcatcttc 1680
 caccgcggat gctggcgcgc acgtaatcgat atagttcggt cgaggaggcg aggagggtcg 1740
 gaccgggtt gctacggggcg ggctgcgtcg ctcggaaagac tatctgcgtc aagatggcat 1800
 gtgagttgga tgatatggt ggacgcttggaa agacggtt gctggcgctc tgagaccta 1860
 cccgcgtacg cacgaaggag cctgcacgtc tagggcgcag cgttagggat cgcgcgtt gttgaccaggc tcggcggtga 1920
 cctttttttt ccacagctcg ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 1980
 gagtccgcat cgaccggatc ggaaaacctc tccgaacccg atccgtactc cgggtctttc cagactctt 2040
 caagatccaa gatgaagcgc gcaagaccgt ctgaagatac cttcaaccccc gtgttatccat 2220
 atgacacggta aaccggctt atgggttca agagagtccc cctccaatgg catgcttgcg accttaccc tccaaatgtat taacactggta aatatctgca 2280
 ccgcacccct aatggtcgcg tgacgactc caaacttagc tagccctgca aacatcaggc cctcaccccc tctaactact 2340
 atgggttca agagagtccc cctccaatgg catgcttgcg accttaccc tccaaatgtat taacactggta aatatctgca 2400
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2460
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2520
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2580
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2640
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2700
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2760
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2820
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2880
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 2940
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3000
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3060
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3120
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3180
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3240
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3300
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3360
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3420
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3480
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3540
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3600
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3660
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3720
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3780
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3840
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3900
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 3960
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4020
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4080
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4140
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4200
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4260
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4320
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4380
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4440
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4500
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4560
 ggatcgaaaa cccgtcgcc ggtttttttt ccacactgtc cttccctgtat gatgtcatac ttatcctgtc 4620

cgccctattt	gttaaaaaat	gagctgattt	aacaaaaatt	taacgcgaat	taattctgtg	4680
aatgtgtgt	cagttagggt	gtggaaagt	cccaggctcc	ccaggcaggc	agaagtatgc	4740
aaagcatgca	tctcaattag	tcagcaacca	ggtgtggaaa	gtccccaggc	tcggcagcag	4800
gcagaagtt	gcaaagcatg	catctcaatt	agttagcaca	catagccccg	ccccctaactc	4860
cggccatccc	gcccataact	ccgcccagg	ccggccattc	tccggcccat	ggctgactaa	4920
ttttttttat	ttatgcagag	gccgaggccg	cctctgcctc	tgagctattc	cagaagtagt	4980
gaggaggc	ttttggaggc	ctaggcttt	gaaaaaagct	cccgggagct	tgtatatcca	5040
tttccggatc	tgatcagcac	gtgttgacaa	ttaatcatcg	gcatagtata	tcggcatagt	5100
ataatacgcac	aaggtgagga	actaaaccat	ggccaagttg	accagtgcgg	ttccgggtgct	5160
cacccgcgcg	gacgtcgccg	gagcggtcga	gttctggacc	gaccggctcg	gttctcccg	5220
ggacttcgt	gaggacgact	tcgcccgggt	ggtccgggac	gacgtgaccc	tgttcatcag	5280
cgcgggtccag	gaccagggtgg	tgccggacaa	caccctggcc	tgggtgtggg	tgccgggct	5340
ggacgagct	tacccggatgt	ggtcggaggt	cgttccacg	aacttccggg	acgcctccgg	5400
gccccggcat	accggatcg	gcgagcagcc	tgggggccgg	gagttccccc	tgccgcaccc	5460
ggccggcaac	tgcgctgact	tcgtggccga	ggagcaggac	tgacacgtgc	tacgagattt	5520
cgattccacc	gcccgcctct	atgaaagg	gggcttcgga	atcgtttcc	gggacgcccgg	5580
ctggatgatc	ctccagcgcg	gggatctcat	gctggagttc	ttcgcccacc	ccaacttgtt	5640
tattgcagct	tataatggtt	acaataaaag	caatagcatc	acaatttca	caaataaaagc	5700
attttttca	ctgcattcta	gttggg	gtccaaactc	atcaatgtat	tttatcatgt	5760
ctgtataccg	tcgacctcta	gctagagctt	ggcgtaatca	tggtcatagc	tgtttcctgt	5820
gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaaagca	taaagtgtaa	5880
aggctgggtt	gcctaattag	tgagctact	cacattaatt	gcgttgcgt	cactgcccgc	5940
tttccagtcg	ggaaaacctg	cgtccagct	gcattaaatga	atcgcccaac	gcccggggag	6000
aggcggtttt	cgtattgggc	gctttccgc	ttcctcgctc	actgactcgc	tgccgtcggt	6060
cgttcggct	cggcgagcgg	tatcagctca	cttcaaaggcg	gtaatacgg	tatccacaga	6120
atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaaggc	cagcaaaaagg	ccaggaacccg	6180
taaaaaggcc	gcgttgctgg	cgttttcca	taggctccgc	ccccctgacg	agcatcaca	6240
aaatcgacgc	tcaagtca	ggggcggaaa	cccgacagga	ctataaaagat	accaggcg	6300
tccccctgga	agctccctcg	tgcgctctc	tgttccgacc	ctgcccctta	ccggataact	6360
gtccgcctt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcagcgt	gtaggatatc	6420
cagttcggt	taggtcggtc	gctccaagct	gggtctgtg	cacgaacccc	cggttcagcc	6480
cgcacccgtc	gccttatacg	gtaactatcg	tcttgcgtt	aacccggtaa	gacacgactt	6540
atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggatag	taggcgg	6600
ta	ca	ttacactt	ggcctaacta	cggtacact	agaaggacag	6660
ctgcgtctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctt	gatccggcaa	6720
acaaaaccacc	gctggtagcg	gtggttttt	tgttgcag	cagcagatta	cgccagaaa	6780
aaaaggatct	caagaagatc	cttgatctt	ttctacgggg	tctgacgctc	agtggAACGA	6840
aaactcacgt	taagggattt	tggtcatag	attatcaaaa	aggatctca	cctagatcct	6900
tttaaattaa	aatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	cttggtctga	6960
cagtaccaa	tgcttaatca	gtgaggcacc	tatctcagcg	atctgtctat	ttcggtcatc	7020
catagttgcc	tgactccccg	tcgtgtat	aactacgata	cgggggggt	taccatctgg	7080
ccccaggctgt	gcaatgatac	cgcgagaccc	acgctaccg	gtccaggat	tatcagcaat	7140
aaaccagcca	gccggaaagg	ccgagcgcag	aagtggct	gcaacttt	ccgcctccat	7200
coagtctatt	aattttgtcc	gggaagctag	agtaagtagt	tcgcccgtt	atagttgcg	7260
caacgttgtt	gccattgtca	caggcatgt	gggtgtcacgc	tcgtcggtt	gtatggctc	7320
attcagctcc	ggttcccaac	gatcaaggcg	agttacatga	tcccccattgt	tgtgcaaaaa	7380
agcggttagc	tccttcggc	ctccgatcg	tgtcagaagt	aagttggccg	cagtgttac	7440
actcatgggt	atggcagcac	tgcataattc	tcttactgtc	atgcacatccg	taagatgtt	7500
ttctgtgtact	ggtgagttact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	7560
ttgctcttgc	ccggcgtcaa	tacgggataa	tacccgcgcca	catagcagaa	ctttaaaagt	7620
gctcatcatt	ggaaaaacgtt	cttcggggcg	aaaactctca	aggatcttac	cgctgttgag	7680
atccaggctcg	atgtaaacca	ctcggtcacc	caactgtatc	ttagcatctt	ttactttcac	7740
cagcgttct	gggtgagca	aaacaggaag	gcaaaatgcc	gcaaaaaagg	gaataaggc	7800
gacacggaaa	tgttgaatac	tcatactt	ccttttcaa	tattattgaa	gcatttatca	7860
gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	7920
ggttccgcgc	acatttcccc	gaaaagtgc	acctgacgtc			7960

<210> 31

<211> 30

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 31
atgggatcca agatgaagcg cgcaagaccg 30

<210> 32
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 32
cactatacg gccgcattct cagtcatctt 30

<210> 33
<211> 7989
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid pDV69

<400> 33
gacggatcg ggatctccc gatcccatt ggtcgactct cagtacaatc tgctctgatg 60
ccgcatacgat tt aaggcaggat ctgctccctg ctttgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatt aagaatctgc 180
tttagggtttag gctgtttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttc agcccatata 300
tggagttcgc cgttacataa ctatcgtaa atggcccgcc tggctgaccg cccaaacgacc 360
cccgccccatt gacgtcaata atgacgtatg ttcccatagt aacgccaaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccaggta catgaccta tgggacttcc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cgggtttggc agtacatcaa tgggctgttga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttgc ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg 780
gtaggcgtgt acgggtggag gtctatataa gcaagactct ctggctacta agagaaccca 840
ctgcttactg gcttatcgaa attaatacgat ctcactatag ggagacccaa gctggcttagc 900
gtttaaactt aagcttggta ccgagctcgg atccactctc ttccgcatacg ctgtctgcga 960
ggccagctg ttggggtgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020
tgcagtttcc caaaaacgag gaggattga tattcacctg gcccgggtg atgcctttga 1080
gggtggccgc atccatctgg tcagaaaaaga caatctttt gttgtcaagc ttggtgccaa 1140
acgaccgcgta gaggcggtt gacagcaact tggcgatggc ggcgcagggtt tggttttgt 1200
cgcgatcgcc gcgctccctt gccgcgtatgt ttagctgcac gtattgcgc gcaacgcacc 1260
gccattcgccg aaagacggcg gtgcgctcg cgggcaccag gtgcacgcgc caaccgcgt 1320
tgtgcagggt gacaaggctca acgctgggtt ctacctctcc gctgttggcgc tcgttggtcc 1380
agcagaggcg gccgccttgc cgcgagcaga atggcggtttag ggggtcttagc tgcgtctcg 1440
ccggggggtc tgcgtccacg gtaaagaccc cgggcaggcg ggcgcgtcg aagtatctc 1500
tcttgcatcc tggcaagtct agcgcctgtt gcoatgcgc ggcggcaagc ggcgcgtcg 1560
atgggtttagt tgggggaccc catggcatgg ggtgggttag cgcggaggcg tacatgccgc 1620
aaatgtcgta aacgttagagg ggctctctga gtattccaag atatgttaggg tagcatctc 1680
caccgcggat gctggcgccg acgtaatcgat atagttcgat cgagggaggcg aggaggctgg 1740
gaccgagggtt gctacggcg ggctgcctcg ctccggaaagac tatctgcctg agatggcat 1800
gtgagttgga tgatatggtt ggacgcttggaa agacgtttaga gctggcgctt gtgagaccta 1860
ccgcgtcacc cacgaaggag gcgttaggat cgccgcagctt gttgaccagc tcggcggtga 1920
cctgcacgtc tagggcgccag tagtccagggtt tttccctgtat gatgtcatac ttatccgtc 1980
ccctttttt ccacagctcg cgggttggaa caaactcttc gcggtctttc cagactctt 2040
ggatcgaaa cccgtcgcc tccgaacgg atccgtactc cgccgcggag ggacctgagc 2100
gagtcccgat cgaccggatc ggaaaacctc tcgagaaaagg cgtctaaccac gtcacagtcg 2160

caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggctt	ccaactgtgc	cttttcttac	tcctccctt	gtatccccca	2280
atgggttca	agagagtccc	cctggggta	tctctttcg	cctatccgaa	cctctagtt	2340
cctccaatgg	catgcttgcg	ctcaaaaatgg	gcaacggct	ctctctggac	gaggccggca	2400
accttacctc	ccaaaatgt	accactgtga	gccccacotct	aaaaaaaaacc	aagtcaaaca	2460
taaacctgga	aatatctgca	cccctcacag	ttacctca	agccctaact	gtggctgccc	2520
ccgcacctct	atgggtcg	ggcaacacac	tcacatgc	atcacaggc	ccgctaaacc	2580
tgcacgactc	caaacttagc	attggcacc	aaggaccct	cacagtgc	gaagggaaagc	2640
tagccgtca	aacatcaggc	cccctcacca	ccacccgatag	cagtaccctt	actatactg	2700
cctcacc	tcttaactact	gccactggta	gcttgggcat	tgacttggaa	gagccattt	2760
atacaca	tgaaaaacta	ggactaaagt	acggggctcc	tttgcattgt	acagacgacc	2820
taaacactt	gaccgttagca	actggtccag	gtgtgactat	taataataact	tccttgcaaa	2880
ctaaaggta	tggagcc	gttttggatt	cacaaggcaa	tatgcaactt	aatgttagcag	2940
gaggactaag	gattgattct	aaaaacagac	gccttataact	tgatgttagt	tatccgttt	3000
atgctca	ccaaactaaat	ctaagactag	gacagggccc	tctttttata	aactcagccc	3060
acaacttgg	tattaactac	aacaaaggcc	tttacttgtt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaac	agcactgcca	aggggttgc	gttgcacgct	acagccatag	3180
ccattaaatgc	aggagatggg	cttgaatttgc	gttacccat	tgccacaaac	aaaaatcccc	3240
tcaaaaacaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttccattaaac	3300
taggacttgg	ccttagttt	gacagcacag	gtgcattac	agtaggaaac	aaaaataatg	3360
ataagcta	tttgcggacc	ggtccaaac	cagaagccaa	ctgcataatt	gaatacggga	3420
aacaaaaccc	agatagcaaa	ctaactttaa	tccttgc	aatggagga	attgttaatg	3480
gatatgtaa	gctaattggg	gcctcagact	acgttaacac	cttattttaa	aacaaaatg	3540
tctccattaa	tgttagacta	tactttgt	ccactggtca	tatattacca	gactcatctt	3600
ctctttaaaac	agatctagaa	ctaaaataca	agcaaaaccgc	tgacttttagt	gcaagagggt	3660
ttatgccaag	tactacagcg	tatccatttgc	tccttcc	tgccggaaaca	cataatgaaa	3720
attatattt	tgttcaatgc	tactacaaag	caagcgatgg	tgcctttttt	ccgttggaaag	3780
ttactttat	gottaataaa	cgcctggcag	atagtcgcac	atctatgtt	atgactttt	3840
tatggtcc	gaatgtcggt	ctagtc	aaactactca	ggcaaccctc	ataacccccc	3900
catttac	tttcttattt	agagaagatg	actgatttt	aagaagcggc	cgctcgagtc	3960
tagggccc	gtttaaacc	gctgatcagc	ctcgactgt	ccttctagtt	gccaggccatc	4020
tgttgg	ccctcccc	tgcccttctt	gaccctggaa	ggtgcactc	ccactgtct	4080
tcccttaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	4140
gggtgggtg	gggcaggaca	gcaaggggg	ggattgggaa	gacaatagca	ggcatgctgg	4200
ggatgcgtg	ggctctatgg	cttctgaggc	ggaaagaacc	sncntagct	ggggctctag	4260
ggggatcc	cacgcgc	gtagcggcgc	attaagcg	gggggtgtgg	tgttacgcg	4320
cagcgtgacc	gotacactt	ccagcgc	agcgc	ccttcgc	tcttccttc	4380
ctttctcgcc	agttcgc	gtttcccc	tcaactct	aatcggggca	tccctttag	4440
gttccgattt	agtgcttac	ggcacctcg	ccccaaaaaa	cttgatttag	gtatgtt	4500
acgtatgtgg	coatcgcc	gatagacgg	tttgc	ttgacgtt	agtccacgtt	4560
ctttaatagt	ggactctt	tccaaacttgg	aacaacactc	aaccctatct	cggtctattc	4620
ttttgattt	taagggattt	tgggattt	ggcctatttgg	ttaaaaaatg	agctgattt	4680
acaaaaattt	aacgcgaatt	aattctgtgg	aatgtgtt	agttagggt	tggaaagtcc	4740
ccaggctccc	caggcaggca	gaagtatgca	aagcatgcat	ctcaatttagt	cagcaaccag	4800
gtgtggaaag	tcccaggct	ccccagcagg	cagaagtatg	caaagcatgc	atctcaatta	4860
gtcagcaacc	atagtcccg	cccttaactcc	gccccatccc	cccttaactc	cgcccaagt	4920
cgcccat	ccggccat	gctgactat	tttttttatt	tatgcagag	ccgaggccgc	4980
ctctgcct	gagttatcc	agaagtagt	aggaggctt	tttggaggcc	taggtttt	5040
aaaaagctc	cgggagct	gtatccat	tttccgatct	gatcagc	tgttgcata	5100
taatcatcg	catagtat	cgcatag	taatacgaca	aggtgaggaa	ctaaaccatg	5160
gccaaggta	coagtgc	tccgggt	accgcgc	acgtgc	agcgggtcg	5220
ttctggacc	accggct	gttctcc	gacttcgt	aggacgactt	cgccgggtgt	5280
gtccggac	acgtgacc	gttcatc	gccccgt	accagg	gcccggacaac	5340
accctgg	gggtgtgg	gcccgc	gacgagctgt	acgccc	gtcgagggtc	5400
gtgtccac	acttccgg	cgcc	ccggccat	gagatcgg	cgagcagccg	5460
tgggggg	agttcg	gccc	gcccgc	cgctgc	cgtggccgag	5520
gagcggact	gacacgtgt	acgagat	gatcc	ccgccttca	tgaaagggt	5580
ggcttgg	tggttcc	ggac	ttgtat	tcac	ggatctatg	5640
ctggagg	tcttcc	ggac	atgc	tgatctt	aaataaaagc	5700
aatagcat	tcgccc	acc	ttttttt	tgatctt	ttgtgttt	5760
tccaaactc	tcaatgtat	ttatcat	tgtatacc	cgac	ctagagctt	5820
cgtaatcat	gttcatag	gttcc	tgaaattt	ctac	aattccacac	5880

aacatacgg	ccggaagcat	aaagtgtaaa	gcctggggtg	cctaatgagt	gagctaaact	5940
acattaattg	cgttgcgctc	actgcccgt	ttccagtcgg	gaaacctgtc	gtgccagctg	6000
cattaatgaa	tccggccaacg	cgcggggaga	ggcggttgc	gtattggcg	ctcttccgt	6060
tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	atcagactcac	6120
tcaaaggcgg	taatacgggt	atccacagaa	tcagggata	acgcaggaaa	gaacatgtga	6180
gcaaaaaggcc	agcaaaaaggc	caggaaccgt	aaaaaggccg	cgttgctggc	gttttccat	6240
aggctccgcc	ccccctgacga	gcatcacaaa	aatcgacgct	caagtcaagag	gtggcgaaac	6300
ccgacaggac	tataaagata	ccaggcggtt	ccccctgaa	gctccctcg	ggcctctcct	6360
gttccgaccc	tggcgctta	cggatcacgt	tccgccttc	tccttcggg	aagctggcg	6420
ctttctcaat	gctcacgctg	taggtatctc	atggcggtt	aggctgttcg	cttccaagctg	6480
ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatctg	6540
ctttagtcca	accccgtaag	acacgactta	tcgcccactgg	cagcagccac	tggtaacagg	6600
attagcagag	cgaggtatgt	aggcggtgct	acagagttct	tgaagtgggt	gcctaactac	6660
ggctacacta	gaaggacagt	atttggtata	tgcgctctgc	tgaagccagt	taccttcgga	6720
aaaagagttg	gtagctctt	atccggcaaa	caaaccacccg	ctggtagcgg	tggtttttt	6780
gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	6840
tctacggggt	ctgacgctca	gtggAACGAA	aactcacgtt	aagggatttt	ggtcatgaga	6900
ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagttt	taaatcaatc	6960
taaagtatat	atgagtaaac	ttggctctgac	agttaccaat	gcttaatcag	tgaggcacct	7020
atctcagcga	tctgtctatt	tcgttcatcc	atagttgcct	gactcccccgt	cgtgtagata	7080
actacgatac	gggaggggctt	accatctggc	cccagtgtg	caatgatacc	gcgagaccca	7140
cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	ccggaaaggc	cgagcgcaga	7200
agtggcctg	caactttatc	cgccctccatc	cagtctatta	atttgtccg	ggaagactaga	7260
gtaagtagtt	cggcagttaa	tagtttgcgc	aacgttgg	ccattgtctac	aggcatcg	7320
gtgtcacgct	cgtcggttgg	tatggcttca	ttcagctccg	gttcccaacg	atcaaggcga	7380
gttacatgtat	cccccatgtt	gtgcaaaaaaaa	gcggtagt	ccttcggtcc	tccgatcg	7440
gtcagaagta	agttggccgc	agtgttatca	ctcatggta	tggcagca	gcataattct	7500
cttactgtca	tgccatccgt	aagatgctt	tctgtgact	gtgagtaact	aaccaagtca	7560
ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgc	cgcggtcaat	acgggataat	7620
accgcgcac	atagcagaac	tttaaaaatg	ctcatcatt	gaaaacgtt	ttcggggcga	7680
aaactctcaa	ggatcttacc	gctgttgaga	tccagttcg	tgtaaaccac	tcgtgcaccc	7740
aactgatctt	cagcatctt	tactttcacc	agcgtttcg	ggtgagaaaa	aacagaaagg	7800
caaaatccg	caaaaaagg	aataaggcgc	acacggaaat	gttgaataact	cataactcttc	7860
cttttcaat	attattgaag	catttatcag	ggttattgtc	tcatgagcgg	atacatat	7920
gaatgtat	agaaaaataaa	acaaataggg	gttccgcgca	catttcccc	aaaagtgc	7980
cctqacg	tc					7989

<210> 34
<211> 7607
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid GRE5-E1-SV40-Hygro

<400>	34					
tctagaagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	gtacaggatg	60
ttcttagtac	tttatttagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	120
gtacaggatg	ticttagctac	tttatttagat	ccgtgtacag	gatgttctag	ctactttatt	180
agatcgatct	ccctggccgtt	cggggtaaaa	aaccagggtt	ggtataaaaa	gggggttgggg	240
gcgcgttcgt	cctcaactc	ttccgcac	ctgtctgcga	ggggccaggat	cgatccctgag	300
aacttcaggg	tgatgttggg	gacccttgat	tgttctttct	ttttcgstat	tgtaaaattc	360
atgttatatg	gaggggggcaa	agtttcagg	gtgttgttta	aatgggaag	atgtcccttg	420
tatcaccatg	gaccctcatg	ataattttgt	ttctttca	ttctactctg	ttgacaacca	480
ttgtctcc	ttattttctt	ttcattttct	gtaactttt	cgttaaactt	tagcttgc	540
ttgttaacgaa	tttttaaatt	cacttttg	tatttgcag	attgtaa	ctttctctaa	600
tcacttttt	ttcaaggca	tcagggtata	ttatattgt	cttcagcaca	gttttagaga	660
acaattgtt	taattaaatg	ataaggtaga	atatttcgc	ataaaaattc	tggcttgcgt	720
ggaatattt	ttatttgtag	aaacaactac	atccgttca	tcatcttgc	tttctcttta	780
tggtttacaat	gatataact	gtttgatag	aggataaaat	actctgatgc	caaaccgggc	840
ccctctgcta	accatgttca	tgcccttctt	tttttccat	agctcctggg	caacgtgctg	900
qttattgtqc	tgtctcatca	tttqqcaaa	qaatttagatc	taaqcttctg	cagctcgagg	960

actcggtcga	ctgaaaatga	gacatattat	ctgccacgga	ggtgttatta	ccgaagaaat	1020
ggccgcgcgt	cttttggacc	agctgatcga	agaggtaactg	gctgataatc	ttccacacctcc	1080
tagccatTTT	gaaccaccta	cccttcacga	actgtatgtat	ttagacgtga	cggccccccga	1140
agatcccaac	gaggaggcgG	tttcgcagat	tttcccgcac	tctgtaatgt	ttgcgggtgca	1200
ggaaggggatt	gacttactca	ctttccgc	ggcccccgggt	tctccggagc	cgcctcacct	1260
ttcccggcag	cccgagcagc	cgagcagag	agcctgggt	ccggtttcta	tgccaaacct	1320
tgtaccggag	gtgatcgtc	ttacctgcca	cgaggctggc	tttccaccca	gtgacgacga	1380
ggatgaagag	ggtgaggagt	ttgtgttaga	ttatgtggag	cacccgggc	acggttgca	1440
gtcttgtcat	tatcaccgga	ggaatacggg	ggacccagat	attatgttt	cgctttgcta	1500
tatgaggacc	tgtggcatgt	ttgtctacag	taagtgaaaa	ttatgggcag	ttgggtgatag	1560
agtgggtgggt	ttgggtgtgg	aattttttt	ttaatttttta	cagtttgtg	gtttaaagaa	1620
ttttgtattt	tgatTTTTT	aaaagggtct	gtgtctgaac	ctgagcctga	gcccggagcca	1680
gaaccggagc	ctgcaagacc	tacccggcgt	cctaaaatgg	cgcctgttat	cctgagacgc	1740
ccgacatcac	ctgtgtctag	agaatgcaat	agtagtacgg	atagctgtg	ctccgggtct	1800
tctaaccacac	ctcctgagat	acacccgggt	gtcccgctgt	gccccattaa	accagttgcc	1860
gtgagagttg	gtgggcgtcg	ccaggctgt	gaatgtatcg	aggacttgc	taacgagcct	1920
gggcaacctt	tggactttag	ctgtaaacgc	cccaggccat	aagggttaaa	cctgtgattt	1980
cgtgtgtgg	taacgcctt	gtttgctgaa	tgagttatgt	taagtttaat	aaagggtgag	2040
ataatgttt	acttgcattt	cgtgttaat	ggggcggggc	ttaaagggtt	tataatgcgc	2100
cgtgggctaa	tcttggttac	atctgaccc	atggaggctt	gggaggtttt	gaaagatttt	2160
tctgctgtgc	gtaacttgc	ggaacagagc	tctaacagta	cctctgggtt	ttggagggtt	2220
ctgtggggct	catcccaaggc	aaagttagtc	tgcagaatta	aggaggat	caagtgggaa	2280
tttggaaagac	ttttggaaatc	ctgtgggt	ctgtttgatt	cttggatct	gggtcaccag	2340
gcgcgtttcc	aagagaaggt	catcaagact	ttggattttt	ccacaccggg	gcgcgtcg	2400
gctgtgttt	ctttttttag	ttttataaa	gataatgg	gcgaagaaac	ccatctgagc	2460
gggggggtacc	tgctggattt	tctggccat	cattctgtgg	gagcgggtgt	gagacacaag	2520
aatcgccctgc	tactgttgc	ttccgtccgc	ccggcgataa	taccgacgga	ggagcagcag	2580
cagcagcagg	aggaagccag	gcggcggcgg	caggagcaga	gcccatggaa	cccgagagcc	2640
ggcctggacc	ctcggaatg	aatgttgc	aggtggctga	actgtatcca	gaactgagac	2700
gcattttgac	aattacagag	gatgggcagg	ggctaaagg	gttaaagagg	gagcgggggg	2760
cttgcgtggc	tacagaggag	gcttaggaatc	tagcttttag	cttaatgacc	agacaccgtc	2820
ctgtgtgtat	tactttcaa	cagatcaagg	ataattgc	taatgagct	atctgctgg	2880
cgcagaagta	ttccatagag	cagtcgacca	cttactggc	gcagccagg	gtatTTTG	2940
aggaggctat	taggttat	gcaaaagggtt	cacttagggc	agatgc	tacaagatca	3000
gcaaaacttgt	aaatatcagg	aattgttgc	acatttctgg	gaacggggcc	gaggtggaga	3060
tagatacgg	ggatagggt	gccttttagat	gtacgatqat	aaatatgtgg	ccgggggtgc	3120
ttggcatgga	cggggtgg	attatgaat	taaggtttac	tggcccaat	tttagcggt	3180
cggttttcct	ggccaaatacc	aaccttatcc	tacacgggt	aagcttctat	gggtttaaaca	3240
atacctgtgt	ggaagcctgg	accgatgtaa	gggttcgggg	ctgtgcctt	tactgctgt	3300
ggaagggggt	ggtgtgtcg	cccaaaagca	gggcttcaat	taagaaatgc	ctctttgaaa	3360
ggtgttaccc	gggtatcctg	tctgagggtt	actccagggt	gcgcacaat	gtggcctc	3420
actgtgttt	cttcatgtc	gtggaaaacg	tggctgtat	taagcataac	atggtatgt	3480
gcaactgcga	ggacaggggcc	tctcagatgc	tgacctgtc	ggacggcaac	tgtcacctgc	3540
tgaagaccat	tcacgttagcc	agccacttc	gcaaggcctg	gccagttt	gagcataaca	3600
tactgaccgg	ctgttccctt	catttggta	acaggaggggg	gtgttccta	ccttaccaat	3660
gcaattttag	tcacactaag	atattgttgc	agcccagag	catgtccaag	gtgaacctga	3720
acgggggttt	tgacatgacc	atgaagatct	ggaaggtgt	gaggtacgt	gagacccgca	3780
ccaggtgcag	accctgcgag	tgtggcggt	aacatattag	gaaccagcct	gtgatgttgc	3840
atgtgaccga	ggagctgagg	cccgatcaat	ttgtgttgc	ctgcacccgc	gctgagtttgc	3900
gctctagcga	tgaagataca	gattgaggt	ctgaaatgt	tggcgttgc	ttaagggtgg	3960
gaaagaataat	ataaagggtgg	ggtcttatgt	agttttgtat	ctgttttgc	gcagccgc	4020
ccgcctatgt	caccaactcg	tttgatggaa	gcattgttgc	ctcatatttgc	acaacgcgc	4080
tggcccccatt	ggccgggggt	cgtcagaat	tgatgggtc	cagcattgtat	gtcgcccc	4140
tcctgcccgc	aaactctact	accttgaccc	acgagaccgt	gtctggaaacg	ccgttggaga	4200
ctgcagcctc	cgccgcgcgt	tcagccgt	cagccacccgc	ccgcgggatt	gtgactgact	4260
ttgcttcct	gagccgcgtt	gcaaggcgt	cagctcccg	ttcatccgc	cgcgatgaca	4320
agttgacggc	tctttggca	caattggatt	cttgacccgc	ggaacttaat	gtcgatctc	4380
agcagctgtt	ggatctgcgc	cagcaggtt	ctgcccgtaa	ggcttcctcc	cctcccaatg	4440
cggtttaaaa	cataaataaa	aaaccagact	ctgtttggat	ttggatcaag	caagtgttt	4500
gctgtctcag	ctgactgcgtt	aagtgcgt	ccgaatttgg	tccaatttgc	atcgatctt	4560
ttaaaggcaga	acttggttat	tgcagcttat	aatggttaca	aataaagcaa	tagcatcaca	4620
aatttcacaa	ataaaggcatt	tttttactg	cattctagtt	gtgggttgc	caaactcata	4680

aatgttatctt atcatgtctg gtcgactcta gactcttccg cttcctcgct cactgactcg 4740
 ctgcgctcg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 4800
 ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagaaaaag 4860
 gccaggaacc gtaaaaaggc cgcgttgcgt gctttttcc ataggctccg cccccctgac 4920
 gacatcaca aaaatcgacg ctcaagtca aggtggcgaa acccgacagg actataaaaga 4980
 taccaggcgt ttccccctgg aagctccctc gtgcgtctc ctgttccgac cctgcccgtt 5040
 accggatacc tgtccgcctt tctccctc ggaagcgtgg cgcttctca tagctcacgc 5100
 tgttaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 5160
 cccgttcagc ccgaccgcgtg cgccttatcc ggttaactatc gtctttagtca caacccggta 5220
 agacacgact tatgccact ggcagcagcc actggtaaca ggatttagcag agcgaggtat 5280
 gttaggcggtg ctacagagtt cttaagggtgg tggcctaact acggctacac tagaaggaca 5340
 gtatccggta tctcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 5400
 tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttggttgc当地 gacgagatt 5460
 acgcgcgagaa aaaaaggatc tcaagaagat cttttatgtt ttcttacggg gtctgacgt 5520
 cagtggaacg aaaactcacg ttaagggttt ttggtcatga gattatcaa aaggatcttc 5580
 acctagatcc tttaaattaa aaaatgaagt tttaaatcaa tcttaaagtat atatgagtaa 5640
 acttggctcg acagttacca atgcttaatc atggaggcac ctatctcagc gatctgtcta 5700
 tttcgttcat ccatagttgc ctgactcccc gtctgttaga taactacgt acgggagggc 5760
 ttaccatctg gccccagtgc tgcaatgata cgcgagacc cacgctcacc ggctccagat 5820
 ttatcagcaa taaaaccagcc agccggaagg gcccagcgca gaagtggtcc tgcaacttta 5880
 tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag ttgcggcagg 5940
 aatagttgc gcaacgttgt gtcatttcg acaggcatcg tggtgc当地 ctgcgtcg 6000
 ggtatggctt cattcagtc cgggtcccaa cgatcaaggc gaggatcatg atccccatg 6060
 ttgtgcaaaa aagccgttag ctcccttcggt ctcggatcg ttgtcagaag taagttggcc 6120
 gcagtgttat cactcatgtt tatggcagca ctgcataatt ctcttactgt catgc当地 6180
 gtaagatgtt ttctgtgac tggtagtac tcaaccaagt cattctgaga atagtgatg 6240
 cggcgaccga gttgctctt cccggcgtca atacgggata ataccgc当地 acatagcaga 6300
 actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6360
 ccgctgttgc gatccagttc gatgttaaccc actcgtgcac ccaactgatc ttcagcatct 6420
 tttactttca ccagcgttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
 ggaataaggc cgacacggaa atgttgaata ctctactct tccttttca atattattga 6540
 agcattttc agggttattt aaacaaatag gggtcccgcc attttttcc cggaaaatgc ctaagaaaacc 6660
 attattatca tgacatattaa ctataaaaat aggcttatca cgaggccctt ttcgtctc当地 6720
 gcgtttcggt gatgacgggtt aaaacctctg acacatgcag ctccggaga cggtc当地 6780
 ttgtctgttaa gcggtatgccc ggagcagaca agcccgtag ggcgc当地 cgggtgttgg 6840
 cgggtgtcgg ggctggctt actatgcggc atcagagcag attgtactga gagtgaccca 6900
 tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgc当地 gaaaattgtt 6960
 agcguttaata ttttgttaaa attcgc当地 taaatttgtt aaatcagctc atttttttaac 7020
 caataggccg aaatccggcaa aatcccttat aaatcaaagg aatagaccga gatagggtt 7080
 agtgtgttc cagttggaa caagagtcca ctataaaaga acgtgactc caacgtcaa 7140
 gggcgaaaaaa ccgttcatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200
 ttttgggtt cgaggtcggc taaagacta aatcggaaacc ctaaaggggag cccccgattt 7260
 agagcttgc gggggaaagcc ggc当地 acgtg gcgagaaaagg aagggaaagg agc当地 7320
 gccccggc当地 gggcgcttcc aatcgc当地 tcaggctc当地 caactgttgg 7440
 gcgcttaatg cgccgctaca gggcgatggc ctcttcgctt ttagccagg tggc当地 7500
 gaagggc当地 cggc当地 gggatgttgc 7560
 gcaaggc当地 taagggtt aacgccagg ttttccaggc acacgtt当地 taaaacgacg 7560
 gccagtgat tgtaatacga ctcaactatag ggc当地 attaa ttcgggg 7607

<210> 35
 <211> 11600
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid MMTV-E2a-SV40-Neo

<400> 35
 gaattccgca ttgcagagat attgtattta agtgccttagc tcgatataat aaacgccatt 60
 tgaccattca ccacatttgcgtt gtc当地 cccgttcc aagcttggcc agaaatgggtt gaaactccc当地 120

gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgaccgg 180
 tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcaaactt 240
 ggcatacgct tgcttgcct ggggttattt ggggaagttg cggttcgtgc tcgcagggt 300
 ctcaccctt actctttaa tagctctct gtcaagattt acaatctaaa caattcggag 360
 aactcgacct tcctccttag gcaaggacca cagccaactt ccttttacaa gccgcattcga 420
 ttttgcctt cagaataga aataagaatg cttgtttttt attatatttt taccaataag 480
 accaatccaa taggttattt attagttact atgttaagaa atgaatcatt atcttttagt 540
 actatttta ctcaattca gaagttagaa atggaaatag aaaatagaaa gagacgctca 600
 acctcaattt aagaacaggt gcaaggacta ttgaccacag gcctagaagt aaaaaagggaa 660
 aaaaagagtg ttttgcctt aataggagac aggtgggtgc aaccaggac ttatagggaa 720
 ctttacatct acagaccaac agatcccccc ttaccatata caggaagata tgacttaaat 780
 tgggataggt ggggtacagt caatggctat aaagtgttat atagatccct ccctttcgt 840
 gaaagactcg ccagagctag acctcccttgg tgtatgttgc ctcaagaaga aaaagacgac 900
 atgaaaacaac aggtacatga ttatattttt cttaggaacag gaatgcactt ttggggaaag 960
 attttccata ccaaggaggg catggcatga gttttatgtt agtaatgggaaatgggaaatgggaa 1020
 atagcctta ttggcccaac ctgttcgttcc ccagggtctt 1080
 ctgttcttaa aacgaggatg tgagacaagt gtttgcctt 1140
 tctgtatcga gctctgatgtt ttcttattttt ctatgttctt 1200
 atgttaatgc ttatgtttttt caagatataa aagagtgcgt 1260
 acagtcctaa cattcaccc tcgtgtgttt gtgtctgttc 1320
 cacttattct tcactttcca gagggtcccc ccgcagaccc 1380
 gactgcggca gctggcgccc gaacaggac cctcggataa 1440
 tactatttgg tgggtgttgc ttatgttgc ttcttgcgtt 1500
 ggctatcatc acaagagcgg cgtccaaagat ggcggcccttcc gcaaggccgg 1560
 ggcggcccttcc gcaaggccgg ggtatcttgc agtttggaa 1620
 acggggtaga agtttggcg ggtacgcgcgt gtgagaatag 1680
 ggcacatcgc tgcgtcttgc ttcaacagaca cgtcgcttcc 1740
 acttgcgttcc cgttgcgttcc gacatgttgc ttatgttgc 1800
 gagcgggttcc cgtcgcttcc ttcttgcgttcc gtcgataatcacttcc 2100
 ttcttgcgttcc gggggggaaatgg gacggggggaaatgg 2160
 ggggggggttcc aggttgcgttcc ttcttgcgttcc tgactccat 2220
 atcttttttgc gcttatagga gaaaggaaatgg gccagtcggg aagaggagca ggcggaaacc 2280
 acccccggac gcgacgcgg ccgtccccgt cgccgcgcgc 2340
 gagtcggagg acgaggaaga cggccatcga cctccggcgcc 2400
 tctcccaagc ccgagcgccc gatcatcaca gacgcgttgc tgccgcgcac 2460
 gaagatgtgg cgcttacaaat ggtgggttcc agcaacccac 2520
 aaaggaggat agcgcacagt cggcggctg aatgaagac 2580
 cggacgcgaag aggaagagga cggctgttgc gacggatgg 2640
 cggctgttgc tggccatgttgc taacgatcta aaggcgaact 2700
 atggacaatgt accacgttgc atgcaagacc tggctgaac 2760
 gtggaaagctc tggccggccgt gacctttgttgc acgatgttgc 2820
 ctgaccttca ccagcaacaa gacctacaatg catcacgagc 2880
 ctgcagtcgt ttgcagaggt ctgcaccgt gcgctgagat 2940
 aataaggagc acgttatttgc gatgttgc gacccgttgc 3000
 gagcagtcta gcaaggccaa tccaaacacccg acgcaagggtt 3060
 ggcaagtttgc gggcatgttgc ttatgttgc aacgcccaga 3120
 atcaaggctt ttatgttgc gacttacatc gatgttgc 3180
 atgccactac ggtgcgttgc cacttacaaatg gacccgttgc 3240
 ctacccaaatg tgactccgtt cggccgttgc gacccgttgc 3300
 tccgacaaga gctgtgttgc ggcggatgttgc ggcggaaatgg 3360
 aaccctgtgtt atcgcaactc ggcggccgtt ggcggaggcc 3420
 tcggccggcccg acctgttgc ggcgttgc ggcggaggcc 3480
 acccgagctcg cgcggatgttgc tggccatgttgc ggcggaggcc 3540
 aacgtgttcc tcggccgttgc gcatagcgttgc ggcggccgtt 3600
 gcatagcgttgc ggcggccgtt gcaactgcga cttcaagata 3660
 tcggccggcccg acctgttgc ggcgttgc ggcggaggcc 3720
 acccgagctcg cgcggatgttgc tggccatgttgc gcaactaaaca 3780
 aacgtgttcc tcggccgttgc gcatagcgttgc ggcggccgtt 3840

ggcgcagacgg caagggtggg ggtaaataat caccgcagag tgtacaaata aaagcattt 3900
 cctttattga aagtgtctct agtacattat ttatcatgt tttcaagtg aaaaaaaa 3960
 gtggcgctcc taatctgcgc actgtggctg cggaagttagg gcgagtggcg ctccaggaag 4020
 ctgttagact gttcctgggtt gcgacgcagg gtgggctgtt cctggggact gttgagcatg 4080
 gagttgggtt ccccggtaat aagggttcatg gtggggttgtt gatccatggg agtttgggc 4140
 cagttggcaa aggctggag aaacatgcag cagaatagtc cacaggcggc cgagttgggc 4200
 ccctgtacgc ttgggtggta ctttccagc gttatacagc ggtcggggaa agaagcaatg 4260
 ggcgtacggc gcaggagtgta ctcgtactca aactggtaaa cctgctttag tcgctggtca 4320
 gaaaagccaa agggctcaaa gaggttagcat gtttttagt gcccgttcca gcacaaggcc 4380
 atccagtgtt cgcggccactt ctcgcgaccg gccgtattga ctatggcga ggcgagctg 4440
 tgtggagaaa caaagcctgg aaagcgctt tcataggtgc ccaaaaaata tgccccacaa 4500
 ccaagatctt tgacaatggc ttccagttc tgctcactgg agcccatggc ggcagctgtt 4560
 gttgtatgtt cttgttctt tatgttgggg cttgtccggc cgagaaggcc tgccgcaggt 4620
 acacggtttccatgatgacggcc cggtgccggc ggtgcacacg gaccacgtc aagacttcaa 4680
 acaaaaacata aagaagggtt ggctcggttca tggatccat atatagggcc cgggttataa 4740
 ttacctcagg tcgacccgttca gggatcttgc tgaaggaaacc ttacttctgt ggtgtgacat 4800
 aattggacaa actacactaca gagatttaaa gctctaaggtaa aatataaaa tttaatgtt 4860
 tataatgtt taaactactgtt attctaattt gttgtgtatt ttagatttcca acctatggaa 4920
 ctgtatgttgg ggagcagtgg tggaaatgcct ttaatgagga aaacctgttt tgctcagaag 4980
 aaatgccatc tagttagtat gaggctactt ctgactctca acatttactt cctccaaaaa 5040
 agaagagaaa ggttagaagac cccaaaggact ttccctttaga attgtctaagt tttttagtgc 5100
 atgctgtgtt tagtaataga actcttgcctt gctttgttat ttacaccaca aaggaaaaag 5160
 ctgcactgtt atacaagaaa attatggaaa aatattctgtt aaccccttata aataggcata 5220
 acagttataa tcataacata ctgttttttccatccca caggcataga gtgtctgcta 5280
 ttaataacta tgctcaaaaa ttgtgtaccc tttagctttt aattttagaa ggggttataa 5340
 aggaatattt gatgtatagt gccttgacta gagatcataa tcagccatac cacatttgc 5400
 gaggttttac ttgctttaaa aaacctccca cacccccc tgaacctgaa acataaaaatg 5460
 aatgcaattt ttgtttttaa ctgttttattt gcaacttata atggttacaa ataaagcaat 5520
 agcatcacaa atttcacaaa taaagcattt ttttactgc attcttagtt tggtttgtcc 5580
 aaactcatca atgtatcttca tcatgtctgg atccggctgtt ggaatgtgtg tcagtttaggg 5640
 tgtggaaatg cccaggctt cccaggcggc agaagtatgc aaagcatgca tctcaatttag 5700
 tcagcaacca ggtgtggaaa gttcccccggc tcccccggc gcaagaatgtt gcaaaaggcatg 5760
 catctcaattt agtcagcaac catatgtcccg cccctaactt cccccatccc gcccctaact 5820
 ccgccccatgtt ccgccccatcc tccgccccat ggctgactaa tttttttat ttatgcagag 5880
 gccgaggccg cctccggctt tgagctattt cagaagtagt gaggaggctt ttttggaggc 5940
 ctaggctttt gcaaaaagct tcacgtgtcc gcaaggactc agggcgcaag ggctgttaaa 6000
 ggaagcggaa cacgtagaaa gcccgtccgc agaaaacgggtt ctgaccggg atgaatgtca 6060
 gctactgggc tatctggaca agggaaaacg caagcgaaa gagaaagcag gtagcttgca 6120
 gtgggcttac atggcgatag cttagactggg cgggtttatg gacagcaagc gaaccggaaat 6180
 tggcagctgg ggcggccctt ggttaagggtt ggaaggccctt gaaagtaaac tggatggctt 6240
 ttttggccgc aaggatctga tggcgccagg gatcaagatc tgatcaagag acaggatgag 6300
 gatcttttcg catgatggaa caagatggat tgcacgcagg ttctccggcc gcttgggtgg 6360
 agaggctatt cggctatgac tgggcacaaac agacaatcggtt ctgctctgtat gccggccgtgt 6420
 tccggctgtc agcgcagggg cggccgggtt ttttgcataa gaccgacccgt tccggtgccc 6480
 tgaatgaact gcaggacggc gcagcgccgc tatcggtttt ggcacacgac ggcgttccctt 6540
 ggcgcagctgt gtcgtacgtt gtcactgttgc cgggaaggga ctggctgtca ttgggcgaag 6600
 tgccggggca ggatctccttgc tcatctcacc ttgtctctgc cgagaaagta tccatcatgg 6660
 ctgtatgttgcat gcccggcttgc catacgcttgc atccggctac ctgcccattt gaccaccaag 6720
 cggaaacatcg catcgagcga gcacgtactt cggatggaaacg cggctctgtc gatcaggatg 6780
 atctggacga agagcatcg gggctcgccgc cggccgtactt gttcgccagg ctcaaggccgc 6840
 gcatggccgc cggcgaggat ctcgtctgtt cccatggcga tccgtctgtt cggaaatatca 6900
 tggcggaaaaa tggccgtttt tgggtttatca tggactgtgg cggctgtgggt gtggcggacc 6960
 gctatcggaa catagcggtt gctacccgtt atattgtgtt gggacttggc ggcgaatggg 7020
 ctgaccgtttt cttcggtttt tacggatcc cccgttccgc ttgcacgcgc atcgctttt 7080
 atcgcccttctt tgacgagttt ttctggccgg gactctgggg ttgcataatga cccaccaagc 7140
 gacgccccaaac ctgccccatcc gagatttcgat ttccacccggc gccttctatg aaagggttggg 7200
 cttcggtttt gtttccggg acggccgttgc gatgtatcc cagcgcgggg atctcatgt 7260
 ggagttcttc gcccaccccg ggctcgatcc cttcggtttt gggacttggc gtcgtccgtt 7320
 gctggacgc ctcggggact tctacccggca gtgcataatcc gtcggcatcc agggaaaccag 7380
 cagcggttat cccgcgtatcc atgcggccggacttgcaggag tggggaggca cgtatggccgc 7440
 ttgggtcccg gatctttgtt aaggaaacccctt actctgttgc tggacataa ttggacaaac 7500
 tacctacaga gatttaaagc tctaaggtaa atataaaaattttaatgttta taatgtgttta 7560

aactactgt	tcttaatttgtt	tgtgtat	tttt	agattccaaac	ctatggaaact	gatgaatggg	7620
agcagtggtg	gaatgcctt	aatgaggaaa		acctgtttt	ctcagaagaaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac		attctactcc	tccaaaaaaag	aagagaaaagg	7740
tagaagaccc	caaggactt	ccttcagaat		tgctaagttt	tttgagtcatt	gctgtgttta	7800
gtaatagaac	tottgcttgc	tttgcattt		acaccacaaa	ggaaaaaaagct	gcactgctat	7860
acaagaaaaat	tatggaaaaaa	tattctgtaa		ccttataag	taggcataac	agttataatc	7920
ataacacact	gttttttctt	actccacaca		ggcatagagt	gtctgttatt	aataactatg	7980
ctcaaaaatt	gtgtacctt	agcttttaa		tttgttaaagg	ggttaataag	gaatatttga	8040
tgtagatgtc	cttgactaga	gatcatatac		agccatacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctccccctg		aacctgaaac	ataaaatgaa	tgcaattgtt	8160
gttgttaact	tgtttattgc	agcttataat		ggttacaat	aaagcaatag	catcacaaat	8220
ttcacaaaata	aagcatttt	ttcaactgcat		tctagttgt	gttgtccaa	actcatcaat	8280
gtatcttac	atgtctggat	ccccaggaag		ctccctctgt	tcctcataaa	ccctaaccctc	8340
ctctacttga	gaggacattc	caatcatagg		ctgcccattcc	accctctgtg	tcctcctgtt	8400
aattaggtca	cttaacaaaaa	aggaaattgg		gtaggggttt	ttcacagacc	gctttctaag	8460
ggtaatttt	aaatatctgg	gaagtcctt		ccactgtgt	gttccagaag	tgttggtaaa	8520
cagccccacaa	atgtcaacag	cagaaacata		caagctgtca	gcttgcaca	agggcccaac	8580
accctgtca	tcagaagaagc	ctgtgttgc		tgtttagta	atgtcaaaa	caggaggcac	8640
atttccccca	cetgtttagg	ttccaaaata		tctagtttt	tcatttttac	ttggatcagg	8700
aacccagcac	tccactggat	aagcattatc		cttacaaa	acagccttgt	ggtcagtgtt	8760
catctgtga	ctgtcaactg	tagcatttt		tggggttaca	gtttgagcag	gatattttgt	8820
cctgtagttt	gctaacaacac	cctgcagctc		caaaggttcc	ccaccaacag	caaaaaaaatg	8880
aaaatttgac	ccttgaatgg	gtttccagc		accattttca	tgagttttt	gtgtccctga	8940
atgcaagttt	aacatagcag	ttaccccaat		aacctcagtt	ttaacagtaa	cagttccca	9000
catcaaaaata	tttccacagg	ttaagtcttc		attnaaatta	ggcaaaaggaa	ttcttgaaga	9060
cgaaaagggcc	tctgtatacg	cctattttt		taggttaatg	tcatgataat	aatggtttct	9120
tagacgtcag	gtggcactt	tcggggaaat		gtgcgcggaa	cccttattt	tttatttttc	9180
taaatacatt	caaatatgtt	tccgctcatg		agacaataac	cctgataat	gettcaataa	9240
tattgaaaaa	ggaaagtagat	gagtacttca		catttccgt	tcgccttat	tcccttttt	9300
gcggcattt	gccttcctgt	ttttgtcac		ccagaaacgc	tgtgaaaagt	aaaagatgct	9360
gaagatcagt	tgggtgcacg	agtgggttac		atcgaactgg	atctcaacag	cggtaagatc	9420
cttgagagtt	ttcgccccga	agaacgtttt		ccaatgatga	gcacttttaa	agttctgtca	9480
tgtggcgcgg	tattatcccg	ttttgtaccc		gggcaagagc	aactcggtcg	ccgcatacac	9540
tattctcaga	atgacttggt	tgagactacta		ccagtcacag	aaaagcatct	tacggatggc	9600
atgacagtaa	gagaattatg	cagtgtgcc		ataaccatga	gtgataaacac	tcgcggccaac	9660
ttacttctga	caacgatcgg	aggaccgaag		gagctaaccg	cttttttgc	caacatgggg	9720
gatcatgtaa	ctcgcccttga	tcgtgtggaa		ccggagctga	atgaagccat	acccaaacgcac	9780
gagcgtgaca	ccacgatgcc	tgcagcaatg		gcaacaacgt	tgcgc当地	attaactggc	9840
gaactactta	ctctaggttc	ccggcaacaa		ttaataagact	ggatggaggc	ggataaaagt	9900
gcaggaccac	ttctgcgctc	ggcccttccg		gctggcttgt	ttatttgc	taaatcttga	9960
gccgggtgagc	gtgggtctcg	cggtatcatt		gcagcactgg	ggccagatgg	taagccctcc	10020
cgtatcgtag	ttatctacac	gacggggagt		caggcaacta	tggatgaacg	aaatagacag	10080
atcgctgaga	taggtgcctc	actgattaag		cattggtaac	tgtcagacca	agtttactca	10140
tataacttt	agattgattt	aaaacttcat		tttaatttta	aaaggatcta	ggtgaagatc	10200
ctttttgata	atctcatgac	caaataccct		taacgtgagt	tttgc	ctgagcgtca	10260
gacccctgt	aaaagatccaa	aggatcttct		tgagatcctt	tttttgc	cgtaatctgc	10320
tgcttgcataa	caaaaaaaaa	accgcttacca		gcgggtgttt	gttgc	tcaagagcta	10380
ccaaactctt	ttccgaaggt	aactggctt		agcagagcgc	agatacaaa	tactgtctt	10440
ctagtgtac	cgttagttag	ccaccaattc		aagaactctg	tagcaccgc	tacatacc	10500
gctctgttac	tcctgttacc	agtggctgtc		gccagtggcg	ataagtcgt	tcttaccggg	10560
ttggactcaa	gacgatagtt	accggataag		gcbcagcgg	cgggctgaa	gggggggtcg	10620
tgcacacacg	ccagcttgg	gcaacgcacc		tacaccgaac	tgagataac	acagcgtgag	10680
ctatgagaaa	gcccacgc	tcccaaggg		agaaaggcgg	acaggtatcc	gttaagcggc	10740
agggtcgaa	caggagagcg	cacgagggag		cttccagggg	gaaacgcctg	gtatctt	10800
agtccctgtcg	ggtttgc	cctctgactt		gagcgtcgat	tttgc	ctcg	10860
ggcgccgg	atatggaaaaa	cgccagcaac		gcggcccttt	tacgg	tttgc	10920
tggccctttt	ctcacatgt	cttccctgc		ttatccctg	attctgttgg	taaccgtt	10980
accgccttt	agtggactgt	taccgc		cgcagcggaa	cgaccgagc	cagecgtca	11040
gtgagcggagg	aagcggaa	gcccgtatgt		cgtat	tccttgc	tctgtcggt	11100
atttcacacc	gcatatgtt	cactctcgt		acaatctgt	ctgatgc	atagttaa	11160
cagtatctgc	tccctgtt	tgtgttggag		gtcgctgagt	atgtgc	cgag	11220
gctacaacaa	ggcaaggc	gaccgacaat		tgcatgaa	atctgtt	ggttaggcgt	11280

tttgcgctgc ttcgcgtatgt acgggccaga tatacgcgta tctgagggga ctagggtgtg 11340
tttaggcgaa aaggccccctac tcgggtgtac gcgggttagga gtcccccctcag gatatagttag 11400
tttcgcgtttt gcataaggag gggggaaatgt agtcttatgc aatacacattg tagtcttgca 11460
acatggtaac gatgagtttag caacatgcct tacaaggaga gaaaaaagcac cgtgcacatgcc 11520
gattgggtgga agtaagggtgg tacgatcggt ccttatttagg aaggcaacag acgggtctga 11580
catggattgg acgaaccact 11600

<210> 36
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 36
gtcactcgag gactcggtcg actgaaaatg agacatatta tctgcccacgg acc

53

<210> 37
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 37
cgagatcgat cacctccggt acaaggtttg gcatacg

36

<210> 38
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 38
catgaagatc tggaagggtgc tgaggtacga tgagacc

37

<210> 39
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 39
gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c

51

<210> 40
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 40
cacgaattcg tcagcgcttc tcgtcgcgctc caagaccc

38

<210> 41
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 41
caccccccgggg aggccccggc gacggggacg gg 32

<210> 42
<211> 7231
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid pDV80

<400> 42
ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatt aagaatctgc tttagggttag gcgttttgcg 120
ctgcttcgcg atgtacggc cagatatacg cgttgacatt gattattgc tagttattaa 180
tagtaatcaa ttacggggtc attagttcat agccatata tggagttccg cgttacataa 240
cttacggtaa atggcccgcc tggctgaccg cccaaacgacc cccgcccatt gacgtcaata 300
atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggac 360
tatttacggt aaactgccc cttggcagta catcaagtgt atcatatgcc aagtacgccc 420
ccatttgcac tcaatgacgg taaatggccc gcctggcatt atgcccagta catgaccta 480
tgggactttc ctacttggca gtacatctac gtatttgtca tcgcttattac catggtgatg 540
cggttttggc agtacatcaa tgggcgttga tagcggtttgc actcacgggg atttccaatg 600
ctccacccca ttgacgtcaa tgggagtttgc tttggcacc aaaatcaacg ggactttcca 660
aaatgtcgta acaactccgc cccattgcac caaatggcg gtaggcgtgt acgggtggag 720
gtcttatataa gcagagctct ctggctaact agagaaccca ctgcttactg gcttatcgaa 780
attaatacga ctcactatag ggagacccaa gctggcttagc gtttaaactt aagcttggta 840
ccgagctcg atccactctc ttccgcattcg ctgtctgcga gggccagctg ttgggttgag 900
tactccctct gaaaagcggg catgacttct gcgctaagat tgtcagttc caaaaacgag 960
gaggatttga tattcacctg gcccgcgtg atgccttgcg gggtggccgc atccatctgg 1020
tcagaaaaga caatctttt gttgtcaagc ttggtggcaa acgacccgta gagggcgttg 1080
gacagcaact tggcgatggc ggcgcagggt tggtttttgt cgccatcgcc gcgcctctg 1140
gcccgcgtgt ttagtgcac gtattcgccgc gcaacgcacc gccattcggg aaagacgggt 1200
gtgcgcgtcg tggcaccagg gtgcacgcgc caaccgcggcgt tgcgcagggt gacaagggtc 1260
acgctggtgg ctacccctcc gcgtaggcgc tcgttggtcc agcagaggcg gccgcctctg 1320
cgcgagcaga atggcggtag ggggtcttagc tgctgtctcg ccggggggtc tgcgtccacg 1380
gtaaagaccc cgggcagcag ggcgcgtcg aagtatgtca tcttgcattc ttgcaagtct 1440
agcgcctgt gccatgcgcg ggcggcaagc gcgcgcgtcg atgggttgag tgggggaccc 1500
catggcatgg ggtgggtgag cgcggaggcg tacatgcgcg aaatgtcgta aacgttagagg 1560
ggctctctga gtattccaag atatgttaggg tagcatcttc caccgcggat gctggcgcgc 1620
acgtaatcgat atagttcgat cgaggggaggcg aggaggctgg gaccggagggt gctacggggc 1680
ggctgtctgt ctgcgaagac tatctgcgt aagatggcat gtgagttggta tgatatgggt 1740
ggacgcgtgg agacgttggaa gctggcgatgt gtgagaccta cgcgcgtcgc cacgaaggag 1800
gcgttaggat cgccgcgtgtt gttgaccagg tcggcggtga cctgcacgtc tagggcgcag 1860
tagtccagggt tttccctgtat gatgtcatat ttatccgtc cctttttttt ccacagctcg 1920
cggttggagga caaactcttc gcggtcttc cagtagtctt ggatcgaaaa cccgtcgccc 1980
tccgaacgag atccgtactc cggccgcgcg ggacctgagc gagtcgcgcgat cgaccggatc 2040
ggaaaacccc tcgagaaagg cgtctaaacc gtcacagtgc caagatccaa gatgaagcgc 2100
gccccccccca gcgaaagatga ttcaacccct gtatcccccct atggctacgc gcggaatcag 2160
aatatccccct tcctcactcc cccctttgtc ttctccgtg gattaaaaaaa cttccccccct 2220
ggggtactgt cactcaaact ggctgtatcca atcaccatta ccaatggggta tttatccccct 2280
aagggtggag gtggctcac tttgcagat ggaaggctaa ctgtaaaccc taaggctcca 2340
ctgcgaagtta atactgataa aaaacttggat cttgcattatg ataattccatt tgaaaagtgt 2400
gtaataaaac ttagttaaa agtaggacat ggattaaaag tattagatga aaaaagtgt 2460

gccccgttaa aagatttaat tggcaaactt gtggtttaa caggaaaagg aataggcact 2520
 gaaaatttag aaaatacaga tggtagcagc agaggaattg gtataaatgt aagagcaaga 2580
 gaagggttga cattgacaa tgatggatac ttggtagcat ggaaccaaa gtatgacacg 2640
 cgcacactt ggacaacacc agacacatct ccaaactgca caattgctca agataaggac 2700
 tctaaactca ctgggtact tacaaagtgt ggaagtcaaa tattagctaa tgtgtcttg 2760
 attgtggtcg cagggaaagta ccacatcata aataaaga caaatccaaa aataaaaaagt 2820
 tttaacttta aactgttatt taataagaac ggagtgcctt tagacaactc aatcttgg 2880
 aaagcttatt ggaactttag aagtggaaat tccaatgttt cgacagctta tgaaaaagca 2940
 attggttta tgcctaattt ggtagcgtat cccaaaccca gtaattctaa aaaaatatgca 3000
 agagacatag ttatggAAC tatatatctt ggtggaaaac ctgatcagcc agcagtcatt 3060
 aaaactaccc ttaaccaaga aactggatgt gaatactcta tcacattaa cttagttgg 3120
 tccaaaacct atgaaaatgt tgaatttga accaccttctt ttaccttctc ctatattgcc 3180
 caagaatgaa agagcgcccg ctcgagtcata gaggcccgt taaaacccgc tgatcagcct 3240
 cgactgtgcc ttctagttgc cagccatctg ttgttgcCc ctcggccgtg cttcccttga 3300
 ccctggaaagg tgccactccc actgtccctt cctaataaaa tgagggaaat gcatcgcatt 3360
 gtctgagtag gtgtcattctt attctggggg gtgggggtggg gcaggacagc aagggggagg 3420
 attgggaaga caatacgagg catgtctggg atgcgggtggg ctctatggct tctgaggcgg 3480
 aaagaaccag ctggggctc aggggttac cccacgcgc ctgtagcggc gcattaagcg 3540
 cggcgggtgt ggtgttacg cgcagcgtga cogtacact tgccagcggc cttagccccg 3600
 ctcccttcgc tttcttccct tcccttcgc ccaacgttcgc cggcttcccc cgtcaagctc 3660
 taaatcgggg catccctta aacttgattt ggggtccgat tttagtgcctt acggcacctc gaccccaaaa 3720
 tcacgtatg ggggtatggg ttctttaata gttggactctt gttccaaact ggaacaacac 3840
 tcaaccctat ctcgtctat tctttgtatt tataagggt tttgggatt tcggcctatt 3900
 gtttaaaaaaa tgagctgatt taacaaaaat ttaacgcgaa ttaatctgt ggaatgtgtg 3960
 tcagttaggg tggaaagt ccccgagctc cccaggcagg cagaatgtg caaagcatgc 4020
 atctcaatta gtcgaacc acgtgtggaa agtccccagg ctcccccagg ggcagaagta 4080
 tgcaaaagcat gcatctcaat tagtcagcaa ccatagtcctt gcccccaact cggcccatcc 4140
 cgcgccttaac tccggccagt tccggccattt otccggccca tggctgacta attttttta 4200
 tttatgcaga ggcggaggcc gcctctgcct ctgagctatt ccagaatgtg tgaggaggct 4260
 ttttggagg cctaggctt tgcaaaaagc tccggggagc ttgtatatcc attttcgat 4320
 ctgatcagca cgtgttgaca attaatcatc ggcatagtat atcggcatag tataatacga 4380
 caagggtgagg aactaaacca cgacgtcggcc ggagcggtcg ggaggacgac tccggccattt otccggccca tggctgacta attttttta 4200
 ggaccagggtg gtgcgggaca gtacggcggag tggccaaagg tggccaaagg tggccatcc 4440
 gaccggatc ggcgagcagc ctgctgtcac tggccgggca ggagttcgcc acaccctggc ctgggtgtgg tgccggccat 4500
 ctgcgtgcac ttcgtggccg cgtggggcg aggagcagga ctgacacgtg acgtgttccac gaatttcggc acgtgttccg ggcggccat 4560
 cgccgccttc tatggaaaggt tgggcttcgg aatcggtttc tgccggccat 4620
 cctccagcgc gggatctca tgctggagtt ctgcggccac ccaacttgt ttattgcagc 4680
 ttataatggt tacaataaa gcaatagcat cacaatatttca cacaataaaag cattttttt 4740
 actgcattct agttgtggtt tgcattaaact catcaatgtt tgcattatcatg tctgtatacc 5040
 gtcgacctct agcttagagct tggcgtaatc atggctatgc tggcttcgt tggaaattg 5100
 ttatccgctc acaattccac acaacatcag acggcggaaagc acaatgttca aagcctgggg 5160
 tgcctaatga gtgactaac ggcattaaatgc aatcggtttc tgccggccat 4800
 gggaaacccgt tcgtggccagc gcttccgtt aatcggtttc tgccggccat 4860
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5220
 gccggcgagcg gtatcagctc taacgcagga aagaacatgt gagcaaaaagg ccagcaaaaag gccaggaacc gtcattaaatgc aatcggtttc tgccggccat 4920
 cgcgttccgt gctttttcc ctcaagtcaag aggtggcgaa aagctccctc gtgactaac tgcattaaatgc aatcggtttc tgccggccat 4980
 ctgcgttccgtt aatcggtttc tgccggccat 5040
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5100
 gccggcgagcg gtatcagctc taacgcagga aagaacatgt gagcaaaaagg ccagcaaaaag gccaggaacc gtcattaaatgc aatcggtttc tgccggccat 5160
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5220
 gccggcgagcg gtatcagctc taacgcagga aagaacatgt gagcaaaaagg ccagcaaaaag gccaggaacc gtcattaaatgc aatcggtttc tgccggccat 5280
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5340
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5400
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5460
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5520
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5580
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5640
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5700
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5760
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5820
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5880
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 5940
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 6000
 gctgtattggg cgcgttccgtt actcaaaaggc ggttaatacgg ttatccacag aatcagggg 6060
 tcaagaagat ccttgatct tttctacggg gtcgtacgtc cagtggaaacg aaaactcagc 6120
 ttaaggatt ttggtcatga gattatcaa aaggatcttcc acctagatcc ttttaaaatta 6180

```

aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggctcg acagttacca 6240
atgcttaatc agtgaggcac ctatctcagc gatctgtcta ttcgttcat ccatagttgc 6300
ctgactcccc gtcgtgtaga taactacat acgggagggc ttaccatctg gcccagtgc 6360
tcaaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 6420
agccggaagg gcccagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat 6480
taatttgtgc cgggaagcta gagtaagtag ttgcgcagtt aatagttgc gcaacgttgc 6540
tgccattgtc acaggcatcg tggtgtcacg ctcgtcggtt ggtatggctt cattcagctc 6600
cggttcccaa cgatcaaggc gagttacatg atccccatg ttgtgcaaaa aagcggtag 6660
ctccttcggc cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatgtt 6720
tatggcagca ctgcataatt ctcttactgt catgcctcc gtaagatgtt tttctgtgac 6780
tgggtgactac tcaacaatg cattctgaga atagtgtatg cggcgaccga gttgctctt 6840
cccgccgtca atacggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 6900
tggaaaacgt tcttcggggc gaaaacttc aaggatctt cgcgtgtga gatccagttc 6960
gatgtAACCC actcggtcac ccaactgatc ttcaagcatct tttacttca ccagcggttc 7020
tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7080
atgttgaata ctcataactct tccttttca atattattga agcatttatac agggttattt 7140
totcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 7200
cacatttccc cgaaaaagtgc cacctgacgt c 7231

```

<210> 43
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 43
tgtcttggat ccaagatgaa gcgcccgccccc cccagcgaag atgacttc

48

<210> 44
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 44
aaacacggcg gccgctcttt cattcttg

28

<210> 45
<211> 17
<212> PRT
<213> Ad 37 N-terminus

<400> 45
Met Ser Lys Arg Leu Arb Val Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
1 5 10 15

<210> 46
<211> 6
<212> PRT
<213> artificial sequence

<400> 46
Lys Arg Ala Arg Pro Ser
1 5

<210> 47
<211> 17

<212> PRT

<213> Ad5 modified N-terminus

<400> 47

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
1 5 10 15

<210> 48

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 48

ggatccatgg gatacttggt agca

24

<210> 49

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 49

gcaactcgag tcattttgg gcaatatagg

30

<210> 50

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 50

cgcgcgtgact cttaaggact agtttc

26

<210> 51

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 51

gcgcctaatt aacatcatca ataataacc ttat

37